text,chunk_id,title,publication_date,authors,disease
"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome Short-chain enoyl-CoA hydratase, encoded by <italic toggle=""yes"">ECHS1,</italic> plays a major role in the valine catabolic pathway and mitochondrial fatty acid β-oxidation. Deficiency of this enzyme causes Leigh syndrome. Herein, we report a case of <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome with a prominent ketone body spectrum",0_0,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"syndrome with a prominent ketone body spectrum on magnetic resonance spectroscopy during acute exacerbation. A 6-month-old boy with mild motor developmental delay presented with disturbances of consciousness and hypercapnia without prior infection or feeding failure. Upon admission, investigations revealed prominent ketosis and elevated 2,3-dihydroxy-2-methylbutyric acid excretion. Brain magnetic resonance imaging revealed symmetrical T2 prolongation with restricted diffusion in the basal ganglia. Magnetic",0_1,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"diffusion in the basal ganglia. Magnetic resonance spectroscopy showed a prominent ketone body spectrum in the cerebral white matter, and prominent ketone bodies, elevated lactate and markedly decreased N-acetylaspartate levels in the basal ganglia. Genetic analysis identified compound heterozygous variants of <italic toggle=""yes"">ECHS1</italic>. Short-chain enoyl-CoA hydratase deficiency is a disease for which a valine-restricted diet is reported to be beneficial, and early diagnosis is desirable. Severe",0_2,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"and early diagnosis is desirable. Severe ketosis and the ketone body magnetic resonance spectroscopy spectrum during acute exacerbation may aid in the diagnosis of this disease. Short-chain enoyl-CoA hydratase (SCEH), encoded by <italic toggle=""yes"">ECHS1</italic> (MIM*602292), plays a major role in valine catabolism and mitochondrial fatty acid β-oxidation. SCEH deficiency caused by <italic toggle=""yes"">ECHS1</italic> variants leads to Leigh syndrome with acute episodes of encephalopathy, neurological",0_3,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"acute episodes of encephalopathy, neurological deterioration, severe developmental delay, movement disorders, and epilepsy <xref rid=""bib0001"" ref-type=""bibr"">[1</xref>,<xref rid=""bib0002"" ref-type=""bibr"">2]</xref>. Leigh syndrome is typically associated with defective oxidative phosphorylation due to mitochondrial or nuclear gene mutations, and its clinical manifestations differ from those of other fatty acid β-oxidation disorders <xref rid=""bib0003"" ref-type=""bibr"">[3</xref>,<xref rid=""bib0004""",0_4,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"ref-type=""bibr"">[3</xref>,<xref rid=""bib0004"" ref-type=""bibr"">4]</xref>. Although hyperintensities on T2-weighted images in the bilateral basal ganglia and elevated lactate levels on magnetic resonance spectroscopy (MRS) are common in SCEH deficiency, as in Leigh syndrome <xref rid=""bib0001"" ref-type=""bibr"">[1]</xref>, specific radiologic findings have not been reported. In SCEH deficiency, as accumulation of toxic intermediates from valine catabolism induces neurodegeneration, some patients benefit from a",0_5,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"neurodegeneration, some patients benefit from a valine-restricted diet, and prompt diagnosis is desirable to initiate effective early treatment <xref rid=""bib0005"" ref-type=""bibr"">[5</xref>,<xref rid=""bib0006"" ref-type=""bibr"">6]</xref>. Herein, we report a case of SCEH deficiency with acute episodes of encephalopathy and neurological deterioration, in which MRS revealed a prominent ketone body spectrum that may be key for diagnosis. A 6-month-old boy, born to healthy, nonconsanguineous parents with no",0_6,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"to healthy, nonconsanguineous parents with no reported perinatal problems, was hospitalized with disturbed consciousness and hypercapnia without prior infection or feeding failure. This patient was intubated and required ventilatory management for 5 days after admission. The patient's weight (6.8 kg, -1.4SD), height (65 cm, -1.2SD), and head circumference (44 cm, +0.5SD) at 6 months were within the normal range. Mild motor developmental delays had been observed during infancy. The patient had held his head",0_7,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"during infancy. The patient had held his head up at 4 months while not yet rolling over and sitting up independently. Biochemical analyses upon admission indicated prominent ketosis (blood pH 6.9, total ketone bodies, 15,200 µmol/L) and slightly elevated serum lactate levels (24 mg/dL) without hypoglycemia (blood glucose, 77 mg/dL). Urinary organic acid profiling revealed elevated excretion of 2,3-dihydroxy-2-methylbutyric acid. Although the newborn hearing test results were normal, the auditory brainstem",0_8,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"test results were normal, the auditory brainstem response after disease onset showed severe bilateral sensorineural hearing loss. No hepatomegaly, cardiomyopathy, or ocular abnormalities, such as optic atrophy or corneal clouding, were observed. Brain magnetic resonance imaging (MRI) on the third day of admission revealed symmetrical T2 prolongation with restricted diffusion in the caudate nucleus, putamen, globus pallidus, medial thalamus, and substantia nigra (<xref rid=""fig0001"" ref-type=""fig"">Figs.",0_9,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"nigra (<xref rid=""fig0001"" ref-type=""fig"">Figs. 1</xref>A-C). MRS (point resolved spectroscopy, repetition time/echo time/number of excitations = 5,000/30/32, volume of interest = 15 × 15 × 20 mm<sup>3</sup>) spectra from the white matter were quantitatively analyzed with LCModel. MRS spectra from the basal ganglia were semi-quantitatively analyzed as ratios with creatine (Cr) to prevent underestimation of the metabolite concentration shown on LCModel due to high proton and prolonged T2 values. Values",0_10,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"to high proton and prolonged T2 values. Values deviating from mean ± 2SD for age-matched controls were considered abnormal. Brain MRS on the same day revealed a peak at 2.2 ppm in the cerebral white matter (1.37 mM; nil in controls) (<xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>A) and in the basal ganglia (ketone bodies/Cr 1.25; nil in controls) (<xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>B), indicating the presence of ketone bodies. By this time, serum pH and ketone bodies (200 µmol/L) had",0_11,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"time, serum pH and ketone bodies (200 µmol/L) had normalized. Elevation of glutamine (5.53 mM; age-matched control, 2.10 ± 0.28 mM) and mild reduction of N-acetylaspartate (NAA) (4.12 mM; age-matched control, 6.60 ± 0.50 mM) levels in the white matter (<xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>A), and marked elevation of lactate/Cr (2.26; nil in controls) and a decrease in NAA/Cr (0.33; age-matched control, 1.06 ± 0.07) levels in the basal ganglia (<xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>B)",0_12,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>B) were also observed. Follow-up brain MRI and MRS on the 11th day of admission showed the disappearance of diffusion restriction and the ketone body peak in the white matter and basal ganglia (<xref rid=""fig0002"" ref-type=""fig"">Figs. 2</xref>C and <xref rid=""fig0002"" ref-type=""fig"">D</xref>). MRI on the 26th day showed progression of cystic degeneration of the basal ganglia and cerebral atrophy (<xref rid=""fig0001"" ref-type=""fig"">Figs. 1</xref>D and F). The",0_13,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"ref-type=""fig"">Figs. 1</xref>D and F). The findings at 1 year and 9 months after the onset did not change significantly (<xref rid=""fig0001"" ref-type=""fig"">Figs. 1</xref>G and I).<fig id=""fig0001""><label>Fig. 1</label><caption><p>Brain MRI findings of the patient. (A-C) Brain MRI at 6 months of age on the third day of admission (A, B: T2-weighted image, C: ADC) reveals symmetrical T2 signal prolongation with restricted diffusion in the caudate nucleus, putamen, globus pallidus, medial thalamus, and",0_14,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"putamen, globus pallidus, medial thalamus, and substantia nigra (white arrow). (D-F) Brain MRI on the 26th day of admission (D, E: T2-weighted image, F: ADC) shows progression of liquid degeneration of the basal ganglia and cerebral atrophy. (G-I) Brain MRI at 1 year and 9 months after onset (G, H: T2-weighted image, I: ADC) shows severe liquid degeneration of the basal ganglia and cerebral atrophy.</p><p>MRI, magnetic resonance imaging; ADC, apparent diffusion coefficient.</p></caption><alt-text",0_15,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"diffusion coefficient.</p></caption><alt-text id=""alt0001"">Fig 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""celink0001""></graphic></fig><fig id=""fig0002""><label>Fig. 2</label><caption><p>Brain MRS findings of the patient. (A and B) Brain MRS on the third day of admission (A: left white matter; B: left basal ganglia) revealed a peak at 2.2 ppm, which was assumed to be the ketone body spectrum. Elevation of glutamine level, mild reduction of NAA level in the white matter, marked elevation",0_16,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"NAA level in the white matter, marked elevation of lactate level, and a decrease in NAA level in the basal ganglia were also observed. (C and D) MRS on the 11th day of admission (C: left white matter, D: left basal ganglia) showing disappearance of the ketone body peak in the white matter and basal ganglia.</p><p>MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate; Cho, choline; Cr, creatine; Gln, glutamine; Lac, lactate.</p></caption><alt-text id=""alt0002"">Fig 2</alt-text><graphic",0_17,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"id=""alt0002"">Fig 2</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""celink0002""></graphic></fig> Mitochondrial respiratory chain enzymatic activity in skin fibroblasts on the 35th day was normal; however, the oxygen consumption rate, measured using a Seahorse XF96, showed a significant reduction in oxidative metabolism. Maximum respiration rates were low—58% in presence of glucose (cutoff, 71.6%) and 65% in the presence of galactose—compared with those in the control. Exome sequencing and",0_18,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"with those in the control. Exome sequencing and sequencing chromatograms identified compound heterozygous variants in NM_004092.4 (<italic toggle=""yes"">ECHS1</italic>), c.833C>T: p.Ala278Val and c.489G>A: p.Pro163=, leading to a diagnosis of <italic toggle=""yes"">ECHS-1</italic> related Leigh syndrome. Parents were carriers of 1 variant. Upon admission, the tentative diagnosis of acute encephalopathy led to vitamin supplementation (B1, C, E, biotin, carnitine, and CoQ10). The MRI findings and oxygen",0_19,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"and CoQ10). The MRI findings and oxygen consumption rate measurements indicated mitochondrial encephalopathy. A low-protein diet was initiated on the 10th day, but no neurological improvement was observed. Development regressed; at the age of 2 years; the patient was unable to hold his head up, was bedridden, and tube-fed, although he was able to follow objects and smile. Nystagmus was also observed. Based on the genetic analysis, a valine-restricted diet was initiated at the age of 2 years and 2 months,",0_20,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"was initiated at the age of 2 years and 2 months, and its effectiveness is currently being verified. Written informed consent was obtained from the guardians for their participation in the study and publication of images. Genetic analyses were only used for clinical diagnosis and did not require approval from the ethics committee of our institution. The patient presented with Leigh syndrome, marked ketosis, and characteristic MRS findings of ketone bodies in the brain even after normalization of blood",0_21,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"in the brain even after normalization of blood ketone body levels during acute exacerbation. The MRS findings of this patient are considered to reflect severe ketosis, and severe ketosis has been reported in cases with acute episodes of <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome. Leigh syndrome, caused by variants in other genes, was not linked to severe ketosis or changes in the ketone body MRS spectrum. Therefore, MRS can be useful for diagnosing <italic",0_22,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"MRS can be useful for diagnosing <italic toggle=""yes"">ECHS1</italic>-related diseases, even when blood ketone body levels are normalized. Patients with acute episodes of encephalopathy and neurological deterioration in SCEH deficiency sometimes present with marked hyperketonemia, similar to our findings <xref rid=""bib0007"" ref-type=""bibr"">[7</xref>,<xref rid=""bib0008"" ref-type=""bibr"">8]</xref>. One of the causes of hyperketonemia in SCEH deficiency is presumed to be impaired ATP production, possibly",0_23,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"presumed to be impaired ATP production, possibly through several mechanisms. The first mechanism is impaired mitochondrial fatty acid β-oxidation in SCEH deficiency <xref rid=""bib0009"" ref-type=""bibr"">[9]</xref>. Second, inadequate conversion of methacrylyl-CoA into 3-OH-isobutyryl-CoA,and acryloyl-CoA into 3-OH-propionyl-CoA, caused by the disruption of key SCEH activity, results in accumulation of toxic precursors <xref rid=""bib0001"" ref-type=""bibr"">[1]</xref>. Intramitochondrial methacrylyl-CoA reacts",0_24,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"Intramitochondrial methacrylyl-CoA reacts with mitochondrial enzymes containing cysteine residues, including pyruvate dehydrogenase complex and respiratory chain enzymes, and reduces their activities and ATP production <xref rid=""bib0010"" ref-type=""bibr"">[10</xref>,<xref rid=""bib0011"" ref-type=""bibr"">11]</xref>. A study using <italic toggle=""yes"">ECHS1</italic> “knockout” cells demonstrated reduced mitochondrial oxidoreductase activity and mitochondrial oxygen consumption rates <xref rid=""bib0009""",0_25,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"oxygen consumption rates <xref rid=""bib0009"" ref-type=""bibr"">[9]</xref>. Third, accumulation of methacrylyl-CoA depletes mitochondrial pools of thioredoxin and glutathione, which are involved in mitochondrial redox reactions <xref rid=""bib0011"" ref-type=""bibr"">[11]</xref>. It, however, remains unclear whether hyperketonemia in patients with SCEH deficiency results solely from impaired ATP production, because other genetic variants that cause Leigh syndrome may also impair ATP production without",0_26,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"syndrome may also impair ATP production without hyperketonemia. Additionally, since ketone bodies are produced from acetyl-CoA, impaired β-oxidation is expected to decrease the production of acetyl-CoA and ketone bodies. Therefore, the mechanism underlying ketosis during SCEH deficiency remains unclear. Blood glucose (4.3 mM) multiplied by the total ketone body (15.2 mM) in our case was 65, and the ratio of free fatty acid to total ketone bodies was less than 0.3 <xref rid=""bib0012""",0_27,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"bodies was less than 0.3 <xref rid=""bib0012"" ref-type=""bibr"">[12]</xref>, indicating impaired ketone body utilization, which requires further investigation. MRS is often useful for the diagnosis of numerous inborn errors of metabolism and neurodegenerative disorders, including amino acid metabolism disorders, urea cycle disorders, organic acid disorders, lysosomal disorders, peroxisomal disorders, mitochondrial disorders, fatty acid oxidation disorders, lactic acidosis disorders, leukodystrophies, lipid",0_28,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"acidosis disorders, leukodystrophies, lipid metabolism disorders, and so on <xref rid=""bib0013"" ref-type=""bibr"">[13]</xref>. Additionally, MRS is also effective as a predictor of outcomes for perinatal hypoxic–ischemic encephalopathy <xref rid=""bib0014"" ref-type=""bibr"">[14]</xref> and acute excitotoxic encephalopathy <xref rid=""bib0015"" ref-type=""bibr"">[15]</xref>, as well as for the differentiation of brain tumors <xref rid=""bib0016"" ref-type=""bibr"">[16]</xref>. Moreover, MRS can serve as a biomarker for",0_29,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"Moreover, MRS can serve as a biomarker for evaluating treatment effectiveness in metabolic diseases, and it also provides valuable insights into the pathophysiology of various disorders to support the development of new therapies <xref rid=""bib0017"" ref-type=""bibr"">[17]</xref>. MRS is an effective noninvasive method for examining various brain metabolites and a valuable diagnostic tool for pediatric metabolic and neurological disorders. In conclusion, SCEH deficiency requires early diagnosis. Severe",0_30,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
SCEH deficiency requires early diagnosis. Severe ketosis and ketone body MRS spectrum during acute exacerbation may help diagnose SCEH deficiency early. Written informed consent was obtained from the guardians for their participation in the study and publication of images.,0_31,"Increased ketone levels as a key magnetic resonance spectroscopic findings during acute exacerbation in <italic toggle=""yes"">ECHS1</italic>-related Leigh syndrome",24 9 2024,,Leigh_Syndrome
"A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum Background: Leigh syndrome spectrum (LSS) is a novel nomenclature that encompasses both classical Leigh syndrome and Leigh-like phenotypes. Given the heterogeneity of disease presentation, a new consensus published recently addressed the main issues and proposed general guidelines towards diagnosis. Based on these recommendations, we developed a simple pipeline that can be useful in the diagnosis of LSS. Methods: We combined previously",1_0,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"diagnosis of LSS. Methods: We combined previously published criteria with our own experience to achieve a diagnostic framework that can provide faster satisfactory results with fewer resources. Results: We suggest adding basic biochemical tests for amino acids, acylcarnitine, and urinary organic acids as parallel investigations, as these results can be obtained in a short time. This approach characterized 80% of our cohort and promoted specific intervention in 10% of confirmed cases. Conclusions: Genetic",1_1,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"in 10% of confirmed cases. Conclusions: Genetic studies are crucial in the diagnosis of LSS, but they are time-consuming and might delay tailored interventions. Therefore, we suggest adding more affordable and less complex biochemical studies as primary tests when investigating treatable causes of LSS. Leigh syndrome (LS) is the most frequent mitochondrial neurodegenerative disorder in childhood, affecting approximately 1:40.000 live births [<xref rid=""B1-diagnostics-14-02133""",1_2,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"live births [<xref rid=""B1-diagnostics-14-02133"" ref-type=""bibr"">1</xref>,<xref rid=""B2-diagnostics-14-02133"" ref-type=""bibr"">2</xref>,<xref rid=""B3-diagnostics-14-02133"" ref-type=""bibr"">3</xref>] with predominantly neurologic involvement, such as neurodevelopmental delay, regression, or psychiatric symptoms [<xref rid=""B4-diagnostics-14-02133"" ref-type=""bibr"">4</xref>,<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>,<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>]. The first case",1_3,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"ref-type=""bibr"">6</xref>]. The first case was described by Denis Archibald Leigh in 1951 and revealed a constellation of isolated neurological findings in the autopsy of a 7-month-old boy [<xref rid=""B7-diagnostics-14-02133"" ref-type=""bibr"">7</xref>]. Currently, the term “spectrum” is a new designation merging Leigh and Leigh-like syndrome that highlights the disease as a continuum and includes suspicious cases that exhibit atypical presentations in the Leigh syndrome “universe” [<xref",1_4,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"in the Leigh syndrome “universe” [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>,<xref rid=""B8-diagnostics-14-02133"" ref-type=""bibr"">8</xref>]. Symptoms primarily result from the dysfunction of the central nervous system and manifest as epilepsy, motor and/or speech delay, hypotonia, apnea, pyramidal signs, and movement disorders [<xref rid=""B4-diagnostics-14-02133"" ref-type=""bibr"">4</xref>]. These clinical manifestations correspond to neuroimaging features of bilateral symmetric basal",1_5,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"features of bilateral symmetric basal ganglia involvement as well as brainstem and spinal cord regions. Typically, the first symptoms begin in the first years of life, but there is an increasingly number of cases with adulthood presentation [<xref rid=""B9-diagnostics-14-02133"" ref-type=""bibr"">9</xref>]. Atypical and/or mild presentations have been observed in adulthood mimicking Parkinson disease, spinocerebellar ataxia, and multiple sclerosis [<xref rid=""B10-diagnostics-14-02133""",1_6,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"sclerosis [<xref rid=""B10-diagnostics-14-02133"" ref-type=""bibr"">10</xref>]. An intact oxidative phosphorylation (OXPHOS) system is essential to the aerobic metabolism. When hampered, glycolytic products such as lactate (L) and/or pyruvate (P) are abnormally high, demonstrating an ineffective aerobic metabolism. Lactate is an intermediate compound of energy production, considered a noble part in the redox signaling state and a regulator of homeostasis, representing a relevant source of energy [<xref",1_7,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"representing a relevant source of energy [<xref rid=""B11-diagnostics-14-02133"" ref-type=""bibr"">11</xref>]. Lactate and pyruvate can accumulate in body fluids such as blood, urine, and cerebral spinal fluid (CSF). Double lactate peaks or a pyruvate peak in magnetic resonance spectroscopy (MRS) in correspondent topography for LSS is valued as biochemically supportive of the diagnosis [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>]. Because pyruvate has a variable range of sensitivity and a",1_8,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"has a variable range of sensitivity and a strong specificity threshold, it is usually considered in association with lactate, using the ratio between them (an L/P ratio higher than 20) as a more specific biomarker for mitochondrial disorders (MDs) [<xref rid=""B12-diagnostics-14-02133"" ref-type=""bibr"">12</xref>]. High alanine can also reflect a glycolytic metabolism through the conversion of lactate to alanine; therefore, it is an important marker in suspected MDs. OXPHOS functional studies (OXPHOS complex",1_9,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"MDs. OXPHOS functional studies (OXPHOS complex activities), usually performed in muscle biopsies, are closest to mitochondrial metabolism, as they are considered to “mirror” the patient’s metabolic condition [<xref rid=""B13-diagnostics-14-02133"" ref-type=""bibr"">13</xref>]. Despite being highly recommended in clinical practice, deep tissue biopsy requires invasive procedures and anesthesia, adding risks for patients. LSS may arise either from mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations via",1_10,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"DNA (mtDNA) or nuclear DNA (nDNA) mutations via autosomal dominant, autosomal recessive, X-linked, or maternal inheritance. Identification of the inheritance mode is crucial for genetic counseling. <italic toggle=""yes"">MT-ATPase6</italic> m.8993T>G/C stands out as a frequent pathological variant in mtDNA marked by hypocitrullinemia in most cases, while in nuclear genome human surfeit 1 (<italic toggle=""yes"">SURF1</italic>), leucine rich pentatricopeptide repeat containing (<italic",1_11,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"rich pentatricopeptide repeat containing (<italic toggle=""yes"">LRPPRC</italic>) complex IV (COX) and complex I (CI) deficiencies are more frequently seen [<xref rid=""B3-diagnostics-14-02133"" ref-type=""bibr"">3</xref>]. However, the absence of a straightforward genotype–phenotype relationship is a characteristic of many genetic diseases, such as LSS, and arises largely due to incomplete penetrance and variable expressivity [<xref rid=""B14-diagnostics-14-02133"" ref-type=""bibr"">14</xref>,<xref",1_12,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"ref-type=""bibr"">14</xref>,<xref rid=""B15-diagnostics-14-02133"" ref-type=""bibr"">15</xref>]. The phenotype of mtDNA carriers linked to LSS is variable, which indicates that the associated genetic background and/or environmental variables can alter the expression and penetrance of disease-causing variants. Their interactions might result in a multitude of clinical presentations with varying degrees of severity, making it difficult to predict the outcome associated with a specific pathological variant [<xref",1_13,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"with a specific pathological variant [<xref rid=""B16-diagnostics-14-02133"" ref-type=""bibr"">16</xref>,<xref rid=""B17-diagnostics-14-02133"" ref-type=""bibr"">17</xref>,<xref rid=""B18-diagnostics-14-02133"" ref-type=""bibr"">18</xref>]. LSS criteria were recently revisited by the Clinical Genome Resource (ClinGen) Mitochondrial Disease Gene Curation Expert Panel (Mito GCEP) [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>]. A patient displaying a combination of neurologic symptoms and compatible",1_14,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"combination of neurologic symptoms and compatible neuroradiologic criteria supported by biochemical findings most likely has LSS. Neuroimaging criteria include bilateral, typically symmetric, T2-weighted hyperintensities on MRIs or hypodensities on CT scans of the brainstem and/or basal ganglia with or without bilateral T2 hyperintensity on MRIs or hypodensity on CT scans of the thalamus, cerebellum, subcortical white matter, and/or spinal cord [<xref rid=""B5-diagnostics-14-02133""",1_15,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"spinal cord [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>]. The observation of neurological symptoms, such as delay, regression, or psychiatric symptoms, obtained with predefined biochemical tests and neuroimaging studies might not result in a definitive diagnosis. Current diagnostic strategies include mandatory genetic confirmation [<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>,<xref rid=""B8-diagnostics-14-02133"" ref-type=""bibr"">8</xref>,<xref rid=""B19-diagnostics-14-02133""",1_16,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"rid=""B19-diagnostics-14-02133"" ref-type=""bibr"">19</xref>,<xref rid=""B20-diagnostics-14-02133"" ref-type=""bibr"">20</xref>].  In high-income countries, whole exome sequencing (WES) is often a readily available first line test. However, in other economies, technical and financial constraints interfere with following such guidelines, turning the diagnostic process into an odyssey for patients and their families. Moreover, not all cases are solved through genetic studies, and inconclusive results are more",1_17,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"studies, and inconclusive results are more frequent than desired.  We propose a cost- and time-effective pipeline based on Mito GCEP work [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>] and our own experience, prioritizing frequent and treatable causes, which can be adjusted to clinical practices of different realities. We revisited a cohort of 50 LSS-suspected individuals (23 males and 27 females) investigated at our center during the last three decades. These patients were studied through",1_18,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"decades. These patients were studied through a sequential gene-targeted approach for the most frequent mtDNA and nDNA mutations in diagnosed LSS cases [<xref rid=""B21-diagnostics-14-02133"" ref-type=""bibr"">21</xref>,<xref rid=""B22-diagnostics-14-02133"" ref-type=""bibr"">22</xref>]. We identified practical cases in which a more comprehensive initial approach than that proposed by the Mito GCEP would benefit a timelier diagnosis and phenotype–genotype correlation, enabling adaption to each service. Other causes",1_19,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"enabling adaption to each service. Other causes of LSS with easily obtainable biochemical markers identified through a literature review from other groups were also included. Neuroimaging patterns and criteria were previously defined [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>] and are outside the focus of this work. Considering our expertise and the literature reviewed, we propose a diagnostic protocol for the diagnosis of LSS, focusing on treatable causes and shortening diagnostic time.",1_20,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"treatable causes and shortening diagnostic time. Primarily based on the Mito GCEP’s recommendations, our approach can be adapted to distinct economies, as shown in <xref rid=""diagnostics-14-02133-f001"" ref-type=""fig"">Figure 1</xref>. From a clinical perspective, the phenotype is still a relevant factor and can suggest a molecular diagnosis, such as <italic toggle=""yes"">NDUFV2</italic> mutations identified in two siblings of our cohort displaying encephalopathy and cardiomyopathy. However, MDs are such a",1_21,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"and cardiomyopathy. However, MDs are such a heterogenic group of disorders that they require the more robust support given by the following steps of investigation [<xref rid=""B21-diagnostics-14-02133"" ref-type=""bibr"">21</xref>,<xref rid=""B22-diagnostics-14-02133"" ref-type=""bibr"">22</xref>]. To support our suggestions, we revisited data previously collected through phenotype characterization and basic biochemical studies leading to a genetic diagnosis in a few of our cases. <italic",1_22,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"genetic diagnosis in a few of our cases. <italic toggle=""yes"">MT-ATPase6</italic> mutations, especially m.8993T>G/C, were the most frequently found variants (16/50). <italic toggle=""yes"">MT-ATPase6</italic> m.8993T>G/C and m.9176T>G/C impact complex V (CV) and result in low to absent citrulline levels in approximately 80% of patients [<xref rid=""B23-diagnostics-14-02133"" ref-type=""bibr"">23</xref>,<xref rid=""B24-diagnostics-14-02133"" ref-type=""bibr"">24</xref>,<xref rid=""B25-diagnostics-14-02133""",1_23,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"rid=""B25-diagnostics-14-02133"" ref-type=""bibr"">25</xref>,<xref rid=""B26-diagnostics-14-02133"" ref-type=""bibr"">26</xref>]. Amino acid studies are also helpful in distinguishing MDs from pyruvate dehydrogenase deficiency (PDHD), a known cause of LSS in which branched chain amino acids follow plasma alanine levels. According to the Nijmegen mitochondrial disease criteria scoring system, alanine levels above 450 μM are a highly sensitive parameter for MDs [<xref rid=""B27-diagnostics-14-02133""",1_24,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"for MDs [<xref rid=""B27-diagnostics-14-02133"" ref-type=""bibr"">27</xref>,<xref rid=""B28-diagnostics-14-02133"" ref-type=""bibr"">28</xref>]. Organic acidurias are also a known cause of LSS commonly detected through a urinary organic acids profile. Mitochondrial enzyme defects HIBCHD and ECHS1D are well established causes of LSS resulting from an impairment in valine metabolism [<xref rid=""B29-diagnostics-14-02133"" ref-type=""bibr"">29</xref>,<xref rid=""B30-diagnostics-14-02133"" ref-type=""bibr"">30</xref>,<xref",1_25,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"ref-type=""bibr"">30</xref>,<xref rid=""B31-diagnostics-14-02133"" ref-type=""bibr"">31</xref>]. They differ from each other biochemically by urinary and acylcarnitine profile and represent a treatable cause of LSS [<xref rid=""B29-diagnostics-14-02133"" ref-type=""bibr"">29</xref>]. In our experience, 10% of characterized cases (4/40) corresponded to treatable etiologies, with two cases bearing <italic toggle=""yes"">SLC19A3</italic> mutations and two with <italic toggle=""yes"">HIBCH</italic> mutations [<xref",1_26,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"toggle=""yes"">HIBCH</italic> mutations [<xref rid=""B21-diagnostics-14-02133"" ref-type=""bibr"">21</xref>]. An <italic toggle=""yes"">HIBCH</italic> patient presented failure to thrive in early months of life. Urinary organic acids displayed valine pathway metabolites, which led us to first consider ECSH1D, another treatable cause of LSS. However, acylcarnitine profile showed high levels of 3-hydroxyisobutyryl carnitine, which is more frequently seen in HIBCHD [<xref rid=""B29-diagnostics-14-02133""",1_27,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"in HIBCHD [<xref rid=""B29-diagnostics-14-02133"" ref-type=""bibr"">29</xref>]. In this case, two variants were identified in <italic toggle=""yes"">HIBCH</italic>: a definitively pathogenic variant associated with a variant of unknown significance (VUS) according to ACMG criteria [<xref rid=""B32-diagnostics-14-02133"" ref-type=""bibr"">32</xref>]. Based on the distinctive biochemical profile, we proposed the reclassification of the latter variant. From our perspective, basic metabolic studies are mandatory for all",1_28,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"basic metabolic studies are mandatory for all patients, including an L/P ratio [<xref rid=""B33-diagnostics-14-02133"" ref-type=""bibr"">33</xref>], plasma amino acids and acylcarnitine profiles, and urinary organic acids, which achieved up to 80% (40/50) of the diagnostic rate, as shown in <xref rid=""diagnostics-14-02133-f002"" ref-type=""fig"">Figure 2</xref>. The <italic toggle=""yes"">SLC19A3</italic> patient displayed episodic ataxia and regression after intercurrent illness (previously diagnosed with two",1_29,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"illness (previously diagnosed with two encephalitis episodes). Neuroimaging revealed cavitations in the basal ganglia area with brain atrophy, a mandatory differential diagnosis with CI deficiency by NADH:ubiquinone oxidoreductase core subunit S1 (<italic toggle=""yes"">NDUFS1</italic>) and NADH:ubiquinone oxidoreductase core subunit V1 (<italic toggle=""yes"">NDUFV1</italic>) mutations [<xref rid=""B34-diagnostics-14-02133"" ref-type=""bibr"">34</xref>], as biotin responsive basal ganglia disorders (BBGDs) are",1_30,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"responsive basal ganglia disorders (BBGDs) are treatable. <italic toggle=""yes"">SLC19A3</italic> mutations were identified through a targeted nuclear gene panel, allowing personalized treatment with higher doses of thiamine and biotin with full recovery. In non-critically ill patients, a stepwise sequential and targeted approach can be cost-effective. Nevertheless, selected cases require invasive procedures. A deep tissue biopsy can be performed ad initium for specific organ manifestation (e.g., liver",1_31,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"for specific organ manifestation (e.g., liver disease), rapidly progressive symptoms, critically ill patients, and in cases where access to a mitochondrial/rare disorders center is delayed [<xref rid=""B1-diagnostics-14-02133"" ref-type=""bibr"">1</xref>,<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>,<xref rid=""B35-diagnostics-14-02133"" ref-type=""bibr"">35</xref>]. In the remaining cases, tissue studies prove useful for heteroplasmy confirmation or clarifying biochemical and/or genetically unclear",1_32,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"clarifying biochemical and/or genetically unclear results as functional assay proof [<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>,<xref rid=""B35-diagnostics-14-02133"" ref-type=""bibr"">35</xref>,<xref rid=""B36-diagnostics-14-02133"" ref-type=""bibr"">36</xref>]. For biochemical assays, liver, muscle, and cultivated fibroblasts cells are the main sources selected to perform tests related to mitochondrial fusion/fission defects, and OXPHOS deficiency, and mitochondrial respiratory chain enzymatic",1_33,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"and mitochondrial respiratory chain enzymatic activity tests. LSS is a common presentation of primary MDs with high clinical heterogeneity in clinical manifestation [<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>]. Several patients face multidisciplinary evaluations that delay diagnosis and appropriate treatment for years [<xref rid=""B5-diagnostics-14-02133"" ref-type=""bibr"">5</xref>,<xref rid=""B6-diagnostics-14-02133"" ref-type=""bibr"">6</xref>]. This work represents previously recommended",1_34,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"This work represents previously recommended criteria in clinical practice for diagnosing LSS to which we associated our experience accumulated over the years [<xref rid=""B21-diagnostics-14-02133"" ref-type=""bibr"">21</xref>,<xref rid=""B22-diagnostics-14-02133"" ref-type=""bibr"">22</xref>,<xref rid=""B25-diagnostics-14-02133"" ref-type=""bibr"">25</xref>,<xref rid=""B37-diagnostics-14-02133"" ref-type=""bibr"">37</xref>,<xref rid=""B38-diagnostics-14-02133"" ref-type=""bibr"">38</xref>]. Although we acknowledge that our",1_35,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"Although we acknowledge that our cohort of patients was not large, we also believe that the framework presented here facilitates the early diagnosis of treatable conditions. The clinical presentation of LSS includes diverse neurological and radiological features. Since its first description in 1951, several questions related to the underlying causes of the disease remain without a definitive answer. The lack of detailed diagnostic criteria has delayed appropriate interventions and optimal prognosis. The",1_36,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"interventions and optimal prognosis. The incorporation of basic assays can enhance the number of diagnosed cases, as molecular assessment is unevenly accessible across diagnostic centers. As the diagnostic framework improves, we anticipate an adjustment in the pathway towards medical interventions in centers where NGS is not yet widely available to avoid preventable consequences and increase the quality of life of affected individuals. Growth/differentiation factor 15 (GDF-15) and fibroblast growth factor",1_37,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"factor 15 (GDF-15) and fibroblast growth factor 21 (FGF-21) are cytokine stress markers of mitochondrial dysfunction and have gained attention for their potential use in the diagnosis of MDs [<xref rid=""B11-diagnostics-14-02133"" ref-type=""bibr"">11</xref>]. GDF-15 is produced in response to cellular stress, playing essential roles in both regulatory stress and inflammatory response. It was also identified in the hindbrain, where its receptor GFRAL is overtly expressed, although its exact role in MDs remains",1_38,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"expressed, although its exact role in MDs remains elusive [<xref rid=""B66-diagnostics-14-02133"" ref-type=""bibr"">66</xref>]. Most reports claim statistical significance firmly correlating it to mitochondrial translation and deletions defects [<xref rid=""B11-diagnostics-14-02133"" ref-type=""bibr"">11</xref>,<xref rid=""B67-diagnostics-14-02133"" ref-type=""bibr"">67</xref>]. FGF-21 is a hormone-like cytokine linked to mitochondrial myopathies, disease severity, and respiratory chain deficient fibers [<xref",1_39,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"and respiratory chain deficient fibers [<xref rid=""B68-diagnostics-14-02133"" ref-type=""bibr"">68</xref>,<xref rid=""B69-diagnostics-14-02133"" ref-type=""bibr"">69</xref>]. Additionally, in genetically confirmed mitochondrial hepatopathies and translation defects, a stronger correlation is seen with GDF-15 levels rather than FGF-21 levels [<xref rid=""B70-diagnostics-14-02133"" ref-type=""bibr"">70</xref>]. In vanishing white matter neurodegeneration, a non-mitochondrial early degenerative disease, GDF-15 is",1_40,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"early degenerative disease, GDF-15 is markedly elevated in CSF [<xref rid=""B66-diagnostics-14-02133"" ref-type=""bibr"">66</xref>]. These biomarkers are also identified in multiple disorders, such as cardiovascular disorders [<xref rid=""B71-diagnostics-14-02133"" ref-type=""bibr"">71</xref>], type 2 diabetes [<xref rid=""B72-diagnostics-14-02133"" ref-type=""bibr"">72</xref>], and pediatric headaches [<xref rid=""B73-diagnostics-14-02133"" ref-type=""bibr"">73</xref>]. Therefore, a more extensive work-up validation for",1_41,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
a more extensive work-up validation for adoption in routine screening for MDs is required.,1_42,A Comprehensive Approach to the Diagnosis of Leigh Syndrome Spectrum,25 9 2024,,Leigh_Syndrome
"Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome Swallowing, both nutritive and non-nutritive, is highly dysfunctional in children with Leigh Syndrome (LS) and contributes to the need for both gastrostomy and tracheostomy tube placement. Without these interventions aspiration of food, liquid, and mucus occur resulting in repeated bouts of respiratory infection. No study has investigated whether mouse models of LS, a neurometabolic",2_0,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"whether mouse models of LS, a neurometabolic disorder, exhibit dysfunctions in neuromuscular activity of swallow and breathing integration. We used a genetic mouse model of LS in which the NDUFS4 gene is knocked out (KO) specifically in Vglut2 or Gad2 neurons. We found increased variability of the swallow motor pattern, disruption in breathing regeneration post swallow, and water-induced apneas only in Vglut2 KO mice. These physiological changes likely contribute to weight loss and premature death seen in",2_1,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"to weight loss and premature death seen in this mouse model. Following chronic hypoxia (CH) exposure, swallow motor pattern, breathing regeneration, weight, and life expectancy were not changed in the Vglut2-Ndufs4-KO CH mice compared to control, indicating a rescue of phenotypes. These findings show that like patients with LS, Ndufs4 mouse models of LS exhibit swallow impairments as well as swallow-breathing dyscoordination alongside the other phenotypic traits described in previous studies. Understanding",2_2,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"described in previous studies. Understanding this aspect of LS will open roads for the development of future more efficacious therapeutic intervention for this illness. Swallowing serves two physiological functions: passing food to the stomach for nutrition, and pharyngeal clearance for airway protection. Difficulty feeding and swallowing are some of the first symptoms of Leigh Syndrome (LS) (<xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3"" ref-type=""bibr"">3</xref>). LS is the most frequent form of",2_3,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"LS is the most frequent form of pediatric mitochondrial disease, affecting 1 in every 40,000 births (<xref rid=""R4"" ref-type=""bibr"">4</xref>). Clinical manifestations of LS typically appear in childhood, within the first 2 years of life, though adult-onset of the disease has also been reported (<xref rid=""R5"" ref-type=""bibr"">5</xref>–<xref rid=""R9"" ref-type=""bibr"">9</xref>). These manifestations of the disease are marked by symmetrical lesions to the basal ganglia, brainstem, and spinal cord which are",2_4,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"ganglia, brainstem, and spinal cord which are associated with multiple and heterogenous symptoms such as psychomotor regressions, hypotonia, dystonia, seizures, movement disorders, ataxia, feeding and swallowing disorders, respiratory disorders, neuropathy, and myopathy (<xref rid=""R10"" ref-type=""bibr"">10</xref>, <xref rid=""R11"" ref-type=""bibr"">11</xref>). It has been reported that up to 45% of LS patients have some type of feeding and swallowing disorder (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref",2_5,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"(<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R9"" ref-type=""bibr"">9</xref>, <xref rid=""R12"" ref-type=""bibr"">12</xref>) described as “feeding difficulties” (<xref rid=""R10"" ref-type=""bibr"">10</xref>, <xref rid=""R12"" ref-type=""bibr"">12</xref>), “difficulty or inability to suck” (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R3"" ref-type=""bibr"">3</xref>), “dysphagia” (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R6"" ref-type=""bibr"">6</xref>), “decreased pharyngeal reflex” (<xref rid=""R7""",2_6,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"“decreased pharyngeal reflex” (<xref rid=""R7"" ref-type=""bibr"">7</xref>), “swallowing dysfunction” (<xref rid=""R9"" ref-type=""bibr"">9</xref>), and “regurgitation or vomiting during or after feeding” (<xref rid=""R2"" ref-type=""bibr"">2</xref>). These impairments contribute to a high risk of developing respiratory infections (aspiration pneumonia), respiratory failure, a failure to thrive (<xref rid=""R6"" ref-type=""bibr"">6</xref>, <xref rid=""R13"" ref-type=""bibr"">13</xref>), which are all common causes of death in",2_7,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"which are all common causes of death in LS (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R4"" ref-type=""bibr"">4</xref>, <xref rid=""R8"" ref-type=""bibr"">8</xref>, <xref rid=""R9"" ref-type=""bibr"">9</xref>, <xref rid=""R14"" ref-type=""bibr"">14</xref>). The lack of understanding in how mitochondrial dysfunction disrupts swallow-breathing neurocircuitry has resulted in a limited number of therapies designed to combat malnutrition and airway protection. Gastrostomy (G-tube) and tracheostomy placement are",2_8,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"(G-tube) and tracheostomy placement are common procedures used to promote growth by increasing caloric and fluid intake, and to safely clear secretions, respectively (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R5"" ref-type=""bibr"">5</xref>, <xref rid=""R9"" ref-type=""bibr"">9</xref>, <xref rid=""R13"" ref-type=""bibr"">13</xref>, <xref rid=""R15"" ref-type=""bibr"">15</xref>, <xref rid=""R16"" ref-type=""bibr"">16</xref>). Although these procedures have shown positive impacts on growth, nutrition, and respiratory",2_9,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"impacts on growth, nutrition, and respiratory health, they are associated with several complications, including local infection, vomiting and gastroesophageal reflux (<xref rid=""R17"" ref-type=""bibr"">17</xref>). In addition, it is worth noting that these and other therapeutic options to address feeding and swallow difficulties available to date are not curative, their goal is to reduce neurodegeneration, respiratory disturbances, and improve feeding using G-tube (<xref rid=""R5"" ref-type=""bibr"">5</xref>). LS",2_10,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"(<xref rid=""R5"" ref-type=""bibr"">5</xref>). LS is associated with more than 80 genes of the nuclear or mitochondrial genome, making its diagnosis and treatment complicated (<xref rid=""R10"" ref-type=""bibr"">10</xref>). Mutation to the NADH dehydrogenase (ubiquinone reductase) iron-sulfur protein 4 (NDUFS4) gene causes early-onset severe LS that results in early death (<xref rid=""R18"" ref-type=""bibr"">18</xref>). NDUFS4 encodes for the NADH: ubiquinone oxioreductase subunit S4 of mitochondrial complex I, a key",2_11,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"subunit S4 of mitochondrial complex I, a key structural component for the assembly, stability and activity of complex I (<xref rid=""R19"" ref-type=""bibr"">19</xref>). Mice harboring a whole-body homozygous KO of this gene constitute a well validated model of the disease and has been shown to exhibit several key clinical phenotypic traits of LS (<xref rid=""R20"" ref-type=""bibr"">20</xref>). Interestingly, Bolea et al. recently demonstrated that different neuronal cell types drive distinct sets of LS symptoms.",2_12,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"cell types drive distinct sets of LS symptoms. In particular, they showed that excitatory, not inhibitory, neurons drive the development of motor and breathing deficits in the LS Ndufs4 KO mice (<xref rid=""R11"" ref-type=""bibr"">11</xref>). These phenotypes were observed in mice with Ndufs4 KO restricted to Vglut2 neurons (Vglut2-Ndufs4-KO). These Vglut2-Ndufs4-KO mice also exhibited decreased body weight, food intake, and life expectancy (<xref rid=""R11"" ref-type=""bibr"">11</xref>), indicating a possible",2_13,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"ref-type=""bibr"">11</xref>), indicating a possible feeding and swallowing disorder likely leading to failure to thrive. Swallow and breathing are both dependent of motor function and are tightly coordinated to ensure proper gas exchange during breathing and prevent aspiration during swallowing (<xref rid=""R21"" ref-type=""bibr"">21</xref>). However, direct assessments of these functions have yet to be conducted in these LS mice. Here we investigated and described swallow motor activity and its coordination",2_14,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"swallow motor activity and its coordination with breathing in healthy and Vglut2-Ndufs4-KO mice. We hypothesize that an LS-causing mutation of the NDUFS4 gene can disrupt not only normal breathing but also swallow motor activity. These phenotypes may arise from the mutation related mitochondrial and excitability dysfunctions in excitatory neurons of swallow and breathing medullary regions such as the Ventral Respiratory Column (VRC), postinspiratory complex (PiCo), and the nucleus of the solitary tract",2_15,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"(PiCo), and the nucleus of the solitary tract (NTS) (<xref rid=""R22"" ref-type=""bibr"">22</xref>–<xref rid=""R24"" ref-type=""bibr"">24</xref>). Further, we hypothesized that exposure to chronic hypoxia, a therapeutic approach that has proven to protect against oxidative stress and neurodegeneration in LS models (<xref rid=""R25"" ref-type=""bibr"">25</xref>, <xref rid=""R26"" ref-type=""bibr"">26</xref>), will prevent swallow and breathing abnormalities, rescue body weight and life span in Vglut2-Ndufs4-KO mice.  All",2_16,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"and life span in Vglut2-Ndufs4-KO mice.  All electroneurogram (ENG) and EMG activity were amplified and band-pass filtered (0.03 – 1 KHz) by a differential AC Amplifier (A-M System model 1700, Sequim, WA, USA), acquired in an A/D converter (CED 1401; Cambridge Electronic Design, Cambridge, UK) and stored using Spike2 software (Cambridge Electronic Design, Cambridge, UK). Using the Spike2 software, data was further processed using a band pass filtered (200–700Hz, 40Hz transition gap) then rectified and",2_17,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"40Hz transition gap) then rectified and smoothed (20ms). Using the Spike2 software, the ECGdelete 02.s2s script is used to remove heart artifact, when present, from the ENG and EMG recordings. We evaluated swallows that were trigged by injection of water into the oral cavity. <italic toggle=""yes"">Total swallow duration</italic> was determined by the onset of the submental complex to the termination of the laryngeal complex EMG activity. <italic toggle=""yes"">Submental complex (SC)</italic> was determined by",2_18,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"complex (SC)</italic> was determined by the onset to the termination of the submental complex EMG activity. <italic toggle=""yes"">Laryngeal complex (LC)</italic> was determined by the onset to the termination of the laryngeal complex EMG activity. <italic toggle=""yes"">Swallow sequence</italic> was calculated as the time difference between the peak activation of the laryngeal and submental complex EMG activity. <italic toggle=""yes"">Schluckatmung</italic> duration was determined by the onset to the",2_19,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"duration was determined by the onset to the termination of the diaphragm EMG activity during a swallow. <italic toggle=""yes"">Diaphragm inter-burst interval (IBI)</italic> was calculated as the offset of the diaphragm EMG activity to the onset of the subsequent breath. <italic toggle=""yes"">Inspiratory delay</italic> was calculated as the offset of the swallow-related laryngeal complex EMG activity to the onset of the subsequent breath. Duration and amplitude of each nerve and muscle was determined by the",2_20,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"of each nerve and muscle was determined by the onset to the termination of that respective nerve/muscle activity during swallow. All durations are reported in milliseconds (ms) unless otherwise stated. Line graphs of swallow frequency in relation to inspiration were created by the phase of breathing in which swallow occurred in, calculated as the onset of inspiration to the onset of swallow divided by the respiratory cycle duration and plotted against the number of swallows that occurred within the 1/10",2_21,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"number of swallows that occurred within the 1/10 binned respiratory phase, (<italic toggle=""yes"">swallow onset: insp onset)</italic>. Swallow was also plotted in relation to the peak activation of the diaphragm as a duration with zero equaling the peak of the inspiratory related diaphragm activity, (<italic toggle=""yes"">swallow onset: insp peak)</italic>. All data are expressed as mean ± standard deviation (SD), unless otherwise noted. Statistical analyses were performed using GraphPad Prism 10 (GraphPad",2_22,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"were performed using GraphPad Prism 10 (GraphPad Software<sup>®</sup>, Inc. La Jolla, USA). Differences were considered significant at <italic toggle=""yes"">p</italic> ≤ 0.05. Investigators were not blinded during analysis. Sample sizes were chosen on the basis of previous studies. Upon completion of experiments, animals underwent deep anesthesia using 4% isoflurane in 100% oxygen and were subsequently perfused via the ascending aorta with 20 ml of phosphate buffered saline (PBS; pH 7.4), followed by 20 ml",2_23,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"buffered saline (PBS; pH 7.4), followed by 20 ml of 4% phosphate-buffered paraformaldehyde (0.1 M; pH 7.4), obtained from Electron Microscopy Sciences, Fort Washington, PA. The brains were then extracted and immersed in the perfusion fixative for 4 hours at 4 °C, followed by an additional 8 hours in 20% sucrose solution. Coronal brain sections (25 μm) were obtained using a cryostat and stored in a cryoprotectant solution at −20°C (consisting of 20% glycerol and 30% ethylene glycol in 50 ml phosphate",2_24,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"and 30% ethylene glycol in 50 ml phosphate buffer, pH 7.4) prior to histological processing. All histochemical procedures were conducted on free-floating sections. IBA-1 was identified using a rabbit anti-IBA-1 antibody (19-19741; Fujifilm Wako Chemicals USA Corp) at a dilution of 1:1000. The antibody was diluted in phosphate buffer (PB) containing 2% normal donkey serum (017-000-121, Jackson ImmunoResearch Laboratories) and 0.3% Triton X-100, and incubated for 24 hours. Following multiple rinses, the",2_25,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"for 24 hours. Following multiple rinses, the sections were incubated with donkey anti-rabbit Alexa 594 (711-585-152, Jackson ImmunoResearch Laboratories) at a dilution of 1:400 in PB for 4 hours at room temperature. After further rinsing in PB, the sections were mounted sequentially in rostrocaudal order onto gelatin-coated slides and cover-slipped with DPX mounting medium (06522; Sigma Aldrich) for histological examination. For cell counting, imaging, and data analysis, a VS120-S6-W Virtual Slide Scanner",2_26,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"data analysis, a VS120-S6-W Virtual Slide Scanner (Olympus) was utilized to scan all sections, with images captured using a Nikon DS-Fi3 color camera. To mitigate potential biases, photomicrography and counting were performed by an anatomist blinded to the experimental conditions. Cell counting was conducted using Image J (version 1.41; National Institutes of Health, Bethesda, MD), while line drawings were created using Canvas software (ACD Systems, Victoria, Canada, v. 9.0). Brain sections were analyzed",2_27,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"Canada, v. 9.0). Brain sections were analyzed in a one-in-two series of 25-μm sections per mouse, spaced 50 μm apart. The analyzed area was delineated based on previous reports (Anderson et al., 2016). Counts were performed bilaterally, averaged, and reported as mean ± standard deviation (SD). Section alignment was referenced to a standard section, as previously described (Anderson et al., 2016), and based on Paxinos and Franklin (Paxinos & Franklin, 2019). Image J software (W.S. Rasband/National",2_28,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"2019). Image J software (W.S. Rasband/National Institutes of Health, USA, <ext-link http://www.w3.org/1999/xlink href=""http://rsb.info.nih.gov/ij"" ext-link-type=""uri"">http://rsb.info.nih.gov/ij</ext-link>) was also utilized for morphological analysis (fractal and skeleton) of microglia labeled in 40x magnification photomicrographs. The total number of IBA-1 labeled microglia was counted using a cell counter plugin in 4 photomicrographs per analyzed region (VRC, PiCo and NTS). For morphological analysis,",2_29,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"(VRC, PiCo and NTS). For morphological analysis, binary photomicrographs were first converted into skeletonized images using the Analyze Skeleton Plugin to quantify the number of endpoints and the size of each cell branch (process length). All collected data were normalized by the total number of cells in each slice. Additionally, 6 cells in binary images were chosen per animal using a rectangle tool (width: 215 μm; height: 175 μm). These isolated cells were converted into outline cells and analyzed using",2_30,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"converted into outline cells and analyzed using the FracLac plugin. This plugin calculates various parameters including fractal dimension (regression slope (In(N)/In(Ɛ)), where N is the number of pixels and Ɛ is a particular scale), cell density (number of pixels within cell outline/ area of convex hull), span ratio (convex hull eclipse longest length/convex hull eclipse longest width), lacunarity (variation in pixel density), and circularity (circularity of the convex hull (4π×area⁄perimeter<sup>2</sup>,",2_31,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"the convex hull (4π×area⁄perimeter<sup>2</sup>, for a circle it is 1). Fractal dimension reflects cell complexity, lacunarity indicates cell heterogeneity, density corresponds to cell size, span ratio reflects cell elongation, and circularity indicates cell circularity (Forsberg et al., 2017; Lima-Silveira et al., 2019; Morrison et al., 2017). The data are reported as the mean ± standard deviation. Statistical analysis was performed using GraphPad Prism10. An ordinary one-way ANOVA followed by Tukey’s",2_32,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"An ordinary one-way ANOVA followed by Tukey’s multiple comparisons test was used.  Dysphagia and breathing disturbances are typical for children with Leigh syndrome. Management of dysphagia is important in preventing airway obstruction, aspiration, malnutrition, and dehydration leading to weight loss, failure to thrive, aspiration pneumonia, and contribute to spontaneous death (<xref rid=""R31"" ref-type=""bibr"">31</xref>). Mutations to the NDUFS4 gene cause severe and early-onset LS (<xref rid=""R18""",2_33,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"cause severe and early-onset LS (<xref rid=""R18"" ref-type=""bibr"">18</xref>). Here we have described alterations in swallow and breathing activity in Vglut2cre-Ndufs4-KO mice, but not the Gadcre-Ndufs4-KO mice. Homozygous KO of NDUFS4 in glutamatergic neurons resulted in increased variability to the swallow motor pattern, disrupted breathing regeneration, and water-induced apneas. All of which likely contribute to weight loss and premature death seen in this mouse model. Exposure to chronic hypoxia",2_34,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
in this mouse model. Exposure to chronic hypoxia prevented alterations to swallow and breathing physiology which resulted in weight maintenance and life expectancy.,2_35,Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome,15 9 2024,,Leigh_Syndrome
"Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity 
<boxed-text position=""float""><p>
<bold>Elevated Susceptibility to Exogenous Seizure Triggers and Impaired Interneuron Excitability in a Mouse Model of Leigh Syndrome Epilepsy</bold>",3_0,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</p><p>Manning A, Han V, Stephens A, Wang R, Bush N, Bard M, Ramirez JM, and Kalume F. <italic toggle=""yes"">Neurobiol Dis</italic>. 2023;187:106288</p><p>Mutations in the nicotinamide adenine dinucleotide dehydrogenase (ubiquinone reductase) iron-sulfur protein 4 (<italic toggle=""yes"">NDUFS4</italic>) gene, which encodes for a key structural subunit of the OXFOS complex I, lead to the most common form of mitochondrial disease in children known as Leigh syndrome (LS). As in other mitochondrial diseases,",3_1,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"(LS). As in other mitochondrial diseases, epileptic seizures constitute one of the most significant clinical features of LS. These seizures are often very difficult to treat and are a sign of poor disease prognosis. Mice with whole-body <italic toggle=""yes"">Ndufs4</italic> KO are a well-validated model of LS; they exhibit epilepsy and several other clinical features of LS. We have previously shown that mice with <italic toggle=""yes"">Ndufs4</italic> KO in only GABAergic interneurons (Gad2-<italic",3_2,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"KO in only GABAergic interneurons (Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO) reproduce the severe epilepsy phenotype observed in the global KO mice. This observation indicated that these mice represent an excellent model of LS epilepsy isolated from other clinical manifestations of the disease. To further characterize this epilepsy phenotype, we investigated seizure susceptibility to selected exogenous seizure triggers in Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. Then, using electrophysiology,",3_3,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"mice. Then, using electrophysiology, imaging, and immunohistochemistry, we studied the cellular, physiological, and neuroanatomical consequences of <italic toggle=""yes"">Ndufs4</italic> KO in GABAergic interneurons. Homozygous KO of <italic toggle=""yes"">Ndufs4</italic> in GABAergic interneurons leads to a prominent susceptibility to exogenous seizure triggers, impaired interneuron excitability, and interneuron loss. Finally, we found that the hippocampus and cortex participate in the generation of seizure",3_4,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"cortex participate in the generation of seizure activity in Gad2- <italic toggle=""yes"">Ndufs4</italic>-KO mice. These findings further define the LS epilepsy phenotype and provide important insights into the cellular mechanisms underlying epilepsy in LS and other mitochondrial diseases.</p></boxed-text>",3_5,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"Leigh syndrome (LS) is one of the most common forms of mitochondrial disease in children.<sup>
<xref rid=""bibr1-15357597241257031"" ref-type=""bibr"">1</xref>",3_6,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> LS is due to one of several mutations in genes involved in mitochondrial function, especially Complex I of the oxidative phosphorylation component of the respiratory chain. One particular gene found to be involved in patients with LS is <italic toggle=""yes"">Ndusf4</italic>, which encodes a subunit of Complex I that provides structural stability to the complex.<sup>
<xref rid=""bibr2-15357597241257031"" ref-type=""bibr"">2</xref>",3_7,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> Mitochondrial diseases including LS commonly feature seizures that are often the first sign of disease and are particularly difficult to control with medications. These diseases and their related animal models, also feature many other phenotypes that confound study of the seizures and epilepsy. Patients who have intractable seizures are at a high risk of dying from sudden unexpected death in epilepsy (SUDEP).<sup>
<xref rid=""bibr3-15357597241257031"" ref-type=""bibr"">3</xref>",3_8,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> LS can be associated with early, sudden, and unexpected death.<sup>
<xref rid=""bibr4-15357597241257031"" ref-type=""bibr"">4</xref>
</sup> Manning et al<sup>
<xref rid=""bibr5-15357597241257031"" ref-type=""bibr"">5</xref>",3_9,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> set out to characterize cellular, physiological, and neuroanatomical changes in a mouse model of LS that they developed in which the <italic toggle=""yes"">Ndusf4</italic> gene is knocked out only inhibitory neurons (Gad2-Ndufs4-KO; Gad2 mutant). This mouse prominently features increased susceptibility to seizures as well as spontaneous seizures, but does not manifest most other disease-associated abnormalities, making it a nice model in which to examine mechanisms for the seizures independent of the",3_10,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"mechanisms for the seizures independent of the other signs and symptoms. Notably, they previously determined that these mice had an increased death rate that they believe was associated with seizures and suggestive of SUDEP events.<sup>",3_11,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"<xref rid=""bibr6-15357597241257031"" ref-type=""bibr"">6</xref>
</sup> In this study,<sup>
<xref rid=""bibr5-15357597241257031"" ref-type=""bibr"">5</xref>",3_12,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> to determine whether these mice had increased seizure susceptibility they employed two experimental models. First, they challenged animals with an ordinarily sub-convulsive dose of the chemo-convulsant, pentylenetetrazol (PTZ). They found that this lower dose of PTZ was sufficient to induce generalized convulsive seizures in the Gad2 mutant, but only induced lesser myoclonic seizures in wildtype mice. Second, they exposed the animals to moderate exercise to create a metabolic challenge. This was",3_13,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"to create a metabolic challenge. This was sufficient to induce seizures in the Gad2 mutant mice, but not in wildtypes. This is a somewhat unusual seizure-induction method. While exercised-induced seizures are rare in patients,<sup>",3_14,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"<xref rid=""bibr7-15357597241257031"" ref-type=""bibr"">7</xref>
</sup> exercise does cause measurable changes in electroencephalogram that could be conducive to seizures.<sup>
<xref rid=""bibr8-15357597241257031"" ref-type=""bibr"">8</xref>",3_15,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> Since the mutation was only expressed in GABAergic neurons, they examined whether it had any effect on GABAergic neuron function. For this, they performed whole-cell current clamp recordings from CA1 hippocampal interneurons and found that ∼60% of the studied neurons had a biphasic response with increased firing following lower depolarization currents and reduced action potential firing ranging up to abject failure to produce action potentials at higher depolarization current injections. These",3_16,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"higher depolarization current injections. These neurons also displayed impaired action potential dynamics as evidenced by reduced capacitance, reduced rheobase, reduced action potential height, increased action potential width, increased input resistance, and increased afterhyperpolarization. These changes are generally consistent with a hypoactivity phenotype. The other ∼40% of neurons did not demonstrate an appreciable reduction in firing rate and showed lesser changes in action potential dynamics",3_17,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"lesser changes in action potential dynamics compared to neurons from control mice. To determine whether the mutation affected the interneuron number, they performed immunohistochemistry on the brains of mutants. They found a reduction in GABAergic neurons in the caudal portion of the hippocampal CA1 region and the central and posteromedial cortical amygdala nuclei. No cell loss was noted in the dentate gyrus, rostral CA1, or CA2/CA3. Finally, to determine which areas were activated in response to seizures,",3_18,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"areas were activated in response to seizures, they euthanized a subset of animals shortly after thermally—induced seizures and measured immunoreactivity of the immediate early gene, <italic toggle=""yes"">cFos</italic>. With this method, they identified increased activity in the dentate gyrus of the hippocampus and frontal cortex. Epilepsies are generally due to excitation–inhibition imbalance with either excessive excitation or insufficient inhibition; with the latter often leading to the former. Here they",3_19,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"the latter often leading to the former. Here they identify a specific role of the <italic toggle=""yes"">Ndufs4</italic> mutation in reducing excitability in inhibitory interneurons. It will be important to identify which interneuron subtype (eg, somatostatin, parvalbumin, etc) is primarily involved as interneuron types are not uniformly affected by mitochondrial abnormalities. It is intriguing that they found two different populations of interneurons, one demonstrating impaired firing due to the <italic",3_20,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"demonstrating impaired firing due to the <italic toggle=""yes"">Ndufs4</italic> mutation and one that was relatively intact. It will be interesting to understand more rigorously what specific single-cellular mechanisms may be at play to orchestrate the differences in phenotypes. Single nuclear RNA sequencing might be a good way to examine this. They chose to probe for increased seizure susceptibility using PTZ, a GABAergic antagonist. Given that these mice already harbored the mutation in GABAergic neurons",3_21,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"harbored the mutation in GABAergic neurons and demonstrated impaired GABAergic neuron function, they considered this model a “second hit” leading to heightened excitability and seizure proclivity. This is comparable to the human phenotype in which seizures are provoked by some additional extrinsic stimulus such as increased metabolic demand. The authors postulated that the concept of seizures also increasing metabolic demand may explain why neuronal activity is more affected in older animals who have",3_22,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"is more affected in older animals who have experienced more lifetime seizures and cumulative metabolic derangement. This study employed a relatively crude means to identify brain regions activated by seizures; however, this is a reasonable way to screen for affected areas. Perhaps it would be beneficial to follow up with a technique such as fiber photometry to assess calcium activity or multi-unit electrophysiology to verify increased activity in these regions and perhaps determine which specific cells are",3_23,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"and perhaps determine which specific cells are involved. Coupling these methods with a technique to express calcium indicators or opsins only in activated cells, such as targeted recombination in active populations would be a powerful way to examine activated circuits.<sup>",3_24,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"<xref rid=""bibr9-15357597241257031"" ref-type=""bibr"">9</xref>
</sup> Mitochondria are energetic powerhouses, presenting innumerable potential nodes at which to alter cellular energetics and by extrapolation, excitability. It follows that mitochondrial dysfunction is at the heart of a wide range of neurological diseases.<sup>
<xref rid=""bibr10-15357597241257031"" ref-type=""bibr"">10</xref>",3_25,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> Despite this, mitochondrial signaling is relatively unexplored in the development of anti-seizure medications. When patients are refractory to medications, several alternative therapies are considered including surgical management, device implantation (eg, vagal, deep brain/thalamic, or responsive neural stimulators), or dietary therapies. A mainstay of dietary therapies is the ketogenic diet.<sup>
<xref rid=""bibr11-15357597241257031"" ref-type=""bibr"">11</xref>",3_26,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"</sup> The ketogenic diet exerts its action at least in part through altering mitochondrial energetics. Many studies have been undertaken to try to identify potentially druggable targets to produce a pharmacological ketogenic diet of sorts. The mutation examined in this study may represent such a druggable target. It will be interesting to see whether these findings could be translatable to other mitochondrial disorders. Could manipulating <italic toggle=""yes"">Ndufs4</italic> such that its function was",3_27,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"such that its function was enhanced in other mitochondrial disorders correct various phenotypes, especially seizures, in these other diseases? Similarly, could this be generalizable to other intractable epilepsies? Novel avenues for drug development are desperately needed for the millions of patients worldwide with intractable epilepsy.<sup>",3_28,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"<xref rid=""bibr12-15357597241257031"" ref-type=""bibr"">12</xref>
</sup>",3_29,Leigh has no Brakes: Impaired Inhibition in a Mouse Model of Leigh Syndrome Leads to Enhanced Seizure Sensitivity,12 6 2024,,Leigh_Syndrome
"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency Leigh syndrome (LS), also referred to as subacute necrotizing encephalopathy, is the most prevalent mitochondrial disease in childhood and is caused by mutations in both mitochondrial and nuclear genes [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. LS was first reported by Denis Archibald Leigh in 1951 [<xref ref-type=""bibr"" rid=""CR2"">2</xref>], with an estimated prevalence of 1:40,000",4_0,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"with an estimated prevalence of 1:40,000 [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Although the incidence rate of LS is low, the clinical symptoms deteriorated rapidly and likely leading to death in infancy [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. LS is defined by the degeneration of the central nervous system, including the brain, spinal cord, and optic nerve, which is manifested by the loss of motor skills, appetite, vomiting, irritability, and/or seizures,",4_1,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"vomiting, irritability, and/or seizures, as well as overall weakness, reduced muscle tone, and lactic acidosis, resulting in cardiac, hepatic, gastrointestinal and renal tubular dysfunction [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Currently, more than 100 pathogenic genes have been reported to be associated with LS [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. LS is strongly associated with the oxidative phosphorylation system (OXPHOS) [<xref ref-type=""bibr"" rid=""CR7"">7</xref>], and 80% of LS patients",4_2,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"rid=""CR7"">7</xref>], and 80% of LS patients exhibit deficiencies of OXPHOS complexes [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. While defects in each of the five OXPHOS complexes have been detected in LS patients, complex I deficiency is the most prevalent, with nearly a third of the LS causative genes linked to complex I deficiency [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Isolated complex IV deficiency and multiple OXPHOS defects are commonly as well [<xref",4_3,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"OXPHOS defects are commonly as well [<xref ref-type=""bibr"" rid=""CR11"">11</xref>], providing evidence of biochemical defects to support a clinical diagnosis of LS. <italic toggle=""yes"">IARS2</italic> encodes a mitochondrial isoleucyl-tRNA synthetase, which is a class I mitochondrial aminoacyl-tRNA synthetase (ARS) [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. There are 37 members of the ARS family, which are associated with cytoplasmic or mitochondrial translation [<xref ref-type=""bibr""",4_4,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"mitochondrial translation [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Mutations in genes encoding ARSs can produce highly diverse clinical phenotypes that affect tissues with particularly high metabolic needs [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. As a nuclear-encoded mitochondrial protein, IARS2 needs to be imported from the cytoplasm into the mitochondria, and catalyzes the attachment of an isoleucine residue to a cognate mt-tRNA<sup>Ile</sup> [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. The",4_5,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"[<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. The patients with <italic toggle=""yes"">IARS2</italic> variants present broad clinical phenotypes including LS, West syndrome and CAGSSS syndrome (cataract, growth hormone deficiency, sensory neuropathy, sensorineural deafness-skeletal dysplasia syndrome) [<xref ref-type=""bibr"" rid=""CR14"">14</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. To date, 28 cases with <italic toggle=""yes"">IARS2</italic> mutations have been reported worldwide and 25 variants have",4_6,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"have been reported worldwide and 25 variants have been discovered [<xref ref-type=""bibr"" rid=""CR19"">19</xref>], 14 of them have shown LS characteristic features [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. However, the pathogenesis and molecular mechanism of the <italic toggle=""yes"">IARS2</italic> variants still unclear. In this study, we reported two unrelated patients with",4_7,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"study, we reported two unrelated patients with LS harboring compound heterozygous <italic toggle=""yes"">IARS2</italic> variants (c.1_390del and c.2450G > A from a 4-year-old boy, and c.2090G > A and c.2122G > A from a 5-year-old boy) by next-generation sequencing. We applied patient-derived immortalized lymphocytes and <italic toggle=""yes"">IARS2</italic>-knockdown HEK293T cells to explore the pathogenesis of the variants.   In this study, we identified four heterozygous variants of <italic",4_8,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"identified four heterozygous variants of <italic toggle=""yes"">IARS2</italic> (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A) from two unrelated Chinese patients of LS, of which c.1_390del and c.2090G > A were novel. Functional studies showed these <italic toggle=""yes"">IARS2</italic> variants could result in IARS2 deficiency, which in turn led to mitochondrial dysfunction due to a combined deficiency of complexes I and III. Our study revealed that <italic toggle=""yes"">IARS2</italic> was essential",4_9,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"<italic toggle=""yes"">IARS2</italic> was essential for mitochondrial OXPHOS function, particularly in the maintenance of OXPHOS complexes I and III. To the best of our knowledge, this is the first report to elucidate the pathogenesis of <italic toggle=""yes"">IARS2</italic> variants. Although exons account for less than 2% of the human genome, they contain over 85% of known pathogenic mutations. WES is currently the most widely used DNA sequencing technology in clinical practice due to its cost-effectiveness",4_10,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"clinical practice due to its cost-effectiveness and high sequencing depth. However, WES focuses solely on the protein-coding regions, including exons and adjacent intron/exon boundaries, and is unable to detect large fragment indels. In contrast, WGS analyzes the entire genome, encompassing nearly all exon sequences of genes, as well as intron sequences, intergenic regions, and can simultaneously detect mtDNA variations. Moreover, it can identify genomic structural variations such as large fragment",4_11,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"structural variations such as large fragment deletions, copy number variations, and other gene structural alterations. If WES and mitochondrial genome sequencing fail to detect potential pathogenic gene mutations, WGS can be utilized for reassessment to uncover possible pathogenic gene mutations. In this study, we reported two unrelated children with LS. For patient 1, compound heterozygous <italic toggle=""yes"">IARS2</italic> variants (c.2090G > A and c.2122G > A) were identified by WES, and no clinically",4_12,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"were identified by WES, and no clinically significant mitochondrial genomic-related variants were observed. For patient 2, after filtering with established criteria, WES and mitochondrial genomic sequencing did not detect potential disease-causing gene mutations. Subsequently, whole genome sequencing (WGS) was performed, revealing compound heterozygous <italic toggle=""yes"">IARS2</italic> variants, a deletion variant spanning 1 and 2 exons (c.1_390del), and a site variant c.2450G > A. This demonstrates that",4_13,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"site variant c.2450G > A. This demonstrates that WGS has further improved the efficiency of disease diagnosis. Three patients with <italic toggle=""yes"">IARS2</italic> variants of CAGSSS syndrome were first reported in 2014 [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. To date, 28 cases with <italic toggle=""yes"">IARS2</italic> variants from 10 different countries have been reported. Among these cases, 13 patients exhibited short stature, 4 had hypoparathyroidism, 19 had elevated lactate levels in the blood",4_14,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"19 had elevated lactate levels in the blood or cerebrospinal fluid, 6 patients had sideroblastic anemia, 5 patients had heart problems, and 14 patients had abnormalities on their brain MRI [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>]. According to the clinical phenotype, 12 were diagnosed with LS, 7 were diagnosed with CAGSSS, 4 were",4_15,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"with LS, 7 were diagnosed with CAGSSS, 4 were diagnosed with West syndrome, 2 showed both LS and CAGSSS features, 6 were diagnosed with sideroblastic anemia, and 1 was diagnosed with Wolff-Parkinson-White syndrome [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>]. It seems that LS and CAGSSS are more common in patients with <italic",4_16,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"CAGSSS are more common in patients with <italic toggle=""yes"">IARS2</italic> gene variants. To date, there are 25 reported disease-linked variants have been described in <italic toggle=""yes"">IARS2</italic> gene. Of these, only the <italic toggle=""yes"">IARS2</italic> c.2726 C > T (GenBank Reference: NM_018060.3) and c.2725 C > T (GenBank Reference: NM_018060.3) variants in <italic toggle=""yes"">IARS2</italic> were functionally tested. IARS2 protein level were decreased in patient-derived fibroblasts with",4_17,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"decreased in patient-derived fibroblasts with c.2726 C > T variant compared with control cells, but there was no significant difference in the contents of OXPHOS complexes between patient and control fibroblasts [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. However, IARS2 protein level and OXPHOS complexes levels did not change in the patient‐derived fibroblasts with c.2725 C > T variant compared with control cells [<xref ref-type=""bibr"" rid=""CR34"">34</xref>]. In this study, we reported two unrelated",4_18,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"In this study, we reported two unrelated patients who presented with LS and had biallelic variants (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A) in <italic toggle=""yes"">IARS2</italic>. Among these variants, the variants c.2122G > A and c.2450G > A were previously reported in a patient diagnosed with LS and in a family with two Japanese siblings who exhibited milder symptoms of CAGSSS and West syndrome alongside LS, respectively. However, functional tests had not been conducted in previous",4_19,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"tests had not been conducted in previous studies [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Here, our study revealed that the patient-derived lymphocytes carrying c.1_390del and c.2450G > A variants exhibited decreased IARS2 protein level and impaired mitochondrial function due to the deficiency of OXPHOS complexes I and III contents. We further knockdown <italic toggle=""yes"">IARS2</italic> and found that <italic toggle=""yes"">IARS2</italic> deficiency could",4_20,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"toggle=""yes"">IARS2</italic> deficiency could cause decreased complexes I and III contents, impaired basal respiration and ATP-linked respiration and reduced cellular ATP production, suggesting that <italic toggle=""yes"">IARS2</italic> deficiency led to mitochondrial dysfunction. To verify the pathogenicity of these <italic toggle=""yes"">IARS2</italic> variants, we re-expressed wild‐type <italic toggle=""yes"">IARS2</italic> and mutant <italic toggle=""yes"">IARS2</italic> with c.2450G > A, c.2122G > A or",4_21,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"with c.2450G > A, c.2122G > A or c.2090G > A variants in cells with <italic toggle=""yes"">IARS2</italic> knockdown, respectively. The results showed that IARS2 protein levels were damaged with mutant <italic toggle=""yes"">IARS2</italic>, and contents of OXPHOS complex I and III, basal respiration, ATP-linked respiration and cellular ATP production were also impaired. These data suggested that these <italic toggle=""yes"">IARS2</italic> variants were pathogenic and could cause mitochondrial dysfunction due to",4_22,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"and could cause mitochondrial dysfunction due to the decreased contents of mitochondrial OXPHOS complexes I and III. In summary, we report two unrelated Chinese patients who manifested with LS carrying biallelic <italic toggle=""yes"">IARS2</italic> variants (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A), and reveal that <italic toggle=""yes"">IARS2</italic> deficiency cause combined complexes I and III deficiencies and mitochondrial dysfunction. Our study further expands the gene mutation spectrum",4_23,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"study further expands the gene mutation spectrum of LS, and uncovers that <italic toggle=""yes"">IARS2</italic> is indispensable for the maintenance of mitochondrial complexes I and III, which provides the pathogenic mechanism and functional evidence of <italic toggle=""yes"">IARS2</italic> as a gene causing mitochondrial diseases and contributes to the clinical diagnosis of <italic toggle=""yes"">IARS2</italic> mutation-related diseases.",4_24,"<italic toggle=""yes"">IARS2</italic> mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency",21 8 2024,,Leigh_Syndrome
"Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome Leigh Syndrome is a rare genetic condition characterized by progressive neuromuscular defects. This disorder is highly heterogeneous, due in part to the fact that it can be caused by alterations in at least 75 different genes. All of these genetic alterations lead to mitochondrial dysfunction including reduced or eliminated capacity for oxidative phosphorylation [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Notably, loss of",5_0,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"rid=""CR1"">1</xref>]. Notably, loss of function in one of these genes, <italic toggle=""yes"">COX10</italic>, leads to a severe form of Leigh Syndrome that is typically fatal in the first year of life (Table <xref rid=""Tab1"" ref-type=""table"">1</xref>). Two patients have been reported to survive longer, albeit with significant pathology [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The Cox10 protein is highly conserved in the budding yeast <italic",5_1,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"is highly conserved in the budding yeast <italic toggle=""yes"">Saccharomyces cerevisiae</italic>; indeed, expression of the human <italic toggle=""yes"">COX10</italic> gene in yeast can fully restore function in a strain missing its endogenous <italic toggle=""yes"">COX10</italic> gene [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. The Cox10 enzyme is located on the mitochondrial inner membrane and catalyzes the farnesylation of heme [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. This modified heme group is",5_2,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"rid=""CR5"">5</xref>]. This modified heme group is incorporated as an essential prosthetic group into the cytochrome c oxidase (COX) enzyme, which catalyzes the transfer of electrons from cytochrome c to molecular oxygen. Eleven different point mutations in the human <italic toggle=""yes"">COX10</italic> gene have been described in the literature as leading to disease in humans (Table <xref rid=""Tab1"" ref-type=""table"">1</xref>). Of course, there are many more alleles in the human population and for the",5_3,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"more alleles in the human population and for the majority of these we have no direct evidence as to whether or not they encode functional proteins. As of June 17, 2024, the ClinVar database lists 102 known variants of the Cox10 protein, of which nearly three-quarters are of “uncertain significance”. We have selected 25 <italic toggle=""yes"">COX10</italic> alleles for characterization in yeast. This additional knowledge should be useful to clinicians and genetic counselors faced with patients carrying these",5_4,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
counselors faced with patients carrying these variants.,5_5,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Known pathological variants of human COX10</p></caption><table frame=""hsides"" rules=""groups""><tbody><tr><td align=""left"">M1X</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR6"">6</xref>]</td></tr><tr><td align=""left"">T14I/T377I</td><td align=""left"">Pathogenic</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR3"">3</xref>]</td></tr><tr><td align=""left"">T196K/P225L</td><td align=""left"">Lethal</td><td align=""left"">[<xref",5_6,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR7"">7</xref>]</td></tr><tr><td align=""left"">N204K</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR8"">8</xref>]</td></tr><tr><td align=""left"">N204D</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR9"">9</xref>]</td></tr><tr><td align=""left"">G288R</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR10"">10</xref>]</td></tr><tr><td",5_7,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"rid=""CR10"">10</xref>]</td></tr><tr><td align=""left"">D336V/D336G</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR7"">7</xref>]</td></tr><tr><td align=""left"">D336V/R339W</td><td align=""left"">Pathogenic</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR2"">2</xref>]</td></tr><tr><td align=""left"">P420L</td><td align=""left"">Lethal</td><td align=""left"">[<xref ref-type=""bibr"" rid=""CR3"">3</xref>]</td></tr></tbody></table></table-wrap>",5_8,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"We selected 25 human <italic toggle=""yes"">COX10</italic> alleles whose functions are not clearly understood and expressed them in yeast lacking the endogenous <italic toggle=""yes"">COX10</italic> to determine how functional the encoded proteins are. This species grows efficiently by anaerobic metabolism and therefore can survive without functional Cox10 protein when provided with a fermentable carbon source like glucose (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>A, left column). However, carbon sources",5_9,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"left column). However, carbon sources like glycerol can only be utilized aerobically and thus require a functional Cox10 enzyme. On this fuel source, cells lacking Cox10 do not survive but they thrive if they contain either the yeast or human reference sequence <italic toggle=""yes"">COX10</italic>. Strains with certain <italic toggle=""yes"">COX10</italic> alleles, such as S103A or V356M, survive equally as well as those with the reference sequence <italic toggle=""yes"">COX10</italic>. Other strains, such as",5_10,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"Other strains, such as those with I127T or Q322P, fail to grow when cultured on glycerol (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>A, right column), indicating that these protein variants are nonfunctional.",5_11,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"<fig id=""Fig1""><label>Fig. 1</label><caption><p>Activity of human <italic toggle=""yes"">COX10</italic> variants. (<bold>A</bold>) Ten-fold serial dilutions of yeast cells carrying the indicated <italic toggle=""yes"">COX10</italic> variant or an empty vector were plated on rich media with either glucose or glycerol as the carbon source. (<bold>B</bold>) The same strains were lysed and COX activity was measured. The resulting specific activities were normalized to the sample containing the human <italic",5_12,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"to the sample containing the human <italic toggle=""yes"">COX10</italic> reference sequence. Error bars show one standard deviation</p></caption><graphic http://www.w3.org/1999/xlink href=""13104_2024_6879_Fig1_HTML"" id=""d33e490""></graphic></fig>",5_13,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"We also directly measured the COX activity in each of these yeast strains. We found that the yeast <italic toggle=""yes"">COX10</italic> supports slightly more COX activity than the human reference sequence <italic toggle=""yes"">COX10</italic>, in agreement with a previously published observation [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Yeast strains with certain human <italic toggle=""yes"">COX10</italic> alleles show activities that are close to that provided by the reference sequence while others show",5_14,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"by the reference sequence while others show very low activities (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>B). Unsurprisingly, there is a strong, general correlation between the COX activity measurements and the ability to grow on glycerol. It appears that Cox10 variants that allow approximately 50% of the reference sequence COX activity (see variants S103A, P104L and A328T) grow very efficiently on glycerol and those that allow less than 25% of the reference sequence COX activity (such as I127T and",5_15,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"sequence COX activity (such as I127T and D132Y) fail to grow at all (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>). Among the 16 assayed alleles classified as “uncertain significance” by the ClinVar database [<xref ref-type=""bibr"" rid=""CR16"">16</xref>], we find that six (S103A, D152Y, A174T, F209L, C343R, V356M) encode functional proteins. Four alleles are classified as having “conflicting classifications of pathogenicity”; we find that three of these alleles (P104L, A328T and R431W) encode functional",5_16,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"(P104L, A328T and R431W) encode functional proteins and one (T87I) does not. T221A is classified as “likely pathogenic” and T28I is classified as “benign/likely benign”; our data disagree with these two predictions. We believe that our in vivo measurements of the activity of these alleles will provide important, actionable information for clinicians and genetic counselors who may come across patients with these alleles in their practices. The D336V and R339W alleles were selected for a slightly different",5_17,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"alleles were selected for a slightly different reason. Pitceathly et al. have reported that a human with these two alleles survived to adulthood and that both alleles encode nonfunctional proteins [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. We thought that using more sensitive enzyme assays might reveal partial activity from one or both proteins but found that both are fully nonfunctional (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>). Recently, a second patient with unusual <italic",5_18,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"Recently, a second patient with unusual <italic toggle=""yes"">COX10</italic> alleles has been described who survived past infancy [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. This patient is homozygous for two alleles, T14I and T377I. The second variant is highly similar to the T380I variant that we found to be nonfunctional in that both alterations are located in the sixth transmembrane domain [<xref ref-type=""bibr"" rid=""CR17"">17</xref>], strongly suggesting that the patient’s Cox10 protein will be",5_19,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"that the patient’s Cox10 protein will be nonfunctional. Thus, it remains unclear how either patient has survived when most people with nonfunctional Cox10 variants die in infancy (Table <xref rid=""Tab1"" ref-type=""table"">1</xref>). Perhaps specific alleles of other genes found in these patients can partially suppress the loss-of-function in <italic toggle=""yes"">COX10</italic>. Identifying these genes could potentially point to interventions to treat Leigh Syndrome patients and is an area that our laboratory",5_20,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
patients and is an area that our laboratory is pursuing.,5_21,Phenotypic assessment of Cox10 variants and their implications for Leigh Syndrome,16 8 2024,,Leigh_Syndrome
"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome A 23-month-old boy with poor growth, developmental delay, and hypotonia presented with acute onset of ataxia and fatigue. Magnetic resonance imaging (MRI) of the brain and spinal cord was performed as part of diagnostic work-up. MRI showed bilateral symmetrical lesions in basal ganglia, midbrain, and brainstem consistent with Leigh syndrome. Signal abnormalities were also present within the cervical cord,",6_0,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"were also present within the cervical cord, with enhancement of multiple cranial, spinal, and cauda equina nerve roots. Genetic testing confirmed compound heterozygosity for two pathogenic variants in <italic toggle=""yes"">SURF1</italic> implicated in Leigh syndrome. Whilst nerve root enhancement has been described in other mitochondrial disorders, we believe this is the first published case of both cranial and spinal nerve root enhancement in Leigh syndrome. Mitochondria are complex intracellular",6_1,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"syndrome. Mitochondria are complex intracellular organelles essential for various functions including energy production, fatty acid oxidation, and programmed cell death. Inherited mitochondrial disorders are a heterogeneous group of diseases due to variants in both mitochondrial and nuclear DNA. Many inherited mitochondrial disorders are primarily progressive with high morbidity and mortality, the severest forms being lethal in utero or infancy. The onset of clinical symptoms may be triggered by",6_2,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"onset of clinical symptoms may be triggered by physiological stress such as infection or dehydration [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Leigh syndrome, also known as subacute necrotizing encephalomyelopathy, is a neurodegenerative disorder encompassing disruptions to the mitochondrial electron transport chain, involved in ATP production, and as such commonly affects locations within the central nervous system with the highest energy requirements [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Children",6_3,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"ref-type=""bibr"" rid=""CR2"">2</xref>]. Children commonly present before the age of 2 years with psychomotor delay or regression, hypotonia, and signs of basal ganglia or brainstem dysfunction, which may manifest as swallowing and respiratory difficulties, ataxia, nystagmus, or ophthalmoplegia; death is usually before 10 years of age [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Diagnosis involves magnetic resonance imaging (MRI) of the neuroaxis, identifying symmetrical signal abnormalities within the basal",6_4,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"symmetrical signal abnormalities within the basal ganglia, thalami, and brainstem. Pathologically this is correlated with spongiform degeneration, demyelination, gliosis, and neuronal loss. Serum or cerebrospinal fluid (CSF) may display elevation of lactate [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Surfeit locus protein 1 (<italic toggle=""yes"">SURF1</italic>) encodes an assembly factor maintaining cytochrome c oxidase stability. Cytochrome c oxidase deficiency due to loss of function variants in <italic",6_5,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"due to loss of function variants in <italic toggle=""yes"">SURF1</italic> has been implicated in both Leigh syndrome (the clinical manifestation of mitochondrial complex IV deficiency, nuclear type 1; OMIM 220110) and Charcot-Marie-Tooth disease (type 4 K; OMIM 616684). More than 100 different variants are recorded in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome, and although neuroimaging features may vary, <italic toggle=""yes"">SURF1</italic>-related phenotypes often spare the putamina,",6_6,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"phenotypes often spare the putamina, favouring greater involvement of the brainstem. Leukoencephalopathy and cerebellar atrophy are common features, with or without dentate nucleus involvement [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Despite these typical MRI findings, demonstrably Leigh syndrome can involve any level of the neuroaxis, with atypical presentations. Whilst there are a few reports describing inherited mitochondrial disorders with acute signal abnormalities in spinal [<xref ref-type=""bibr""",6_7,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"abnormalities in spinal [<xref ref-type=""bibr"" rid=""CR3"">3</xref>–<xref ref-type=""bibr"" rid=""CR5"">5</xref>] and cranial [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>] nerves, as far as we are aware, this is the first published case of both cranial and spinal nerve involvement in Leigh syndrome. A 23-month-old non-dysmorphic boy was under investigation for developmental delay, hypotonia, and feeding difficulties. Born at term",6_8,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"hypotonia, and feeding difficulties. Born at term via emergency Caesarean section for fetal distress, to non-consanguineous parents, there had been no perinatal issues. Following sudden onset of ataxia, fatigue, and myoclonus, the child was admitted to hospital and found to be alert with no visual or hearing deficits, but had gross and fine motor delay, central and peripheral hypotonia, and involuntary truncal/peripheral choreiform movements. Despite absent lower limb reflexes, the patient had normal nerve",6_9,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"lower limb reflexes, the patient had normal nerve conduction studies. CSF showed elevated lactate of 3.1 mmol/L (normal range < 2.0 mmol/L) and elevated protein of 0.79 g/L (normal range 0.10–0.35 g/L), but no micro-organisms were cultured. Inflammatory markers were mildly elevated with C-reactive protein 16 mg/L, neutrophils 9.7 x10^9/L. Family history was non-contributory, and previous creatinine kinase measurements, electroencephalogram, and hearing test were normal. An MRI of the brain showed fairly",6_10,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"were normal. An MRI of the brain showed fairly symmetrical but widespread grey matter involvement, with increased T2/fluid attenuated inversion recovery (FLAIR) signal within the posterior putamina, subthalamic nuclei, cerebral peduncles, midbrain (periaqueductal grey matter and inferior colliculus), pons (central tegmental tracts and medial longitudinal fasciculus), superior cerebellar peduncles, dentate hilus, and medulla (with focal expansion of the inferior olivary nuclei) (Fig. <xref rid=""Fig1""",6_11,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"inferior olivary nuclei) (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>).<fig id=""Fig1""><label>Fig. 1</label><caption><p>T2-weighted magnetic resonance images through the brain demonstrate features of Leigh syndrome in a 23-month-old boy with confirmed <italic toggle=""yes"">SURF1</italic> variants. <bold>a</bold>–<bold>c </bold>Axial images demonstrate T2 hyperintensity in the bilateral posterior putamina (<italic toggle=""yes"">arrows</italic> in <bold>a</bold>), globi pallidi interna (<italic",6_12,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"<bold>a</bold>), globi pallidi interna (<italic toggle=""yes"">arrowheads</italic> in <bold>b</bold>), subthalamic nuclei (<italic toggle=""yes"">broken arrows</italic> in <bold>b</bold>), substantia nigra (<italic toggle=""yes"">arrows</italic> in <bold>c</bold>), red nuclei (<italic toggle=""yes"">arrowheads</italic> in <bold>c</bold>), and periaqueductal grey matter (<italic toggle=""yes"">broken arrows</italic> in <bold>c</bold>). <bold>d</bold>–<bold>f</bold> Axial images at the level of superior cerebellar",6_13,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"Axial images at the level of superior cerebellar peduncles (<bold>d</bold>), middle cerebellar peduncles (<bold>e</bold>), and medulla (<bold>f</bold>) demonstrate hyperintensity within the central tegmental tracts (<italic toggle=""yes"">arrows</italic> in <bold>d</bold> and <bold>e</bold>), medial longitudinal fasciculi (<italic toggle=""yes"">arrowheads</italic> in <bold>d</bold> and <bold>e</bold>), trigeminal sensory nuclei (<italic toggle=""yes"">broken arrows</italic> in <bold>e</bold> and",6_14,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"arrows</italic> in <bold>e</bold> and <bold>f</bold>), cerebellar dentate nuclei (<italic toggle=""yes"">thick arrows</italic> in <bold>e</bold>), and inferior olivary nuclei (<italic toggle=""yes"">arrows</italic> in <bold>f</bold>). <bold>g</bold>, <bold>h</bold> Axial (<bold>g</bold>) and sagittal (<bold>h</bold>) images demonstrate spinal cord involvement with increased signal in the central cord grey matter (<italic toggle=""yes"">arrows</italic>) and dorsal columns (<italic toggle=""yes"">broken",6_15,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"and dorsal columns (<italic toggle=""yes"">broken arrows</italic>)</p></caption><graphic http://www.w3.org/1999/xlink href=""247_2024_6005_Fig1_HTML"" id=""MO2""></graphic></fig> Punctate foci of restricted diffusion were visible in the pallidi, subthalamic nuclei, cerebral peduncles, midbrain (red nuclei), dorsal pons (central tegmental tracts), superior cerebellar peduncles, dentate nuclei, and medulla anteriorly (inferior olivary nuclei) (Fig. <xref rid=""Fig2"" ref-type=""fig"">2</xref>). Heterogeneous",6_16,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"ref-type=""fig"">2</xref>). Heterogeneous enhancement was only visible within the medulla. The white matter was spared. MR spectroscopy showed elevated lactate peaks.<fig id=""Fig2""><label>Fig. 2</label><caption><p>Cranial nerve involvement in a 23-month-old boy with Leigh syndrome and confirmed <italic toggle=""yes"">SURF1</italic> variants. <bold>a</bold>–<bold>c</bold> Axial T1 post-gadolinium images show enhancement of the oculomotor nerves (<italic toggle=""yes"">arrows</italic> in <bold>a</bold>),",6_17,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"toggle=""yes"">arrows</italic> in <bold>a</bold>), trigeminal nerves (<italic toggle=""yes"">arrows</italic> in <bold>b</bold>), and facial nerves (<italic toggle=""yes"">arrows</italic> in <bold>c</bold>). <bold>d</bold> Sagittal post-gadolinium image demonstrates diffuse thickening and enhancement of the cauda equina nerve roots. <bold>e</bold> Coronal T2 fat saturated image shows small T2 hyperintense optic nerves (<italic toggle=""yes"">arrows</italic>). <bold>f</bold> Coronal T1 post-gadolinium Dixon",6_18,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"<bold>f</bold> Coronal T1 post-gadolinium Dixon image shows associated optic nerve enhancement (<italic toggle=""yes"">arrows</italic>)</p></caption><graphic http://www.w3.org/1999/xlink href=""247_2024_6005_Fig2_HTML"" id=""MO3""></graphic></fig> Abnormalities in multiple cranial nerves were visible, most markedly the thinned and atrophic optic nerves, which displayed high T2/FLAIR signal and bilateral retrobulbar and pre-chiasmatic post-contrast enhancement. There was also pathological enhancement of the",6_19,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"There was also pathological enhancement of the cisternal oculomotor, cisternal (and within Meckel’s cave) trigeminal nerves, and bilateral cisternal and labyrinthine facial nerves. Spinal cord imaging showed central cord grey matter and dorsal column cervical cord increased T2 signal, extending between the levels of cervical (C) vertebra 2–7, with subtle central cord enhancement at the C2–C3 level. There were thickened enhancing cauda equina nerve roots as well as enhancing cervical and thoracic spinal",6_20,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"as well as enhancing cervical and thoracic spinal nerves. Massively parallel sequencing of a custom neuromuscular gene panel identified two heterozygous variants in <italic toggle=""yes"">SURF1</italic>, c.312_321delinsAT p.(Leu105*) and c.574C > T p.(Arg192Trp), predicted and demonstrated to result in loss of function respectively. Both variants were classified as pathogenic according to American College of Medical Genetics guidelines and presumed in trans, though no parental analysis has yet been",6_21,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"trans, though no parental analysis has yet been performed. The patient was discharged but presented again a few weeks later with metabolic decompensation in the context of rhinovirus infection, and started on a ketogenic diet for Leigh syndrome, with regular serum lactate and urinary ketone testing. Following improvement of acute symptomology, the patient was discharged on a modified ketogenic diet, with urinary ketone monitoring. Alerts were entered into the electronic record to avoid IV dextrose in the",6_22,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"the electronic record to avoid IV dextrose in the event of future acute illness. Neurology and clinical genetics are to be followed-up in outpatient clinics. We believe this is the first published case of both cranial and spinal nerve root enhancement in Leigh syndrome, and only the second case of concomitant cranial and spinal nerve enhancement in a  child with a mitochondrial disorder. The first case was reported by Horst et al. on a background of polymerase-gamma (<italic toggle=""yes"">POLG</italic>)",6_23,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"(<italic toggle=""yes"">POLG</italic>) variant without a Leigh syndrome presentation [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Cranial and spinal nerve root pathological enhancement is rare in children, usually as a result of an inflammatory, traumatic, or malignant process. Whilst cranial nerve enhancement has been documented in other childhood metabolic disorders including metachromatic leukodystrophy and Krabbe’s disease [<xref ref-type=""bibr"" rid=""CR4"">4</xref>], it is a very rare feature of",6_24,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"rid=""CR4"">4</xref>], it is a very rare feature of mitochondrial disorders, with only five cases documented in the literature, the majority (three) being adults. Of these five, two case studies were of individuals with <italic toggle=""yes"">POLG</italic> variants [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>], and two were of patients with mitochondrial neuro-gastro-intestinal encephalopathy syndrome (<italic toggle=""yes"">TYMP</italic>; OMIM 603041) [<xref",6_25,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"toggle=""yes"">TYMP</italic>; OMIM 603041) [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>], the latter cases displaying only cranial nerve and no spinal nerve involvement. A single case has described enhancing spinal nerve roots in a patient with <italic toggle=""yes"">SURF1</italic> variants [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. The reason for nerve enhancement is yet unknown; active demyelination, perivascular inflammation, or cytotoxic metabolite accumulation have",6_26,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"or cytotoxic metabolite accumulation have all been postulated [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Whilst peripheral neuropathy in adults with mitochondrial disease has been well described [<xref ref-type=""bibr"" rid=""CR8"">8</xref>], it is not common in children, particularly rare in those with Leigh syndrome or <italic toggle=""yes"">POLG</italic>-related disorders. Many children having neuroimaging for metabolic disorders have MRIs without intravenous contrast, leading to under reporting of nerve",6_27,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"contrast, leading to under reporting of nerve root enhancement. Given that prior to this current publication, concomitant cranial and spinal nerve enhancement in inherited mitochondrial disorders had only been identified in <italic toggle=""yes"">POLG</italic>-related disorders, this has previously been postulated to be a differentiating factor for these variants [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. However, in this article we present cranial nerve enhancement in Leigh syndrome, confirming that it is",6_28,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"in Leigh syndrome, confirming that it is not a unique feature of <italic toggle=""yes"">POLG</italic>-related disorders. We advise considering post-contrast sequences of the neuroaxis as part of the diagnostic work-up in all children where a neurometabolic disorder is suspected.",6_29,"Cranial and spinal nerve enhancement in <italic toggle=""yes"">SURF1</italic>-associated Leigh syndrome",27 7 2024,,Leigh_Syndrome
"Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2 Mitochondria-related neurodegenerative diseases have been implicated in the disruption of primary cilia function. Mutation in an intrinsic mitochondrial complex I component <italic toggle=""yes"">NDUFAF2</italic> has been identified in Leigh syndrome, a severe inherited mitochondriopathy. Mutations in <italic toggle=""yes"">ARMC9</italic>, which encodes a basal body protein, cause Joubert syndrome, a ciliopathy with",7_0,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"cause Joubert syndrome, a ciliopathy with defects in the brain, kidney, and eye. Here, we report a mechanistic link between mitochondria metabolism and primary cilia signaling. We discovered that loss of NDUFAF2 caused both mitochondrial and ciliary defects in vitro and in vivo and identified NDUFAF2 as a binding partner for ARMC9. We also found that NDUFAF2 was both necessary and sufficient for cilia formation and that exogenous expression of NDUFAF2 rescued the ciliary and mitochondrial defects observed",7_1,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"the ciliary and mitochondrial defects observed in cells from patients with known ARMC9 deficiency. NAD<sup>+</sup> supplementation restored mitochondrial and ciliary dysfunction in ARMC9-deficient cells and zebrafish and ameliorated the ocular motility and motor deficits of a patient with ARMC9 deficiency. The present results provide a compelling mechanistic link, supported by evidence from human studies, between primary cilia and mitochondrial signaling. Importantly, our findings have significant",7_2,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"Importantly, our findings have significant implications for the development of therapeutic approaches targeting ciliopathies.",7_3,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"<graphic http://www.w3.org/1999/xlink href=""jci-134-175560-g184.jpg"" position=""float""></graphic>",7_4,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"Mitochondrial metabolism is linked to primary cilia signaling and ciliopathies via the Leigh syndrome–associated mitochondrial protein NDUFAF2. The primary cilium is a solitary, immobile microtubule-based structure present on the apical surface of many cell types, especially in sensory organs such as the eye and nose. The immobile sensory cilium consists of an array of bundled microtubules (axoneme) that are covered by a plasma membrane. Axonemal microtubules arise from the basal body, a specialized",7_5,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"arise from the basal body, a specialized microtubule-nucleating center (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B5"" ref-type=""bibr"">5</xref>). Defects in ciliary function are associated with a spectrum of human diseases known collectively as ciliopathies, which are characterized by renal cysts, skeletal dysplasia, developmental delay, and retinal degeneration (<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>). A rare form of syndromic ciliopathy, Joubert syndrome,",7_6,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"form of syndromic ciliopathy, Joubert syndrome, is caused by mutations in genes that form the transition zone, the basal region within primary cilia that controls the trafficking of ciliary proteins. One of the Joubert syndrome proteins, ARMC9, is located at the centriole basal body and interacts with CCDC66 and TOGARAM1 to stabilize cilia membrane (<xref rid=""B8"" ref-type=""bibr"">8</xref>). ARMC9 loss causes photoreceptor degeneration and optic nerve and retinal coloboma (<xref rid=""B9""",7_7,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"optic nerve and retinal coloboma (<xref rid=""B9"" ref-type=""bibr"">9</xref>). The precise mechanisms that link genetic mutations in the ciliary transition zone, including of ARMC9, to the systemic impairments in Joubert syndrome are unknown. Optic nerve degeneration is also a feature of Leigh syndrome, a rare and progressive neurological disorder that affects the central nervous system and leads to early death (<xref rid=""B10"" ref-type=""bibr"">10</xref>, <xref rid=""B11"" ref-type=""bibr"">11</xref>). Leigh",7_8,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"<xref rid=""B11"" ref-type=""bibr"">11</xref>). Leigh syndrome is caused by mutations in mitochondrial genes, including some leading to deficiency in mitochondrial complex I (<xref rid=""B12"" ref-type=""bibr"">12</xref>–<xref rid=""B16"" ref-type=""bibr"">16</xref>), such as <italic toggle=""yes"">NDUFAF2</italic>, an essential assembly factor of mitochondrial complex I. <italic toggle=""yes"">Ndufaf2</italic>-knockout mouse fibroblasts exhibit reduced complex I activity and increased oxidative stress and mitochondrial",7_9,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"and increased oxidative stress and mitochondrial DNA deletion (<xref rid=""B17"" ref-type=""bibr"">17</xref>–<xref rid=""B21"" ref-type=""bibr"">21</xref>). However, it is not known whether mitochondrial genes directly affect cilia function. Mitochondria are frequently detected in the base of cilia in cells with motile cilia and photoreceptors (<xref rid=""B22"" ref-type=""bibr"">22</xref>, <xref rid=""B23"" ref-type=""bibr"">23</xref>). A link has been proposed between ciliary and mitochondrial function, but the precise",7_10,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"and mitochondrial function, but the precise mechanism responsible for this link has not been identified. In this study, we describe a mechanism of ciliogenesis based on the interplay between mitochondrial protein NDUFAF2 and centriole protein ARMC9. We first demonstrate that ARMC9-deficient cells derived from a human patient have both ciliary and mitochondrial defects. We next show that NDUFAF2 interacts with ARMC9, restores mitochondrial defects identified in ARMC9-deficient cells, and then mediates cilia",7_11,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"in ARMC9-deficient cells, and then mediates cilia formation by removing CP110, producing ciliary vesicles, and stabilizing the transition zone. Finally, we demonstrate that NAD<sup>+</sup> supplementation rescues both mitochondrial and ciliary defects in ARMC9-deficient cells and ocular motility defects in an ARMC9-deficient patient.  Our data demonstrate that an abnormality of a nuclear-encoded, intrinsic mitochondrial protein, NDUFAF2, impairs the function of a centriole protein, ARMC9, during",7_12,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"function of a centriole protein, ARMC9, during ciliogenesis. We also report that normal NDUFAF2 function during ciliogenesis depends on a tightly regulated ratio of NAD<sup>+</sup>/NADH. Specifically, we find that the mitochondrial protein NDUFAF2 is involved in membrane vesicle docking, CP110 removal, and transition zone stabilization during cilia formation. Importantly, we show that a patient with Joubert syndrome due to ARMC9 mutation had a decreased level of NDUFAF2 protein, deficient mitochondrial",7_13,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"level of NDUFAF2 protein, deficient mitochondrial activity, and increased oxidative stress. Overexpression of NDUFAF2 rescued the mitochondrial defect and cilia formation in JBTS fibroblast cells and <italic toggle=""yes"">armc9</italic>-deficient zebrafish larvae. These findings establish a functional role of mitochondria in supporting the initiation of ciliogenesis and identify a human-disease-relevant linkage between mitochondria and cilia. In this study, we propose that ARMC9 interacts with NDUFAF2 to",7_14,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"we propose that ARMC9 interacts with NDUFAF2 to carry out its functions in the transition zone. Cellular functions such as apoptosis regulation, ER stress response, and phospholipid synthesis are coordinated by relatively stable contacts between the ER and mitochondria (<xref rid=""B44"" ref-type=""bibr"">44</xref>–<xref rid=""B46"" ref-type=""bibr"">46</xref>). Additionally, recent studies have demonstrated that the transition zone acts as a lipid gate and that it plays a conserved role in maintaining the",7_15,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"that it plays a conserved role in maintaining the phosphatidylinositol composition of ciliary membranes (<xref rid=""B47"" ref-type=""bibr"">47</xref>, <xref rid=""B48"" ref-type=""bibr"">48</xref>). Our hypothesis is that overexpression of NDUFAF2 will provide a functional link between mitochondria and the ER that will facilitate the coordination of cellular biological functions, including phospholipid synthesis, and that NDUFAF2 expression will then stabilize transition zone formation. However, the mechanisms by",7_16,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"zone formation. However, the mechanisms by which ARMC9 and NDUFAF2 coordinately influence ciliary composition and function are presently unclear. The mechanism by which NDUFAF2 interacts with ARMC9 is also not fully elucidated. One possibility is that NDUFAF2 is located on the outer membrane of mitochondria, allowing it to interact with ARMC9. Alternatively, NDUFAF2 could be released from mitochondria and interact with ARMC9 after diffusing into the cytosol. This interaction may involve the intrinsically",7_17,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"This interaction may involve the intrinsically disordered protein regions (IDRs), which we hypothesize to play an important role in primary cilia assembly. We base this suggestion on our comparison of centriole protein ARMC9 and mitochondrial protein NDUFAF2 by sequence prediction (Predictor of Natural Disordered Regions, PONDR), which showed that both contain an IDR at the C-terminal region. IDRs are associated with several human diseases and play important roles in diverse cellular processes, including",7_18,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"roles in diverse cellular processes, including transcription, translation, cell signaling, protein interaction, and gene regulation (<xref rid=""B49"" ref-type=""bibr"">49</xref>, <xref rid=""B50"" ref-type=""bibr"">50</xref>). Overall, IDRs may play diverse essential roles in cilia formation, including regulation of protein-protein interactions, molecular flexibility such as intraflagellar transport (IFT), modulation of signaling pathways, and scaffolding of protein complexes. Understanding the functions of IDRs",7_19,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"complexes. Understanding the functions of IDRs in cilia formation is crucial for elucidating the molecular mechanisms underlying ciliary biology and diseases. We found the increase of ARMC9 after stable transfection with NDUFAF2. Furthermore, autophagy is a cellular process responsible for degrading and recycling damaged organelles and proteins, thereby maintaining cellular homeostasis (<xref rid=""B51"" ref-type=""bibr"">51</xref>–<xref rid=""B53"" ref-type=""bibr"">53</xref>). Dysregulation of autophagy has been",7_20,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"Dysregulation of autophagy has been implicated in ciliopathies (<xref rid=""B54"" ref-type=""bibr"">54</xref>–<xref rid=""B57"" ref-type=""bibr"">57</xref>). Here, we hypothesize that this dysregulation may contribute to the pathogenesis of Joubert syndrome by impairing cellular quality control mechanisms and leading to the accumulation of dysfunctional cellular components. However, the exact mechanisms underlying the relationship between NDUFAF2 overexpression and autophagy inhibition in Joubert syndrome require",7_21,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"autophagy inhibition in Joubert syndrome require further investigation. Several over-the-counter supplements increase NAD levels, including niacin, nicotinamide riboside (NR), and nicotinamide mononucleotide, and vitamin B<sub>3</sub> supplementation has been in use for several decades. Because no severe side effects are reported, these interventions are considered relatively safe for human use (<xref rid=""B58"" ref-type=""bibr"">58</xref>). Short-term experiments showed that high doses of nicotinamide are",7_22,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"showed that high doses of nicotinamide are toxic to the liver (<xref rid=""B59"" ref-type=""bibr"">59</xref>). Niacin may cause headaches, flushing of the skin, and dizziness in high doses (<xref rid=""B60"" ref-type=""bibr"">60</xref>). Long-term human trials showed no effect of nicotinamide on the development of diabetes, but animal data contradict this conclusion (<xref rid=""B59"" ref-type=""bibr"">59</xref>), and high doses of NR produce insulin resistance and white adipose tissue dysfunction in mice (<xref",7_23,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"white adipose tissue dysfunction in mice (<xref rid=""B61"" ref-type=""bibr"">61</xref>). Overall, while NAD<sup>+</sup> supplementation holds promise as a treatment for various health conditions, including aging-related diseases (<xref rid=""B62"" ref-type=""bibr"">62</xref>, <xref rid=""B63"" ref-type=""bibr"">63</xref>), further research is needed on its long-term implications and safety profile. Ongoing studies will determine the effects of sustained treatment in specific patient populations, including those with",7_24,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"patient populations, including those with chronic schizophrenia, Parkinson’s disease, chronic fatigue syndrome, and type 1 diabetes (<xref rid=""B58"" ref-type=""bibr"">58</xref>, <xref rid=""B64"" ref-type=""bibr"">64</xref>–<xref rid=""B67"" ref-type=""bibr"">67</xref>). The present results also show that ATP plays a significant role in stabilizing the formation of the ciliary transition zone (<xref rid=""B48"" ref-type=""bibr"">48</xref>). Possible mechanisms by which ATP may act include providing energy for",7_25,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"by which ATP may act include providing energy for intraflagellar transport (<xref rid=""B68"" ref-type=""bibr"">68</xref>, <xref rid=""B69"" ref-type=""bibr"">69</xref>), regulating protein complex assembly (<xref rid=""B70"" ref-type=""bibr"">70</xref>, <xref rid=""B71"" ref-type=""bibr"">71</xref>), maintaining ion gradients (<xref rid=""B72"" ref-type=""bibr"">72</xref>), and modulating signaling pathways (<xref rid=""B73"" ref-type=""bibr"">73</xref>). The findings provide evidence supporting mitochondria’s functional role in",7_26,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"supporting mitochondria’s functional role in ciliogenesis and reveal a link between mitochondria and cilia. Mitochondria play a crucial role in numerous cellular functions, including energy production, metabolism regulation, and cell signaling. Loss or impairment of mitochondrial activity can have significant consequences for various cellular processes. Further research is required to determine exactly how mitochondria play an important role in ciliogenesis. In conclusion, by using evidence from a patient",7_27,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"In conclusion, by using evidence from a patient with a ciliopathy to establish a mechanistic connection between mitochondrial signaling and primary cilia, this research offers a therapeutic perspective for patients with ciliopathies.  CHL designed and carried out all experiments and data analysis and wrote the manuscript. ZL, SC, YH, YS, and WJW contributed to manuscript editing. FL contributed to setting up injections in zebrafish. TJK and KN contributed to setting up cryosections in zebrafish. ARB, CQY,",7_28,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"setting up cryosections in zebrafish. ARB, CQY, and EBK provided patient samples. YJL provided valuable advice and experimental suggestions. YS supervised the project.",7_29,Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2,1 7 2024,,Leigh_Syndrome
"Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome Mitochondrial diseases are mainly caused by dysfunction of mitochondrial respiratory chain complexes and have a variety of genetic variants or phenotypes. There are only a few approved treatments, and fundamental therapies are yet to be developed. Leigh syndrome (LS) is the most severe type of progressive encephalopathy. We previously reported that apomorphine, an anti- “off” agent for Parkinson’s disease, has cell-protective",8_0,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"for Parkinson’s disease, has cell-protective activity in patient-derived skin fibroblasts in addition to strong dopamine agonist effect. We obtained 26 apomorphine analogs, synthesized 20 apomorphine derivatives, and determined their anti-cell death effect, dopamine agonist activity, and effects on the mitochondrial function. We found three novel apomorphine derivatives with an active hydroxy group at position 11 of the aporphine framework, with a high anti-cell death effect without emetic dopamine agonist",8_1,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"death effect without emetic dopamine agonist activity. These synthetic aporphine alkaloids are potent therapeutics for mitochondrial diseases without emetic side effects and have the potential to overcome the low bioavailability of apomorphine. Moreover, they have high anti-ferroptotic activity and therefore have potential as a therapeutic agent for diseases related to ferroptosis. Mitochondrial diseases are caused by pathogenic variants of either nuclear or mitochondrial DNA, resulting in mitochondrial",8_2,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"or mitochondrial DNA, resulting in mitochondrial respiratory chain complex dysfunction or morphological abnormalities<sup><xref ref-type=""bibr"" rid=""CR1"">1</xref>,<xref ref-type=""bibr"" rid=""CR2"">2</xref></sup>. Mitochondrial dysfunction leads to decreased ATP production and oxidative stress, resulting in cell death and a loss of function in affected organs. Among the various phenotypes of mitochondrial diseases, mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes (MELAS),",8_3,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"lactic acidosis, stroke-like episodes (MELAS), Kearns-Sayre syndrome (KSS), and Leigh syndrome (LS) are the three major clinical types of mitochondrial diseases<sup><xref ref-type=""bibr"" rid=""CR3"">3</xref></sup>. LS is one of the most severe types of mitochondrial disease, and its onset occurs during childhood. Patients with LS show progressive developmental regression along with bilateral central nervous system (CNS) lesions, especially in the basal ganglia and brain stem. Basal ganglia and brain stem",8_4,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"and brain stem. Basal ganglia and brain stem symptoms include hypertonia, involuntary movements, hearing loss, dystonia, and respiratory interruption. Epilepsy, cerebellar symptoms and hypotonia may also occur. LS is often diagnosed after an acute exacerbation triggered by infections episodes, resulting in rapid metabolic failure due to an energy crisis. Systemic symptoms may include hepatic and myocardial dysfunction<sup><xref ref-type=""bibr"" rid=""CR4"">4</xref></sup>. An estimated 20–30% of LS infants",8_5,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"An estimated 20–30% of LS infants with an early onset (as young as 6 months after birth) experience progressive regression in both the motor and intellectual functions and 80% mortality by 10 years old<sup><xref ref-type=""bibr"" rid=""CR4"">4</xref>,<xref ref-type=""bibr"" rid=""CR5"">5</xref></sup>. Although medications such as idebenone for Leber hereditary optic neuropathy (LHON) and taurine for MELAS with the m.3243A > G variant have been approved for mitochondrial diseases, LS patients are treated with",8_6,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"diseases, LS patients are treated with supportive therapy of vitamins and OXPHOS complex cofactors. No causative treatment has been established for LS to date, and the development of a targeted therapy is awaited<sup><xref ref-type=""bibr"" rid=""CR1"">1</xref>,<xref ref-type=""bibr"" rid=""CR6"">6</xref></sup>. Apomorphine has been used as a dopamine receptor agonist to treat advanced and drug-resistant Parkinson’s disease (PD) “off” symptoms. In addition, the antioxidant, and neuroprotective effects of",8_7,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"the antioxidant, and neuroprotective effects of apomorphine and its efficacy in non-motor symptoms in patients with PD have been repeatedly reported<sup><xref ref-type=""bibr"" rid=""CR7"">7</xref>,<xref ref-type=""bibr"" rid=""CR8"">8</xref></sup>. In a previous study, apomorphine was screened from a CNS drug library and evaluated for its anti-cell death effect in L-buthionine-(S, R)-sulfoximine (BSO)-loaded LS patient-derived skin fibroblasts<sup><xref ref-type=""bibr"" rid=""CR9"">9</xref></sup>. This suggests the",8_8,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"rid=""CR9"">9</xref></sup>. This suggests the possibility of repositioning apomorphine as a therapeutic agent for mitochondrial diseases. Furthermore, it has also been reported that apomorphine has anti-ferroptotic effects independent of dopamine agonist activity<sup><xref ref-type=""bibr"" rid=""CR10"">10</xref></sup>. The challenges in repositioning apomorphine as a mitochondrial disease drug are its strong dopamine D2 receptor agonist (DA) effect and short biological half-life. The DA effect was originally",8_9,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"half-life. The DA effect was originally demonstrated in PD, but in this case, it led to the side effect of emesis. The biological half-life of apomorphine, as short as 30 min, makes it undesirable as a mitochondrial disease drug<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref>,<xref ref-type=""bibr"" rid=""CR12"">12</xref></sup>. In addition, apomorphine is not suitable for oral administration because of its low bioavailability of less than 4% for first-pass effects, so various other administration routes have",8_10,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"so various other administration routes have been investigated. In the present study, we obtained 20 apomorphine analogs and synthesized 26 derivatives based on the aporphine framework. We then screened their DA activity and anti-cell death effect under oxidative stress to obtain compounds that retain anti-cell death effects similar or superior apomorphine but lack DA activity.  Apomorphine is a dibenzoquinoline aporphine alkaloid and aporphine alkaloids are compounds that possess an aporphine framework and",8_11,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"compounds that possess an aporphine framework and bioactivity. Many natural aporphine alkaloids have been isolated from several plants in nature, and multiple synthetic pathways have been identified<sup><xref ref-type=""bibr"" rid=""CR15"">15</xref></sup>. Natural and synthetic aporphine alkaloids exhibit various pharmacological activities, including antidiabetic, anticancer, and anti-inflammatory effects<sup><xref ref-type=""bibr"" rid=""CR16"">16</xref></sup>. Apomorphine and its derivatives show anti-cell death",8_12,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"and its derivatives show anti-cell death activity, and the inhibition of ferroptosis is one of their actions<sup><xref ref-type=""bibr"" rid=""CR10"">10</xref></sup>. In the present study, we found that apomorphine analogs and derivatives that lack the DA activity but retain anti-cell death effect against BSO or RSL3 on LS patient-derived skin fibroblasts. We obtained as many apomorphine analogs and derivatives as possible and compared their anti-cell death effects under conditions of oxidative stress. The",8_13,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"effects under conditions of oxidative stress. The compounds with high anti-cell death activity had reactive groups at specific positions in the aporphine framework. Apomorphine was first synthesized in 1845 and many studies have focused on apomorphine for its central nervous system effects have been reported such as sleep dysfunction, apathy, fatigue, attention deficit, dementia, and so on<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref>,<xref ref-type=""bibr"" rid=""CR17"">17</xref></sup>. In 1884, its efficacy",8_14,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"rid=""CR17"">17</xref></sup>. In 1884, its efficacy in patients with PD was hypothesized, and 100 years later, in 1954, its efficacy in PD was reported<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref></sup>. Due to its poor bioavailability and short biological half-life, levodopa, an oral dopamine precursor, have appeared in clinical setting<sup><xref ref-type=""bibr"" rid=""CR17"">17</xref>,<xref ref-type=""bibr"" rid=""CR18"">18</xref></sup>. Apomorphine was later approved for treating the “off” symptoms of advanced",8_15,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"for treating the “off” symptoms of advanced PD in 1987<sup><xref ref-type=""bibr"" rid=""CR19"">19</xref></sup>, and then approved in Japan specifically in 2012. Apomorphine is structurally similar to dopamine and, thus, has broad-spectrum dopamine agonist activity. The polycyclic and amine structures of apomorphine make it highly lipophilic and allow it to easily penetrate the blood–brain barrier<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref></sup>. Apomorphine concentrations in the brain may be up to",8_16,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"concentrations in the brain may be up to three-fold higher than those in plasma<sup><xref ref-type=""bibr"" rid=""CR20"">20</xref></sup>. It and other aporphine alkaloids are known to have diverse pharmacological actions, not only at dopamine receptors, but also at serotonin, adrenergic alpha, and acetylcholine receptors<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref>,<xref ref-type=""bibr"" rid=""CR21"">21</xref></sup>. Furthermore, apomorphine has been reported to exert antioxidant activity<sup><xref",8_17,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"reported to exert antioxidant activity<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref>,<xref ref-type=""bibr"" rid=""CR22"">22</xref></sup>, even before the discovery of ferroptosis<sup><xref ref-type=""bibr"" rid=""CR23"">23</xref></sup>, a form of cell death caused by lipid peroxidation. The mechanism of the antioxidant effect of apomorphine has been discussed and dopamine D4 receptor agonist activity is a candidate<sup><xref ref-type=""bibr"" rid=""CR24"">24</xref></sup>. However, we recently reported that the",8_18,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"However, we recently reported that the anti-cell death effect of apomorphine is due to its anti-ferroptotic effect, regardless of its dopamine receptor agonist activities<sup><xref ref-type=""bibr"" rid=""CR10"">10</xref></sup>, and we found that the synthetic aporphine alkaloids also possess anti-ferroptotic activity. Bulbocapnine, an aporphine alkaloid with a hydroxy group at position 11, has been reported to have in vitro CNS activity<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref></sup> along with",8_19,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"rid=""CR21"">21</xref></sup> along with nuciferine and several other naturally occurring aporphine alkaloids, and nuciferin has been reported to exert anti-ferroptotic activity<sup><xref ref-type=""bibr"" rid=""CR25"">25</xref></sup>. The strong antioxidant, or anti-ferroptotic effect, of apomorphine and its derivatives is due to the activity of the hydroxy group at position 11 of the aporphine framework, and modification of the functional group at position 10 or other sites may alter membrane permeability and",8_20,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"other sites may alter membrane permeability and intracellular availability, resulting in an inhibitory effect on cell death. The hydroxy and N-alkyl group at position 11 of aporphine also alter dopamine receptor selectivity. Substitution of the N-methyl group and acylation of the carbon at position 10 have been reported to enhance dopamine D1 receptor affinity<sup><xref ref-type=""bibr"" rid=""CR25"">25</xref></sup>. The dopamine receptor affinities of synthetic aporphine alkaloids should be investigated in",8_21,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"aporphine alkaloids should be investigated in the future. The catechol groups at positions 10 and 11 of aporphine are responsible for the in vivo clearance and low bioavailability, and the pharmacokinetics may differ for the aporphine alkaloids found in this research<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref></sup>. In our compound synthesis and exploration, we first took the approach to discover the pharmacophore involved in the anti-cell death activity. The results showed that the OH group at",8_22,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"activity. The results showed that the OH group at position 11 of the aporphine framework is essential for anti-cell death effect and also contributes to DA activity, while the modified group at position 10 reduces DA activity but retains the anti-cell death effect of the OH group at position 11, indicating that the anti-cell death effect increases or decreases with the functional group. The candidate compounds all retained the OH group at position 11. We succeeded in eliminating DA activity while retaining",8_23,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"in eliminating DA activity while retaining the anti-cell death effect as originally intended. Apomorphine inhibits GDF-15 elevation in the culture supernatant of LS patient-derived skin fibroblasts<sup><xref ref-type=""bibr"" rid=""CR9"">9</xref></sup>, and the three candidate aporphine alkaloids also inhibited GDF-15 elevation. GDF-15 is listed as a biomarker for mitochondrial diseases and is considered a useful endpoint for future in vivo evaluation<sup><xref ref-type=""bibr"" rid=""CR26"">26</xref></sup>. The",8_24,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"ref-type=""bibr"" rid=""CR26"">26</xref></sup>. The brain pathology in LS patients shows white matter vacuolization, increased vascularity and gliosis, microglial expansion, and increased IL-6 levels in the cerebellum and brainstem in NDUFS4<sup>-/-</sup> mice, and neuroinflammation is indicated in LS patients’ brains<sup><xref ref-type=""bibr"" rid=""CR27"">27</xref></sup>. The antioxidative and anti-ferroptotic effects of apomorphine and its derivatives need to be evaluated for pathological alterations when",8_25,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"to be evaluated for pathological alterations when administered to the brain tissue. In the current study, we aimed to eliminate the DA effect from apomorphine, and confirmed that the derivatives have the same antioxidant effect as apomorphine. In the future, it will be necessary to investigate the antioxidant capacity of apomorphine and the derivatives using other methods. The three candidate compounds found in the apomorphine derivatives synthesized in this study will be evaluated in vivo for their",8_26,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"in this study will be evaluated in vivo for their pharmacokinetics and pathophysiological effects to determine the final candidate drugs. Moreover, their high anti- ferroptotic activity have potential as a therapeutic agent for diseases related to ferroptosis.",8_27,Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome,21 5 2024,,Leigh_Syndrome
"Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report Although Leigh syndrome (LS) is a neurodegenerative disorder of infancy, adult-onset LS has also been rarely reported. We report a case of late-onset LS in a 42-year-old female who presented with protracted gastrointestinal manifestations, chronic headaches, ataxia, and loss of consciousness. Brain magnetic resonance imaging (MRI) revealed hyperintensities in the bilateral basal ganglia and brain stem. Serum and",9_0,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"bilateral basal ganglia and brain stem. Serum and cerebrospinal fluid lactate levels were significantly raised. Muscle biopsy showed reduced cytochrome oxidase (COX) activity. She was diagnosed with probable diagnosis of late-onset LS based on her clinical features, radiological findings, biochemical results, and biopsy findings. She responded well to intravenous thiamine, and her symptoms gradually improved. Leigh syndrome (LS) is an uncommon neurogenerative disorder of infancy, characterized by subacute",9_1,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"disorder of infancy, characterized by subacute necrotizing encephalopathy and bilateral symmetrical gray matter necrotizing lesions in the basal ganglia, brain stem, and cerebellum [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. LS typically presents in infancy, with over 50% of cases in the first year of life, mainly before six months of age, with a low prevalence of 1:40,000 births [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. LS is a mitochondrial disorder that may be sporadic or familial, characterized by",9_2,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"may be sporadic or familial, characterized by psychomotor regression or delay with lesions mainly in the brain stem and basal ganglia [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Adult-onset LS, also called late-onset LS, has been underlined in the literature, with only a few cases published. In adult-onset LS, symptoms may appear after two years and not manifest until early adulthood. Compared to the infantile form, adult-onset LS progresses slowly and is more prevalent in males [<xref rid=""REF4""",9_3,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"and is more prevalent in males [<xref rid=""REF4"" ref-type=""bibr"">4</xref>,<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. Herein, we report a case of adult-onset LS in a female who presented with protracted gastrointestinal manifestations. A 43-year-old female presented with protracted generalized abdominal pain and intermittent vomiting for the last two months, for which she used over-the-counter medications with no improvements. She also complained of multiple episodes of throbbing headaches in the last year",9_4,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"episodes of throbbing headaches in the last year and was treated as migraine. Now, she presented with a worsening headache for the last week, which was generalized with no aggravating and relieving factors associated with bilateral ptosis and lightheadedness. She reported no history of febrile illness, seizures, limb weakness, sensory disturbance, or other preceding illnesses. She had no personal or family history of any similar disease. She reported no history of smoking or substance abuse but sporadic",9_5,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"of smoking or substance abuse but sporadic alcohol use. She was hemodynamically stable and well-oriented to time, place, and person on examination. Eye examination revealed bilateral ptosis with horizontal gaze palsy and normal pupil. Fundus examination was unremarkable, with no signs of meningeal irritation. Cranial nerve examination was normal, and neurological examination showed ataxia. The rest of the systemic examination was unremarkable. She underwent brain magnetic resonance imaging (MRI), revealing",9_6,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"brain magnetic resonance imaging (MRI), revealing hyperintense signals in a widespread brain area. Electroencephalography (EEG) showed generalized slowing with no epileptiform activity. Owing to her protracted vomiting and MRI findings, she was diagnosed with a probable diagnosis of Wernicke’s encephalopathy. She was managed with parenteral thiamine, showed marked improvements in her symptomology, and was discharged. Two weeks later, she presented again with a severe headache followed by a loss of",9_7,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"with a severe headache followed by a loss of consciousness. On examination, she had brisk tendon reflexes and extensor plantar reflexes bilaterally. Her lab results were normal except for elevated fasting serum lactate level (Table <xref rid=""TAB1"" ref-type=""table"">1</xref>). Arterial blood gas analysis revealed severe metabolic acidosis with a pH of 7.12. A repeat brain MRI showed hyperintense signals in bilateral basal ganglia, brain stem, and white matter (Figure <xref rid=""FIG1""",9_8,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"stem, and white matter (Figure <xref rid=""FIG1"" ref-type=""fig"">1</xref>). She underwent cerebrospinal fluid (CSF) analysis revealing an elevated lactate level of 3.9 mmol/L (normal: 1.1-2.3). The rest of the CSF biochemistry and cytology was within the normal range. Her blood culture was negative for any organism. She underwent detailed metabolic evaluations, including coagulation profile, serum copper, ceruloplasmin, and urinary copper, which were within normal range. Based on her clinical history and",9_9,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"normal range. Based on her clinical history and imaging and laboratory evaluations, a provisional diagnosis of adult-onset LS was made. She was managed with intravenous thiamine (300 mgm/day) with tapering dose, riboflavin, and co-enzyme-Q. Muscle biopsy from the quadricep muscle exhibited reduced cytochrome oxidase (COX) activity (Figure <xref rid=""FIG2"" ref-type=""fig"">2</xref>). Her muscle deoxyribonucleic acid (DNA) was extracted and analyzed for a complete mitochondrial genome, which showed no",9_10,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"a complete mitochondrial genome, which showed no pathognomonic mutations. She improved gradually and became conscious on day five of admission, with a gradual improvement in headache and ptosis. Her gaze improved over one and a half months, and she started ambulating over the next two months. She remained asymptomatic over subsequent follow-ups. LS is a progressive neurodegenerative disease of infancy and represents the most common pediatric clinical manifestation of mitochondrial disease [<xref rid=""REF3""",9_11,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"of mitochondrial disease [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Patients with LS typically present with episodic neurodegeneration, often leading to death at the age of three years. Although rare, adult-onset LS has also been reported, with only a few cases published. We have tabulated the reported cases of late-onset LS with clinicopathological presentation in Table <xref rid=""TAB2"" ref-type=""table"">2</xref> [<xref rid=""REF4"" ref-type=""bibr"">4</xref>-<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. LS",9_12,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"rid=""REF10"" ref-type=""bibr"">10</xref>]. LS has remarkable clinical and genetic heterogeneity; patients with LS typically present with characteristic neuropathological features. The characteristic manifestations of LS encompass psychomotor regression or delay, limb weakness, generalized hypotonia, tremors, and lactic acidosis detected in the CSF, blood, or urine [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. According to published reports, typical manifestations of LS may also manifest in adult-onset LS.",9_13,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"of LS may also manifest in adult-onset LS. Patients with LS manifest headaches, dementia, intellectual decline, and vertical gaze palsy based on the published data [<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Hong et al. reported that patients with infantile LS manifest delayed development, motor weakness, and ataxia, and patients with late-onset LS present with vertical gaze palsy and motor weakness and ataxia. However, birth history, family history, system organ",9_14,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"birth history, family history, system organ involvement, and time interval from the first clinical manifestation to LS diagnosis were not statistically significant [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. Sakushima et al. proposed the diagnostic criteria for LS in 2011, tabulated in Table <xref rid=""TAB3"" ref-type=""table"">3</xref> [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. Our patient presented with signs and symptoms consistent with the clinical, biochemical, and radiological criteria for LS.",9_15,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"biochemical, and radiological criteria for LS. Muscle biopsy also reinforced the diagnosis of LS with typical imaging findings on imaging modalities. Our patient responded well to the treatment, similar to the case reported by Goldenberg and his colleagues [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Although LS typically manifests in childhood or infancy, adult-onset LS is a rare variant, with onset mainly occurring in the second or third decade of life. Diagnosis of late-onset LS exhibits significant",9_16,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"Diagnosis of late-onset LS exhibits significant challenges due to its diverse clinical manifestations and overlapping features with other neurological syndromes. Compared with infantile LS, late-onset LS has a favorable prognosis. Our case highlights the importance of timely recognition, genetic testing, multidisciplinary care, and individualized treatment in improving the clinical outcomes and quality of life for LS patients.",9_17,Late-Onset Leigh Syndrome With Protracted Gastrointestinal Manifestations: A Rare Case Report,5 5 2024,,Leigh_Syndrome
"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome Mitochondrial dysfunction plays a major role in physiological aging and in many pathological conditions. Yet, no study has explored the consequence of primary mitochondrial deficiency on the blood–brain barrier (BBB) structure and function. Addressing this question has major implications for pharmacological and genetic strategies aimed at ameliorating the neurological symptoms that",10_0,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"at ameliorating the neurological symptoms that are often predominant in patients suffering from these conditions. In this study, we examined the permeability of the BBB in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mouse model of Leigh syndrome (LS). Our results indicated that the structural and functional integrity of the BBB was preserved in this severe model of mitochondrial disease. Our findings suggests that pharmacological or gene therapy strategies targeting the central nervous system in",10_1,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"targeting the central nervous system in this mouse model and possibly other models of mitochondrial dysfunction require the use of specific tools to bypass the BBB. In addition, they raise the need for testing the integrity of the BBB in complementary in vivo models. The blood–brain barrier (BBB) is a highly selective and semi-permeable membrane delineated by endothelial cells of the brain vessels establishing an interface between vascular milieu and the central nervous system. Endothelial cells are",10_2,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"the central nervous system. Endothelial cells are supported by pericytes, both surrounded by a continuous, non-fenestrated basal lamina and astrocytic end-feet. Complex tight junctions between endothelial cells restrict the paracellular transport and force the molecules to take a transcellular route. Except small gaseous molecules or small lipophilic agents, the transcellular traffic requires the presence of specific transport systems, allowing the entry of nutrients, ions or neurotransmitters. Exchanges",10_3,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"nutrients, ions or neurotransmitters. Exchanges are highly regulated in order to maintain a brain microenvironment appropriate for proper neuronal function. It preserves the immune-privileged status of the brain and prevents the entry of blood-circulating neurotoxic agents [<xref rid=""B1-ijms-25-04828"" ref-type=""bibr"">1</xref>]. The disruption of the BBB usually results in a higher blood–brain vessel permeability and consequently an increased vulnerability of the brain parenchyma to toxic endogenous or",10_4,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"of the brain parenchyma to toxic endogenous or exogenous molecules. BBB disruption has been reported during physiological aging and in age-related diseases such as neurodegenerative disorders or diabetes [<xref rid=""B2-ijms-25-04828"" ref-type=""bibr"">2</xref>,<xref rid=""B3-ijms-25-04828"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-25-04828"" ref-type=""bibr"">4</xref>]. Moreover, recent studies examined the integrity of the BBB in genetic disorders and found a breakdown of this barrier for instance in",10_5,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"found a breakdown of this barrier for instance in Huntington’s disease, X-linked adrenoleukodystrophy, cerebellar ataxia or genetically induced schizophrenia [<xref rid=""B5-ijms-25-04828"" ref-type=""bibr"">5</xref>,<xref rid=""B6-ijms-25-04828"" ref-type=""bibr"">6</xref>,<xref rid=""B7-ijms-25-04828"" ref-type=""bibr"">7</xref>,<xref rid=""B8-ijms-25-04828"" ref-type=""bibr"">8</xref>]. Mitochondrial dysfunction is a major hallmark of physiological senescence and is also documented in a large number of genetic and",10_6,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"also documented in a large number of genetic and non-genetic diseases. Mitochondria are responsible for energy metabolism through oxidative phosphorylation involving the respiratory chain complexes. Studies have shown that the pharmacological inhibition of mitochondrial complex I or III activity in endothelial cells is responsible for an increase in BBB permeability both in vitro and in vivo [<xref rid=""B9-ijms-25-04828"" ref-type=""bibr"">9</xref>,<xref rid=""B10-ijms-25-04828"" ref-type=""bibr"">10</xref>]. In",10_7,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"ref-type=""bibr"">10</xref>]. In pathological conditions, it has been demonstrated that mitochondrial dysfunction in endothelial cells was, at least partly, responsible for BBB failure during ischemic stroke or septic encephalopathy [<xref rid=""B10-ijms-25-04828"" ref-type=""bibr"">10</xref>,<xref rid=""B11-ijms-25-04828"" ref-type=""bibr"">11</xref>]. In the context of primary mitochondrial impairment, coenzyme Q10 deficiency caused a leakage in an in vitro model of BBB that was associated with a disruption of",10_8,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"of BBB that was associated with a disruption of tight junctions [<xref rid=""B12-ijms-25-04828"" ref-type=""bibr"">12</xref>]. Surprisingly, the structural and functional status of the BBB has never been assessed in a mouse model of inherited mitochondrial disease. Besides its pathological consequence, the disruption of the BBB can also be considered as a therapeutic opportunity. It has been estimated that more than 90% of small therapeutic molecules are not able to cross the BBB [<xref rid=""B13-ijms-25-04828""",10_9,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"to cross the BBB [<xref rid=""B13-ijms-25-04828"" ref-type=""bibr"">13</xref>]. This include viral vectors used in gene replacement strategies for brain disorders [<xref rid=""B14-ijms-25-04828"" ref-type=""bibr"">14</xref>]. Thus, an increased permeability of the BBB can be seen as an advantage as it facilitates the entry of therapeutic agents inside the cerebral parenchyma. For instance, in the case of Leigh syndrome (LS), one of the most common and severe mitochondrial diseases, pre-clinical studies testing",10_10,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"diseases, pre-clinical studies testing small molecules showed remarkable therapeutic effects in <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice [<xref rid=""B15-ijms-25-04828"" ref-type=""bibr"">15</xref>,<xref rid=""B16-ijms-25-04828"" ref-type=""bibr"">16</xref>,<xref rid=""B17-ijms-25-04828"" ref-type=""bibr"">17</xref>,<xref rid=""B18-ijms-25-04828"" ref-type=""bibr"">18</xref>]. However, conflicting results exist in the literature regarding the ability of theses compound to cross the BBB. Thus, one can wonder",10_11,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"compound to cross the BBB. Thus, one can wonder whether their beneficial effects were facilitated by an increase in BBB permeability or by an indirect action. In the same animal model of LS, gene replacement strategies to reinstate <italic toggle=""yes"">Ndufs4</italic> gene expression have been explored [<xref rid=""B19-ijms-25-04828"" ref-type=""bibr"">19</xref>,<xref rid=""B20-ijms-25-04828"" ref-type=""bibr"">20</xref>,<xref rid=""B21-ijms-25-04828"" ref-type=""bibr"">21</xref>,<xref rid=""B22-ijms-25-04828""",10_12,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"rid=""B22-ijms-25-04828"" ref-type=""bibr"">22</xref>,<xref rid=""B23-ijms-25-04828"" ref-type=""bibr"">23</xref>]. They used different approaches to bypass the BBB but none of them checked if the permeability of the BBB to adeno-associated viral (AAV) vectors was modified. Depending on this information, methods to deliver therapeutic agents could be adapted in this model as well as in other mitochondrial diseases. In this study, we chose to evaluate the integrity of the BBB in the most commonly studied mouse",10_13,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"of the BBB in the most commonly studied mouse model of LS, namely the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mouse [<xref rid=""B24-ijms-25-04828"" ref-type=""bibr"">24</xref>,<xref rid=""B25-ijms-25-04828"" ref-type=""bibr"">25</xref>]. <italic toggle=""yes"">Ndufs4</italic> encodes for a 17-kDa subunit of mitochondrial complex I. This mouse model is of particular interest because it replicates cardinal features of the human pathology. In particular, the neurological phenotype is severe and to the",10_14,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"the neurological phenotype is severe and to the animals’ death around post-natal day 50. Some pathological hallmarks such as inflammation or lipid droplet accumulation could favor alterations of the BBB [<xref rid=""B14-ijms-25-04828"" ref-type=""bibr"">14</xref>,<xref rid=""B26-ijms-25-04828"" ref-type=""bibr"">26</xref>,<xref rid=""B27-ijms-25-04828"" ref-type=""bibr"">27</xref>]. We first assessed the structural and molecular integrity of the BBB in one-month-old <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic>",10_15,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice. Then, we evaluated its permeability to an AAV9 vector as well as to exogenous and endogenous molecules of various sizes. Our results showed that the BBB of <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice was not impaired. This study confirms the necessity to use strategies promoting the passage of therapeutic agents across the BBB in this mitochondrial disease.  Mitochondrial dysfunction occurs during organismal senescence and is observed in a",10_16,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"during organismal senescence and is observed in a plethora of genetic and sporadic diseases in which increased BBB permeability was also reported. Establishing the direct causative role of mitochondrial dysfunction on the vascular integrity is quite challenging as several pathogenic mechanisms contribute simultaneously to the disease. In this study, we chose to address this question in an in vivo model of primary mitochondrial defect. LS is the most common and one of the most severe mitochondrial diseases.",10_17,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"one of the most severe mitochondrial diseases. This pediatric condition causes major neurometabolic symptoms that lead to the death of patients within the first decade of life [<xref rid=""B30-ijms-25-04828"" ref-type=""bibr"">30</xref>]. To date, there is no cure for this fatal disease and LS patients are only offered symptomatic and palliative treatments [<xref rid=""B31-ijms-25-04828"" ref-type=""bibr"">31</xref>]. Among the ~90 genes associated with LS, the ablation of murine <italic",10_18,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"with LS, the ablation of murine <italic toggle=""yes"">Ndufs4</italic>, a gene encoding a structural protein of mitochondrial complex I, faithfully replicates cardinal symptoms observed in LS patients [<xref rid=""B24-ijms-25-04828"" ref-type=""bibr"">24</xref>,<xref rid=""B25-ijms-25-04828"" ref-type=""bibr"">25</xref>,<xref rid=""B27-ijms-25-04828"" ref-type=""bibr"">27</xref>]. Hence, <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice represent a relevant model to explore the consequence of mitochondrial",10_19,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"model to explore the consequence of mitochondrial dysfunction of BBB integrity. Previous studies in <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice showed that tissues are differentially affected and this correlates with their reliance on the oxidative phosphorylation system [<xref rid=""B20-ijms-25-04828"" ref-type=""bibr"">20</xref>,<xref rid=""B24-ijms-25-04828"" ref-type=""bibr"">24</xref>]. Here, we demonstrated that complex I activity is severely impaired in cells constituting the BBB in this mouse",10_20,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"in cells constituting the BBB in this mouse model. Structurally, this does not have a major impact on the cerebral vasculature nor on the expression of proteins of the tight and adherens junctions. The absence of anatomical or molecular abnormalities does not predict a normal permeability as one cannot not assess every single component of these junctions. Therefore, we performed functional experiments with molecules of various size ranging from ~25 nm (AAV vectors) to ~1 kDa (Evans blue). Our results",10_21,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"(AAV vectors) to ~1 kDa (Evans blue). Our results showed that the deletion of <italic toggle=""yes"">Ndufs4</italic> does not affect the permeability to an AAV9-GFP vector injected systemically in 1-month-old mice. These data confirm the rationale of previous studies including ours using methods to bypass the BBB in this mouse model of LS. This included the direct delivery of the viral particles by stereotaxic surgery [<xref rid=""B19-ijms-25-04828"" ref-type=""bibr"">19</xref>,<xref rid=""B20-ijms-25-04828""",10_22,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"rid=""B20-ijms-25-04828"" ref-type=""bibr"">20</xref>,<xref rid=""B21-ijms-25-04828"" ref-type=""bibr"">21</xref>], the injection during the postnatal period at a time where the BBB is still open [<xref rid=""B19-ijms-25-04828"" ref-type=""bibr"">19</xref>,<xref rid=""B20-ijms-25-04828"" ref-type=""bibr"">20</xref>], and the administration of novel AAV capsids with increased ability to cross the BBB [<xref rid=""B22-ijms-25-04828"" ref-type=""bibr"">22</xref>,<xref rid=""B23-ijms-25-04828"" ref-type=""bibr"">23</xref>]. Together",10_23,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"ref-type=""bibr"">23</xref>]. Together with the finding that brain-specific deletion of <italic toggle=""yes"">Ndufs4</italic> replicates pathological features of LS [<xref rid=""B27-ijms-25-04828"" ref-type=""bibr"">27</xref>], these studies consolidate the idea that gene replacement strategies must target the central nervous system in order to provide a robust therapeutic effect. Then, we tested the permeability of the BBB to smaller molecules using standard methods. Our data showed that albumin (66 kDa) bound",10_24,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"Our data showed that albumin (66 kDa) bound or unbound to Evans blue cannot pass the BBB neither in young <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice nor in control littermates. Experiments based on the systemic injection of Evans blue (960 Da) assess not only the short-term passage of albumin but also that of the dye itself from the unbound fraction [<xref rid=""B32-ijms-25-04828"" ref-type=""bibr"">32</xref>,<xref rid=""B33-ijms-25-04828"" ref-type=""bibr"">33</xref>]. Nevertheless, we cannot exclude",10_25,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"Nevertheless, we cannot exclude the possibility that molecules smaller than Evans blue could pass the BBB in this mouse model. Transporter systems play an important role in BBB permeability, most importantly by regulating the entry of more than 90% of the drugs into the central nervous system. This active transport was not examined here because several studies tested the therapeutic effect of candidate compounds in this mouse model of LS. Thereby, the integrity of selective transports has been indirectly",10_26,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"of selective transports has been indirectly investigated. For instance, Perry and colleagues examined concentration of doxycycline (~444 Da) in the brain of <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice and control littermates and found no difference [<xref rid=""B17-ijms-25-04828"" ref-type=""bibr"">17</xref>]. These transporters require ATP consumption. It has been previously described that disruption of complex I activity in this mouse model of LS does not cause a reduction in ATP level [<xref",10_27,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"LS does not cause a reduction in ATP level [<xref rid=""B24-ijms-25-04828"" ref-type=""bibr"">24</xref>]. This supports the hypothesis that ATP-dependent transport is unaffected in this mouse model. Nevertheless, future pharmacological strategies in this model will have to take into consideration the size and the ability of candidate molecules to cross the BBB. This study is the first to examine the structural and functional integrity in a genetic mouse model of primary mitochondrial deficiency. In 2015, Doll",10_28,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"primary mitochondrial deficiency. In 2015, Doll and colleagues reported that rotenone-induced complex I inhibition disrupts the BBB in in vitro and in vivo models. The discrepancy between this report and our findings can be explained by the difference in methodologies. As nicely described by the authors as “a mitochondrial crisis”, this pharmacological approach triggers a sudden and very acute inhibition of complex I activity that is unlikely to be replicated in transgenic mice or in patients. We",10_29,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"replicated in transgenic mice or in patients. We hypothesize that the residual activity of complex I in <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice is sufficient to maintain a permeability similar to that in control mice [<xref rid=""B20-ijms-25-04828"" ref-type=""bibr"">20</xref>,<xref rid=""B24-ijms-25-04828"" ref-type=""bibr"">24</xref>,<xref rid=""B25-ijms-25-04828"" ref-type=""bibr"">25</xref>]. This suggests that a major impairment in oxidative phosphorylation in cells composing the BBB does not",10_30,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"in cells composing the BBB does not significantly affect their function and that they may rely mostly on other metabolic sources [<xref rid=""B34-ijms-25-04828"" ref-type=""bibr"">34</xref>]. With the current set of results, we can only draw the conclusion that the BBB is not structurally or functionally altered in 1-month-old <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice. To broaden this conclusion, it will be essential to carry out similar experiments in other genetic mouse models of LS such as",10_31,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"in other genetic mouse models of LS such as <italic toggle=""yes"">Surf1<sup>−/−</sup></italic> mice that present a deficiency in complex IV activity [<xref rid=""B35-ijms-25-04828"" ref-type=""bibr"">35</xref>]. One step further will be to assess the permeability of the BBB in other models of mitochondrial diseases [<xref rid=""B36-ijms-25-04828"" ref-type=""bibr"">36</xref>]. Mice with coenzyme Q10 deficiency would be good candidates as Wainwright and colleagues [<xref rid=""B12-ijms-25-04828""",10_32,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"and colleagues [<xref rid=""B12-ijms-25-04828"" ref-type=""bibr"">12</xref>] previously reported that the pharmacological depletion of this coenzyme via the inhibition of its biosynthetic pathway in porcine and murine endothelial cell lines leads to an increase in BBB permeability. This would allow us to further ascertain the robustness of approaches combining in vitro models with pharmacological treatments by comparing these results to more relevant in vivo models. Considering that mitochondrial diseases are",10_33,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"Considering that mitochondrial diseases are a very heterogenous family with a wide spectrum of presentation, the fact that we investigated this question in one of the more severe models of mitochondrial disease does not preclude that milder forms caused by deletion of other genes associated with the oxidative phosphorylation system can disrupt the BBB. Since <italic toggle=""yes"">Ndufs4</italic> encodes for a structural sub-unit of complex I, it is possible that deficiency in mitochondrial proteins with",10_34,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"that deficiency in mitochondrial proteins with enzymatic activities may have different consequences on BBB permeability. This stresses the importance of exploring this question in complementary models without assuming that similar results will be found. We cannot exclude the possibility that the BBB may be compromised in older <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice. One-month-old animals were chosen on the basis of previous gene therapy studies and the fact that it corresponds to a time",10_35,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"and the fact that it corresponds to a time window at which patients could be treated [<xref rid=""B22-ijms-25-04828"" ref-type=""bibr"">22</xref>,<xref rid=""B23-ijms-25-04828"" ref-type=""bibr"">23</xref>]. It has been recently shown that 50-day-old <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> mice in which brain-resident microglia have been depleted exhibit peripheral macrophages at the site of necrotic lesions [<xref rid=""B37-ijms-25-04828"" ref-type=""bibr"">37</xref>]. This may reflect a region-specific",10_36,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"This may reflect a region-specific collapse of the BBB at the end-stage of the disease and the subsequent invasion of circulating immune cells. These findings contribute to the continuous characterization of this highly relevant model of LS that remains a powerful tool to explore disease-related mechanisms and to test therapeutic strategies. Unfortunately, we cannot compare these results to clinical observations as no study has yet explored the permeability of the BBB in children affected with LS.",10_37,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"of the BBB in children affected with LS. Altogether, this study represents the first report on the structural and functional integrity of the BBB in a standard model of primary mitochondrial deficiency.",10_38,"The Blood–Brain Barrier Is Unaffected in the <italic toggle=""yes"">Ndufs4<sup>−/−</sup></italic> Mouse Model of Leigh Syndrome",29 4 2024,,Leigh_Syndrome
"Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC) Leigh syndrome French Canadian type (LSFC) is a recessive neurodegenerative disease characterized by tissue-specific deficiency in cytochrome c oxidase (COX), the fourth complex in the oxidative phosphorylation system. LSFC is caused by mutations in the leucine rich pentatricopeptide repeat containing gene (<italic toggle=""yes"">LRPPRC</italic>). Most",11_0,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"gene (<italic toggle=""yes"">LRPPRC</italic>). Most LSFC patients in Quebec are homozygous for an A354V substitution that causes a decrease in the expression of the LRPPRC protein. While LRPPRC is ubiquitously expressed and is involved in multiple cellular functions, tissue-specific expression of LRPPRC and COX activity is correlated with clinical features. In this proof-of-principle study, we developed human induced pluripotent stem cell (hiPSC)-based models from fibroblasts taken from a patient with LSFC,",11_1,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"from fibroblasts taken from a patient with LSFC, homozygous for the <italic toggle=""yes"">LRPPRC</italic>*354V allele, and from a control, homozygous for the <italic toggle=""yes"">LRPPRC</italic>*A354 allele. Specifically, for both of these fibroblast lines we generated hiPSC, hiPSC-derived cardiomyocytes (hiPSC-CMs) and hepatocyte-like cell (hiPSC-HLCs) lines, as well as the three germ layers. We observed that LRPPRC protein expression is reduced in all cell lines/layers derived from LSFC patient compared",11_2,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"lines/layers derived from LSFC patient compared to control cells, with a reduction ranging from ∼70% in hiPSC-CMs to undetectable levels in hiPSC-HLC, reflecting tissue heterogeneity observed in patient tissues. We next performed exploratory analyses of these cell lines and observed that COX protein expression was reduced in all cell lines derived from LSFC patient compared to control cells. We also observed that mutant LRPPRC was associated with altered expression of key markers of endoplasmic reticulum",11_3,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"of key markers of endoplasmic reticulum stress response in hiPSC-HLCs but not in other cell types that were tested. While this demonstrates feasibility of the approach to experimentally study genotype-based differences that have tissue-specific impacts, this study will need to be extended to a larger number of patients and controls to not only validate the current observations but also to delve more deeply in the pathogenic mechanisms of LSFC. Leigh syndrome French Canadian (LSFC; OMIM#220111) is a",11_4,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"syndrome French Canadian (LSFC; OMIM#220111) is a recessive neurodegenerative infantile disease, lethal in most cases within the first 2 years of life, with high incidence in the Saguenay-Lac-St-Jean region of Quebec, (∼1/2,000 births; carrier rate 1/23) (<xref rid=""B13"" ref-type=""bibr"">Merante et al., 1993</xref>; <xref rid=""B16"" ref-type=""bibr"">Morin et al., 1993</xref>). LSFC is caused by mutations in the nuclear-encoded gene leucine rich pentatricopeptide repeat containing protein (<italic",11_5,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"repeat containing protein (<italic toggle=""yes"">LRPPRC</italic>) (<xref rid=""B15"" ref-type=""bibr"">Mootha et al., 2003</xref>). Most LSFC patients in Quebec are homozygous for an A354V substitution, except for one compound heterozygous patient that also carries a truncation variant in exon 35 that results in a premature stop at amino acid 1,277. Other variants in <italic toggle=""yes"">LRPPRC</italic> have been identified in unrelated families in Europe and China (<xref rid=""B18"" ref-type=""bibr"">Olahova et",11_6,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"China (<xref rid=""B18"" ref-type=""bibr"">Olahova et al., 2015</xref>; <xref rid=""B8"" ref-type=""bibr"">Han et al., 2017</xref>; <xref rid=""B21"" ref-type=""bibr"">Piro et al., 2020</xref>). Although associated with a variable phenotypic severity, at the molecular level, all patients exhibit a decrease in the steady-state level of the LRPPRC protein (<xref rid=""B15"" ref-type=""bibr"">Mootha et al., 2003</xref>; <xref rid=""B28"" ref-type=""bibr"">Xu et al., 2004</xref>). LRPPRC is a ubiquitously-expressed mitochondrial",11_7,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"LRPPRC is a ubiquitously-expressed mitochondrial protein that plays various biological roles via direct and indirect protein-protein interactions, including in energy metabolism and maturation of nuclear export of mRNA (<xref rid=""B4"" ref-type=""bibr"">Cui et al., 2019</xref>). LSFC is characterized by tissue-specific deficiency in cytochrome c oxidase (COX), the fourth complex in the oxidative phosphorylation (OXPHOS) system. COX activity is estimated at 10%–20% in brain and liver, 50% in skin fibroblasts",11_8,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"in brain and liver, 50% in skin fibroblasts and skeletal muscle, while close to normal in kidney and heart (<xref rid=""B13"" ref-type=""bibr"">Merante et al., 1993</xref>). Biomolecular analyses conducted in post-mortem tissues from LSFC patients also showed that loss of LRPPRC and its interacting protein SLIRP results in tissue-specific OXPHOS deficiency (<xref rid=""B23"" ref-type=""bibr"">Sasarman et al., 2015</xref>). Tissue-specific differences in the levels of mutant LRPPRC protein could thus partially",11_9,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"of mutant LRPPRC protein could thus partially explain the tissue heterogeneity. To better understand the tissue-dependent impact of the <italic toggle=""yes"">LRPPRC</italic> mutation, additional model systems are needed. Not surprisingly germline knockout (KO) and knock in (KI) mouse models for <italic toggle=""yes"">LRPPRC</italic> are non-viable, with tissue-specific conditional KO are very challenging (e.g., neuron-specific model survives only a few days; hepatocyte-specific model is unstable over time as",11_10,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"model is unstable over time as there is presence of residual amounts of LRPPRC which is likely attributable to liver regeneration). We were therefore interested in determining whether patient-derived hiPSC-based models (<xref rid=""B25"" ref-type=""bibr"">Takahashi and Yamanaka, 2006</xref>) could provide an opportunity to not only study pathogenic mechanisms but also the mechanisms by which certain organs are spared. Furthermore, considering that the mitochondrial complex assembly machinery is specific to",11_11,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"complex assembly machinery is specific to humans, hiPSC-based models offer unique systems to study such diseases (for review (<xref rid=""B10"" ref-type=""bibr"">Inak et al., 2017</xref>)). In this proof-of-principle study, hiPSCs were successfully reprogrammed from fibroblasts from one LSFC patient homozygous for <italic toggle=""yes"">LRPPRC</italic>*354V and one control. We used these cells to specifically assess the impact of the <italic toggle=""yes"">LRPPRC</italic>*354V mutation in (i) hiPSCs, (ii) cells",11_12,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"mutation in (i) hiPSCs, (ii) cells from the three germ layers, namely, definitive endoderm, ectoderm and mesoderm, (iii) hiPSC-derived cardiomyocytes (hiPSC-CMs) and (iv) hiPSC-derived hepatocyte-like cells (hiPSC-HLCs). We observed tissue specific differences in LRPPRC expression in lines derived from the LSFC patient that were consistent with that observed in patient tissues. While these observations need to be extended to additional patients and control individuals, we propose that genotype-specific",11_13,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"individuals, we propose that genotype-specific hiPSC-based models have the potential to help address the molecular basis of tissue specificity in pathophysiology of LSFC.  With the objective of establishing an experimental model to enable the investigation of tissue-specific differences observed in LSFC patients, we set out to generate hiPSC lines from fibroblast lines established from a patient with LSFC as well as from a sex and age-matched control and then differentiate these into the three germ layers,",11_14,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"differentiate these into the three germ layers, as well as into hepatic and cardiac lineages (<xref rid=""s11"" ref-type=""sec"">Supplementary Figure S1</xref>). LSFC is a recessive disorder characterized by tissue-specific deficiency in COX and OXPHOS capacity which is associated with a spectrum of clinical manifestations. (<xref rid=""B16"" ref-type=""bibr"">Morin et al., 1993</xref>; <xref rid=""B6"" ref-type=""bibr"">Debray et al., 2011</xref>). Since identification of <italic toggle=""yes"">LRPPRC</italic> as the",11_15,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"of <italic toggle=""yes"">LRPPRC</italic> as the causal gene for LSFC in 2003, numerous studies have demonstrated its multiple biological roles such as mitochondrial gene translation (<xref rid=""B14"" ref-type=""bibr"">Mili and Pinol-Roma, 2003</xref>), regulating autophagy (<xref rid=""B32"" ref-type=""bibr"">Zou et al., 2013</xref>), and tumorigenesis (<xref rid=""B26"" ref-type=""bibr"">Tian et al., 2012</xref>) and have begun to elucidate its role in the pathogenesis of LSFC. None of the existing models, however,",11_16,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"of LSFC. None of the existing models, however, enable the study of the tissue-specific differences in pathology or the tissue-specific differences in LRPPRC expression observed in children affected with LSFC, most of whom are homozygous for the <italic toggle=""yes"">LRPPRC</italic>*354V mutation. Interestingly, studies conducted in hiPSC lines from patients with other mitochondrial diseases have proven very valuable for functional studies (<xref rid=""B12"" ref-type=""bibr"">Ma et al., 2015</xref>; <xref",11_17,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"ref-type=""bibr"">Ma et al., 2015</xref>; <xref rid=""B9"" ref-type=""bibr"">Hattori et al., 2016</xref>; <xref rid=""B30"" ref-type=""bibr"">Zheng et al., 2016</xref>; <xref rid=""B7"" ref-type=""bibr"">Galera-Monge et al., 2020</xref>). This study was thus undertaken to evaluate if hiPSC-derived cells from LSFC patient could be used as an additional and complementary tool for LSFC research and to specifically assess the tissue-specific impact of <italic toggle=""yes"">LRPPRC</italic>*354V. We show here the first time",11_18,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"We show here the first time that it is possible to generate hiPSCs from an LSFC patient harboring the <italic toggle=""yes"">LRPPRC</italic>*354V homozygous mutation and to differentiate them in various cell lines that can be used to assess the multisystem complexity of this severe metabolic disease. In this proof-of-principle study, we observed that hiPSCs derived from a patient homozygous for the <italic toggle=""yes"">LRPPRC</italic>*354V mutation showed decreased levels of LRPPRC as compared to control",11_19,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"decreased levels of LRPPRC as compared to control hiPSCs homozygous for the ancestral <italic toggle=""yes"">LRPPRC</italic>*A354 allele. HiPSCs were also successfully differentiated in hiPSC-CMs and hiPSC-HLCs. Protein expression analyses showed that while LRPPRC is undetectable in LSFC hiPSC-HLCs its expression was partially reduced (by 70%) in LSFC hiPSC-CMs. This differs from the absence of LRPPRC expression as previously observed in total heart tissue from one LSFC patient post-mortem (<xref rid=""B23""",11_20,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"one LSFC patient post-mortem (<xref rid=""B23"" ref-type=""bibr"">Sasarman et al., 2015</xref>). Regarding the impact of the mutation on the protein levels of COX, they were reduced by 78% in hiPSC-HLCs and by 48% in hiPSC-CMs from LSFC compared to control. Despite changes in LRPPRC and COXIV expression, ATP content as similar in LSFC cells compared to control, at least in hiPSCs cultured in basal conditions. Moreover, preliminary data looking at ATP content in LSFC hiPSC-HLCs compared to control hiPSC-HLCs",11_21,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"in LSFC hiPSC-HLCs compared to control hiPSC-HLCs revealed no major changes in basal condition as well as following 4 h of incubation with 1 mM palmitate, a condition used to mimic metabolic stress. This suggests that altered ATP production is not the primary impact of the mutation in LSFC. Unchanged ATP content has also been previously reported in fibroblasts from LSFC patients despite presence of multiple functional abnormalities in mitochondria, this could be the result of increased glycolytic flux",11_22,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"could be the result of increased glycolytic flux (<xref rid=""B2"" ref-type=""bibr"">Burelle et al., 2015</xref>; <xref rid=""B17"" ref-type=""bibr"">Mukaneza et al., 2019</xref>). As LSFC is a developmental disease, we performed exploratory analyses of the three primary germ layers derived from the hiPSC lines from the LSFC patient and control individual. When comparing these, we observed that the lines from the LSFC patient were noticeably different from the control lines. Specifically, we observed that the",11_23,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"control lines. Specifically, we observed that the mesoderm, from which derives cardiac muscle, seems to be the least affected (35% reduced protein expression) than ectoderm (66% reduced protein expression) and definitive endoderm (81% reduced protein expression), from which derive respectively neural and gastrointestinal tract tissues, including the liver. These results suggest that the impact of <italic toggle=""yes"">LRPPRC</italic>*354V could start as early as during embryogenesis and persist beyond. This",11_24,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"as during embryogenesis and persist beyond. This is consistent with our observations that <italic toggle=""yes"">LRPPRC</italic>*354V knock-in mice embryos were not viable past 10 days of gestation, limiting the window for experimental studies to address embryogenesis. Further studies are however needed to deepen our understanding of the impact of <italic toggle=""yes"">LRPPRC</italic>*354V during early development. Taken together our analyses performed in hiPSC-derived cell lines suggest that the impact of",11_25,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"cell lines suggest that the impact of the <italic toggle=""yes"">LRPPRC</italic>*354V mutation on the LRPPRC protein expression varies depending on cell type. This suggest that hiPSC derived cell lines, complementary to the other cell-based models for LSFC as well as tissue-specific LRPPRC conditional knock-out mice, are relevant experimental models to assess the tissue-specificity impact of the mutation. In our exploratory studies to elucidate the impact of <italic toggle=""yes"">LRPPRC</italic>*354V mutation",11_26,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"toggle=""yes"">LRPPRC</italic>*354V mutation in hiPSC-derived cell lines, we have studied the expression of genes and protein associated with ER stress response or unfolded protein response (UPR). The roles of ER stress in LSFC phenotype is unknown, however, it has been shown in mammalian cell cultures and <italic toggle=""yes"">C. elegans</italic> that knocking down the expression of LRPPRC (or LRPPRC-like gene mma-1 in C. elegans) triggers transient activation of the mitochondrial UPR (mtUPR). CHOP is the",11_27,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"of the mitochondrial UPR (mtUPR). CHOP is the highest inducible gene during ER stress and is one of the first factors involved in mediating the mtUPR, which is an essential mediator of a response to mitochondrial dysfunction (<xref rid=""B1"" ref-type=""bibr"">Anderson and Haynes, 2020</xref>). Our preliminary data suggest increased mRNA levels for <italic toggle=""yes"">CHOP</italic> and <italic toggle=""yes"">BAX</italic> in LSFC hiPSC-HLCs. This increased in <italic toggle=""yes"">CHOP</italic> transcript level",11_28,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"toggle=""yes"">CHOP</italic> transcript level is consistent with what has been reported in whole liver of mouse with hepatocyte-specific inactivation of <italic toggle=""yes"">Lrpprc</italic> (<xref rid=""B5"" ref-type=""bibr"">Cuillerier et al., 2021</xref>). We also looked at the expression of BiP, also known as GRP78, a regulator of ER homeostasis (<xref rid=""B20"" ref-type=""bibr"">Pfaffenbach and Lee, 2011</xref>). We observed that while <italic toggle=""yes"">HSPA5</italic> transcript levels were increased, BiP",11_29,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"transcript levels were increased, BiP protein expression was reduced specifically in hiPSC-HLCs from LSFC patient. The exact impact of this discordance between transcript and protein BiP/GRP78 levels remains to be assessed. However, similarly altered expression of ER stress and mtUPR proteins, increased CHOP and Bcl-2 related proteins and decreased BiP levels, are observed in human hepatic tissue with nonalcoholic fatty liver disease (NAFLD) (<xref rid=""B11"" ref-type=""bibr"">Lee et al., 2017</xref>). This",11_30,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"ref-type=""bibr"">Lee et al., 2017</xref>). This is of interest considering that mice with hepatocyte-specific deletion of <italic toggle=""yes"">Lrpprc</italic> as well as LSFC patients present with major lipid changes evocative of NAFLD, including increased triglyceride and long-chain acylcarnitine levels and altered phospholipid content (<xref rid=""B22"" ref-type=""bibr"">Ruiz et al., 2019</xref>). Further studies are needed to assess the exact impact of these changes in LSFC physiopathology. However,",11_31,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"these changes in LSFC physiopathology. However, considering that persistent ER stress triggers the basic mechanisms involved in the development or pathology of many diseases including metabolic, neurodegenerative and inflammatory diseases (<xref rid=""B3"" ref-type=""bibr"">Chaudhari et al., 2014</xref>; <xref rid=""B27"" ref-type=""bibr"">Wang and Kaufman, 2014</xref>; <xref rid=""B31"" ref-type=""bibr"">Zhu et al., 2014</xref>), our results reinforce the idea that altered mtUPR in the liver could partially underlie",11_32,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"mtUPR in the liver could partially underlie liver impairment in LSFC patients. In conclusion, we report here for the first time the successful generation of hiPSC-derived cells from LSFC patient. While the current findings need to be validated in a larger number of cell lines derived from independent patients, our study highlights the relevance of hiPSC-derived models for studying the mechanistic and tissue-specific impacts of the <italic toggle=""yes"">LRPPRC</italic>*354V mutation, with the hope that this",11_33,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"mutation, with the hope that this model will also contribute to the future development of therapies for this currently incurable disease.",11_34,Human induced pluripotent stem cells (hiPSCs) derived cells reflect tissue specificity found in patients with Leigh syndrome French Canadian variant (LSFC),19 4 2024,,Leigh_Syndrome
"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome Oxidative phosphorylation involves a complex multi-enzymatic mitochondrial machinery critical for proper functioning of the cell, and defects herein cause a wide range of diseases called “primary mitochondrial disorders” (PMDs). Mutations in about 400 nuclear and 37 mitochondrial genes have been documented to cause PMDs, which have an estimated birth prevalence of 1:5000. Here,",12_0,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"an estimated birth prevalence of 1:5000. Here, we describe a 4-year-old female presenting from early childhood with psychomotor delay and white matter signal changes affecting several brain regions, including the brainstem, in addition to lactic and phytanic acidosis, compatible with Leigh syndrome, a genetically heterogeneous subgroup of PMDs. Whole genome sequencing of the family trio identified a homozygous 12.9 Kb deletion, entirely overlapping the <italic toggle=""yes"">NDUFA4</italic> gene. Sanger",12_1,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"<italic toggle=""yes"">NDUFA4</italic> gene. Sanger sequencing of the breakpoints revealed that the genomic rearrangement was likely triggered by Alu elements flanking the gene. <italic toggle=""yes"">NDUFA4</italic> encodes for a subunit of the respiratory chain Complex IV, whose activity was significantly reduced in the patient’s fibroblasts. In one family, dysfunction of NDUFA4 was previously documented as causing mitochondrial Complex IV deficiency nuclear type 21 (MC4DN21, OMIM 619065), a relatively mild",12_2,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"type 21 (MC4DN21, OMIM 619065), a relatively mild form of Leigh syndrome. Our finding confirms the loss of NDUFA4 function as an ultra-rare cause of Complex IV defect, clinically presenting as Leigh syndrome. The mitochondrial respiratory electron transport chain (ETC) is essential to carry out the oxidative phosphorylation (OXPHOS) process, resulting in the generation of ATP, the major source of cell energy, and regulates a spectrum of physiological processes, such as cell death, the production of",12_3,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"processes, such as cell death, the production of reactive oxygen species (ROS), inflammation responses, tumor growth, and thermogenesis. This system is therefore critical to cell metabolism, and germline pathogenic variants in genes coding for components that are required for the OXPHOS process underlie “primary mitochondrial disorders”, PMDs [<xref rid=""B1-genes-15-00500"" ref-type=""bibr"">1</xref>], which cause a spectrum of metabolic conditions. The minimum birth prevalence of PMDs is estimated to be 1 in",12_4,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"birth prevalence of PMDs is estimated to be 1 in 5000 [<xref rid=""B2-genes-15-00500"" ref-type=""bibr"">2</xref>]. These diseases vary in terms of age of onset, rapidity of progression, and organ system involvement. Biochemical changes, myopathy, and neurological anomalies are often co-existent [<xref rid=""B3-genes-15-00500"" ref-type=""bibr"">3</xref>]. The spectrum of phenotypes is wide and includes, for example: deafness, blindness, liver failure, kidney disease, peripheral neuropathy, hormone deficiency,",12_5,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"peripheral neuropathy, hormone deficiency, anemia, diabetes mellitus, and skin and hair anomalies [<xref rid=""B1-genes-15-00500"" ref-type=""bibr"">1</xref>]. Childhood progressive encephalopathies, also those caused by mitochondrial defects, carry an increased mortality risk, particularly if the onset occurs early in life [<xref rid=""B4-genes-15-00500"" ref-type=""bibr"">4</xref>]. The complexity of the clinical manifestations poses a challenge in the recognition of PMDs on clinical grounds. Similarly, the",12_6,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"of PMDs on clinical grounds. Similarly, the genetic bases of PMDs are heterogeneous with about 400 nuclear and 37 mitochondrial DNA (nDNA and mtDNA) genes documented to cause these diseases [<xref rid=""B5-genes-15-00500"" ref-type=""bibr"">5</xref>]. The high number of genes involved reflects the molecular complexity of the mitochondrial ETC, which consists of five enzymatic complexes and two mobile electron carriers (ubiquinone and cytochrome c). Its function is to couple the oxidation of reducing",12_7,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"function is to couple the oxidation of reducing equivalents entering the ETC to the establishment of a proton gradient across the inner mitochondrial membrane that in turn is used to phosphorylate ADP. The mitochondrial ETC Complex IV, or cytochrome <italic toggle=""yes"">c</italic> oxidase (COX), is the terminal enzyme of the ETC. COX is a heme-copper oxidase, composed by 14 subunits where three mtDNA encoded subunits (MT-CO1, MT-CO2, and MT-CO3) form the catalytic core and 11 nDNA encoded subunits (COX4,",12_8,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"core and 11 nDNA encoded subunits (COX4, COX5A, COX5B, COX6A, COX6B, COX6C, COX7A, COX7B, COX7C, COX8, and NDUFA4/COXFA4) are important for COX stability and regulation [<xref rid=""B6-genes-15-00500"" ref-type=""bibr"">6</xref>]. NDUFA4 was initially described as a Complex I subunit but was later resolved to be a protein capable of associating both to Complex I and Complex IV, although its role seems to be critical to maximizing Complex IV enzymatic activity [<xref rid=""B6-genes-15-00500""",12_9,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"enzymatic activity [<xref rid=""B6-genes-15-00500"" ref-type=""bibr"">6</xref>,<xref rid=""B7-genes-15-00500"" ref-type=""bibr"">7</xref>,<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>,<xref rid=""B9-genes-15-00500"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-15-00500"" ref-type=""bibr"">10</xref>]. The main aim of this study was to document that mutation in <italic toggle=""yes"">NDUFA4</italic> mediates ETC deficiency in an unreported patient with mitochondrial Complex IV deficiency nuclear type 21 (MC4DN21,",12_10,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"Complex IV deficiency nuclear type 21 (MC4DN21, OMIM 619065). Whole Genome Sequencing (WGS) analysis unraveled complete loss of the <italic toggle=""yes"">NDUFA4</italic> gene, and we documented significantly reduced COX activity in primary fibroblasts from the patient; these findings explain the patient’s symptoms in line with Leigh syndrome. Genetic studies: The sample DNA was extracted from the whole blood and the whole genome library preparation was performed with the Illumina TruSeq DNA PCR-free Library",12_11,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"with the Illumina TruSeq DNA PCR-free Library Prep Kit (Illumina, San Diego, CA, USA). WGS was then performed with the NovaSeq 6000 system (Illumina, San Diego, CA, USA). The sequence reads were aligned with the human reference genome (hg19), and the SNP, indel, and CNV were called by the Illumina Dragen DNA pipeline (v3.9.3). The median coverage of the sample was 62×, with 89.44% of the genome covered by more than 20 reads and 89.79% covered by more than 10 reads. The coverage per gene was calculated by",12_12,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"10 reads. The coverage per gene was calculated by the tool DepthOfCoverage in the Genome Analysis Toolkit (GATK, v3.8.1) [<xref rid=""B11-genes-15-00500"" ref-type=""bibr"">11</xref>]. For Sanger sequencing of breakpoints, we designed the following primers using Primer3Plus Fwd TGTGGACAGGCATTGCTTTA and Rev TCCACTAACTTCAATGTGCAAAA to amplify the deleted allele, and Fwd GGTAAGGAGCATGGCTGTG and Rev ACCATGGCTTCTTTTTCCAG. DNA sequencing of the PCR products was performed on ABI 3730 with the ABI PRISM BigDye",12_13,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"performed on ABI 3730 with the ABI PRISM BigDye Terminator v. 3.1 sequencing kit (Applied Biosystems, Thermo Scientific, Waltham, MA, USA). Sequencing chromatograms were analyzed using CodonCode Aligner software version 8.0.2 (CodonCode Corp., Centerville, MA, USA). ETC analyses: Fibroblasts were grown in DMEM/high glucose supplemented with 10% FCS. One million subconfluent cells were pelleted, washed in SETH (250 mM Sucrose, 2 mM EDTA, 10 mM Tris, 5 × 10<sup>4</sup> U/L heparin, pH 7.4), and stored at −80",12_14,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"U/L heparin, pH 7.4), and stored at −80 °C until their analyses. Whole cell lysates were used for the enzymatic analyses. Activities of citrate synthase (CS), and the electron transport chain (ETC) activities of Complex I (NADH-quinone oxidoreductase; NQR), Complex II/succinate dehydrogenase (SDH), NADH-cytochrome C reductase (NCR), succinate-cytochrome C reductase (SCR), and cytochrome C oxidase (COX) were performed according to Wibom et al. [<xref rid=""B12-genes-15-00500"" ref-type=""bibr"">12</xref>], and",12_15,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"ref-type=""bibr"">12</xref>], and adapted to robotized analysis on IndikoTM Clinical Chemistry Analyzer (Thermo Scientific, Waltham, MA, USA). Briefly, we used 1 million cells (of separate passages) and prepared freeze–thawed cell lysate as described [<xref rid=""B12-genes-15-00500"" ref-type=""bibr"">12</xref>]. The established procedure has a detection limit (based on signal-to-noise ratio) for each complex. In 2 out of 6 preparations, the amount of extracted mitochondrial complex was below the detection limit",12_16,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"complex was below the detection limit for NQR activity and was consequently excluded. All complexes were related to citrate synthase activity, which means that this exclusion does not influence the range of activities. NQR and SDH activities were determined as the rotenone- and malonate-sensitive oxidation of NADH and succinate, respectively. The results shown are presented relative to the average of the activities in fibroblasts from two healthy donors.  We describe a 4-year-old Somali female presenting",12_17,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"We describe a 4-year-old Somali female presenting with developmental delay, ataxia, dystonia, spasticity, extensive white matter signal changes, and metabolic abnormalities measured in CSF and plasma. The patient was homozygous for a 12.9 Kb deletion entirely overlapping <italic toggle=""yes"">NDUFA4.</italic> Sanger sequencing of the chr7 deletion breakpoints redefined the deletion’s proximal breakpoint and revealed that the deleted region was replaced by a 337 bp insertion from chr19:14427161–14427497. The",12_18,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"bp insertion from chr19:14427161–14427497. The 337 bases on chromosome 19 and the breakpoint’s regions on chr7 contain sequences of the Alu family (<xref rid=""genes-15-00500-f002"" ref-type=""fig"">Figure 2</xref>). The Alu elements are an abundant family of sequence elements that has been amplified by retrotransposition during evolution to represent 10% of the human genome. These elements provide a major source of genome variability, contributing to both evolution and diseases. Alu elements, due to their",12_19,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"and diseases. Alu elements, due to their high copy number and sequence homology, represent very dynamic and unstable genomic regions and may cause genetic diseases. The regions are prone to structural rearrangements through different mechanisms, for example, nonallelic homologous recombination (NAHR) or the Fork Stalling and Template Switching (FoSTeS) model [<xref rid=""B13-genes-15-00500"" ref-type=""bibr"">13</xref>]. The sequence homologies (<xref rid=""app1-genes-15-00500"" ref-type=""app"">Supplementary",12_20,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"ref-type=""app"">Supplementary Materials</xref>) between the Alu elements at chr19:14427161–14427497 and those at the breakpoint’s regions on chr7 have likely triggered the deletion–insertion found in the present family.  <italic toggle=""yes"">NDUFA4</italic> encodes for a protein important for COX stability and regulation. In line with this, significantly reduced COX activity was found in fibroblasts from the patient compared to controls, while the activity of Complex I was within the normal range, further",12_21,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"of Complex I was within the normal range, further supporting the notion that NDUFA4 is a Complex IV subunit [<xref rid=""B6-genes-15-00500"" ref-type=""bibr"">6</xref>,<xref rid=""B7-genes-15-00500"" ref-type=""bibr"">7</xref>,<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>,<xref rid=""B9-genes-15-00500"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-15-00500"" ref-type=""bibr"">10</xref>]. However, it has to be noted that <italic toggle=""yes"">NDUFA4</italic> has two reported paralogues: <italic",12_22,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"has two reported paralogues: <italic toggle=""yes"">NDUFA4L2</italic> [<xref rid=""B14-genes-15-00500"" ref-type=""bibr"">14</xref>] and C15orf48 [<xref rid=""B15-genes-15-00500"" ref-type=""bibr"">15</xref>], which replace NDUFA4 in a cell- and condition-specific manner and, potentially, could serve a role as a backup function in some cells in this patient.  We did not find that the mouse knockout model for <italic toggle=""yes"">Ndufa4</italic> was characterized, but a Cre-Lox neuronal knockout was recently",12_23,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"but a Cre-Lox neuronal knockout was recently reported, where the authors found cellular abnormalities in the cortex, hippocampus, and cerebellum, and calcifications in the cerebellum [<xref rid=""B16-genes-15-00500"" ref-type=""bibr"">16</xref>]. These mice manifested impaired spatial learning capacity and exploratory activity [<xref rid=""B16-genes-15-00500"" ref-type=""bibr"">16</xref>]. Mitochondrial Complex IV deficiency, nuclear-type (MC4DN1, OMIM PS220110), or COX deficiency, is a genetically heterogeneous",12_24,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"or COX deficiency, is a genetically heterogeneous group of disorders with autosomal recessive inheritance caused by defects in more than 20 nDNA genes [<xref rid=""B17-genes-15-00500"" ref-type=""bibr"">17</xref>]. These genes encode for constituent subunits of COX and for proteins involved in the assembly of COX, for example, chaperones, transcriptional and translational activators, metal-binding proteins, and enzymes that complete the biosynthesis and incorporation of the heme group. In addition to the nDNA",12_25,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"of the heme group. In addition to the nDNA genes, mutations in the mitochondrial encoded genes <italic toggle=""yes"">MT-CO1-3</italic> also cause COX deficiency, and their clinical presentation and severity are largely dependent on the level of heteroplasmy [<xref rid=""B17-genes-15-00500"" ref-type=""bibr"">17</xref>]. COX deficiency manifests at an early age, often below 2 years, and can be lethal in childhood. However, mildly affected patients can have a later onset of symptoms and survive into adulthood,",12_26,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"onset of symptoms and survive into adulthood, and intrafamilial variability has also been reported. The clinical phenotypes vary from isolated benign myopathy to infantile fatal form with multiorgan involvement [<xref rid=""B17-genes-15-00500"" ref-type=""bibr"">17</xref>]. The Leigh syndrome spectrum is a genetically heterogeneous PMD, caused by the dysfunction of one of 113 genes [<xref rid=""B18-genes-15-00500"" ref-type=""bibr"">18</xref>], including some related to <italic toggle=""yes"">COX: MT-CO1</italic>,",12_27,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"to <italic toggle=""yes"">COX: MT-CO1</italic>, <italic toggle=""yes"">MT-CO2</italic>, <italic toggle=""yes"">MT-CO3</italic>, <italic toggle=""yes"">COX4I1</italic>, <italic toggle=""yes"">COX8A</italic>, <italic toggle=""yes"">COX10</italic>, <italic toggle=""yes"">COX15</italic>, <italic toggle=""yes"">LRPPRC</italic>, <italic toggle=""yes"">PET100</italic>, <italic toggle=""yes"">PET117</italic>, <italic toggle=""yes"">SCO2</italic>, <italic toggle=""yes"">SURF1</italic>, <italic toggle=""yes"">TACO1</italic>. In addition, one",12_28,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"toggle=""yes"">TACO1</italic>. In addition, one homozygous loss of function variant in <italic toggle=""yes"">NDUFA4</italic> was reported to cause mitochondrial Complex IV deficiency nuclear type 21 (MC4DN21, OMIM 619065) in one family where the four affected family members had phenotypes not unlike our patient, as all had a clinical diagnosis of LS [<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>]. The patients described by Pitceathly et al. [<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>]",12_29,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>] were homozygous for <italic toggle=""yes"">NDUFA4</italic> c.42+4G>C, which caused aberrant splicing, and NDUFA4 was not detected in muscle tissue and cultured skin fibroblasts. In blood, but not in fibroblasts, low levels of the wildtype transcript were detected [<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>]. The low-level expression of the wildtype <italic toggle=""yes"">NDUFA4</italic> transcript was suggested to be responsible for relatively mild",12_30,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"suggested to be responsible for relatively mild phenotypes with slow progression and survival into adulthood [<xref rid=""B8-genes-15-00500"" ref-type=""bibr"">8</xref>]. A clinical comparison of all the patients with pathogenic variants in <italic toggle=""yes"">NDUFA4</italic> is provided in <xref rid=""genes-15-00500-t001"" ref-type=""table"">Table 1</xref>. In the present patient, however, the entire gene was deleted, completely abolishing <italic toggle=""yes"">NDUFA4</italic> expression. In summary, we present a",12_31,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"expression. In summary, we present a second independent patient with MC4DN21, which is an ultra-rare genetic cause of LSS. The complete loss of NDUFA4 in our patient seemed to lead to more extensive leukoencephalopathy and brain stem lesions associated by neurological deficits typical of LSS and clinical presentation before the age of 2 years. The Alu repeat elements flanking the <italic toggle=""yes"">NDUFA4</italic> gene may provide sites of recurrent structural variation, which should be explored",12_32,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"structural variation, which should be explored carefully in patients with LSS of unknown etiology. Identification of additional patients with NDUFA4 deficiency will further delineate the genotype–phenotype correlation in MC4DN21.",12_33,"Biallelic <italic toggle=""yes"">NDUFA4</italic> Deletion Causes Mitochondrial Complex IV Deficiency in a Patient with Leigh Syndrome",17 4 2024,,Leigh_Syndrome
"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency Leigh syndrome is a severe progressive mitochondrial disorder mainly affecting children under the age of 5 years. It is caused by pathogenic variants in any one of more than 75 known genes in the nuclear or mitochondrial genomes. A 19-week-old male infant presented with lactic acidosis and encephalopathy following a 2-week history of",13_0,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"and encephalopathy following a 2-week history of irritability, neuroregression and poor weight gain. He was hypotonic with pathological reflexes, impaired vision, and nystagmus. Brain MRI showed extensive bilateral symmetrical T2 hyperintense lesions in basal ganglia, thalami, and brainstem. Metabolic workup showed elevated serum alanine, and heavy lactic aciduria with increased ketones, fumarate, malate, and alpha-ketoglutarate as well as reduced succinate on urine organic acid analysis. Lactic acidemia",13_1,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"on urine organic acid analysis. Lactic acidemia persisted, with only a marginally elevated lactate:pyruvate ratio (16.46, ref. 0–10). He demised at age 7 months due to respiratory failure. Exome sequencing followed by virtual gene panel analysis for pyruvate metabolism and mitochondrial defects could not identify any nuclear cause for Leigh syndrome. Mitochondrial DNA (mtDNA) genome sequencing revealed 88% heteroplasmy for a novel variant, NC_012920.1(MT-ND6):m.14430A>C p.(Trp82Gly), in blood DNA. This",13_2,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"p.(Trp82Gly), in blood DNA. This variant was absent from the unaffected mother's blood, fibroblast, and urine DNA, and detected at a level of 5% in her muscle DNA. Mitochondrial respiratory chain analysis revealed markedly reduced mitochondrial complex I activity in patient fibroblasts (34% of parent and control cells), and reduced NADH-linked respirometry (less than half of parental and control cells), while complex II driven respirometry remained intact. The combined clinical, genetic, and biochemical",13_3,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"The combined clinical, genetic, and biochemical findings suggest that the novel MT-ND6 variant is the likely cause of Leigh syndrome in this patient. The mitochondrial ND6 protein is a subunit of complex I. An interesting finding was the absence of a significantly elevated lactate:pyruvate ratio in the presence of severe lactatemia, which directed initial diagnostic efforts towards excluding a pyruvate metabolism defect. This case highlights the value of a multidisciplinary approach and complete genetic",13_4,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"a multidisciplinary approach and complete genetic workup to diagnosing mitochondrial disorders in South African patients. Leigh syndrome (subacute necrotizing encephalopathy) is a severe progressive mitochondrial disorder occurring most commonly in infants and young children. Rarely cases may present in adulthood. It is characterised by progressive psychomotor degeneration with characteristic symmetrical T2 hyperintensities in the basal ganglia, thalamus, substantia nigra and/or brainstem. The age of onset",13_5,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"nigra and/or brainstem. The age of onset is usually under 5 years, with most patients presenting between the ages of 3 and 12 months [<xref rid=""bb0005"" ref-type=""bibr"">[1]</xref>, <xref rid=""bb0010"" ref-type=""bibr"">[2]</xref>, <xref rid=""bb0015"" ref-type=""bibr"">[3]</xref>]. More than 100 different genes have been associated with Leigh syndrome in the literature, more than half of which have either definitive or moderate disease associations according to a recent Clinical Genomics (Clingen) expert panel",13_6,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"a recent Clinical Genomics (Clingen) expert panel review [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. Most of these genes either encode essential proteins that make up the human oxidative phosphorylation (OXPHOS) system, or proteins responsible for the assembly, stability and functioning of these components. Fifteen of these genes are located on the mitochondrial DNA (mtDNA) genome. Known pathogenic variants in these mtDNA genes account for only about 10–20% of Leigh cases worldwide, while the remainder",13_7,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"of Leigh cases worldwide, while the remainder are caused by mutations in a growing number of nuclear genes [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>,<xref rid=""bb0020"" ref-type=""bibr"">4</xref>]. Here we describe a novel, likely pathogenic variant in <italic toggle=""yes"">MT-ND6</italic>, encoding the ND6 subunit of complex I in a patient with Leigh syndrome. The patient, a 19-week-old male infant, presented to a local paediatrician with compensated lactic acidosis and encephalopathy. His parents reported",13_8,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"acidosis and encephalopathy. His parents reported persistent irritability following his 14-week vaccines, as well as a 2-week history of lethargy, poor weight gain and neuroregression, including loss of head control, eye contact and social smile. He was the first child born to non-consanguineous, healthy parents. Routine paediatric visits at 6 and 14 weeks found normal development, except for mild head lag. Upon admission, he was hypotonic with significant head lag, pathological tendon reflexes and",13_9,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"head lag, pathological tendon reflexes and intermittent dystonic posturing. He displayed no social interactions or visual response to light. He had sluggish pupillary responses, an intermittent divergent squint and nystagmus. Fundoscopy was normal. His respiratory drive was impaired with a tendency to over-compensate in the presence of physiological stress or infection. An initial uncontrasted CT scan showed bilateral hypodensities in the basal ganglia and brainstem. Brain MRI showed extensive bilateral",13_10,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"brainstem. Brain MRI showed extensive bilateral symmetrical T2 hyperintense and T1 hypointense lesions in the basal ganglia, thalami, and brainstem. See <xref rid=""f0005"" ref-type=""fig"">Fig. 1</xref>.<fig id=""f0005""><label>Fig. 1</label><caption><p>(a) Axial CT and (b) MRI T1 weighted imaging showing hypointensity of the putamina (blue arrows) and thalami (red arrows); (c) T2 hyperintensity of the putamina (blue arrows) and thalami (red arrows); (d) T2 showing midbrain lesions in the substantia nigra",13_11,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"showing midbrain lesions in the substantia nigra (yellow arrow) and red nuclei (green arrow).</p></caption><alt-text id=""al0005"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""lk0005""></graphic></fig> Initial blood gas showed lactatemia (serum lactate of 8.9 mmol/L, ref. 0.5–2.2 mmol/L), while urine organic acid analysis by GC–MS revealed heavy lactaturia and ketonuria, together with elevated fumarate, malate and alpha-ketoglutarate, and a reversed succinate to fumarate ratio (see",13_12,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"and a reversed succinate to fumarate ratio (see <xref rid=""f0010"" ref-type=""fig"">Fig. 2</xref>). In addition, elevated serum alanine (679 μmol/L, ref. 144–348 μmol/L) was found on serum amino acid analysis.<fig id=""f0010""><label>Fig. 2</label><caption><p>Urine organic acid findings indicating significant lactaturia and elevated ketones (3OH butyric acid and acetoacetate), relative to the internal standard (PDA), and elevated Krebs cycle intermediates with a reverse succinate/fumarate",13_13,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"intermediates with a reverse succinate/fumarate ratio.</p></caption><alt-text id=""al0010"">Fig. 2</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""lk0010""></graphic></fig> The serum lactate to pyruvate ratio was only marginally elevated (16.46, ref. 0–10), which in the presence of the high lactate, as well as the clinical picture and neuroimaging, suggested a possible defect of pyruvate metabolism as the cause of the Leigh syndrome in this patient. A high fat, restricted carbohydrate diet was",13_14,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"A high fat, restricted carbohydrate diet was introduced (ketogenic diet), providing ketone bodies as an alternative fuel to the tricarboxylic acid cycle via beta-oxidation. The patient's lactate levels initially responded well but he developed refractory keto-acidosis once serum ketones rose above 2 mmol/L. A percutaneous endoscopic gastrostomy was inserted for enteral feeding, and he severely decompensated post-operatively requiring non-invasive respiratory support. Further metabolic decompensation",13_15,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"support. Further metabolic decompensation occurred after urgent surgery for an incarcerated inguinal hernia a few weeks later. He demised at the age of 7 months due to respiratory failure.   Leigh syndrome is the most common cause of mitochondrial disease in children and is frequently associated with mitochondrial complex I deficiency, with genetic defects reported in 22 complex I subunits, and 8 complex I assembly factors known associated with this disease. The novel m.14430A>C variant identified in this",13_16,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"The novel m.14430A>C variant identified in this patient’s mtDNA results in a Tryptophan to Glycine change at position 82 of the NADH dehydrogenase (complex I) subunit 6 protein. At least six other variants in <italic toggle=""yes"">MT-ND6</italic> have been associated with Leigh syndrome, including the m.14430A>G, p.(Trp82Arg) variant recently reported in a patient with complex 1 deficiency, affecting the same nucleotide with a different amino acid change [<xref rid=""bb0045"" ref-type=""bibr"">9</xref>]. This",13_17,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"rid=""bb0045"" ref-type=""bibr"">9</xref>]. This variant is absent from population databases, including Genbank, GnomAD, and Helix, is predicted to be likely pathogenic by Apogee2 (pathogenicity score of 0.854, probability: 0.977) [<xref rid=""bb0050"" ref-type=""bibr"">10</xref>], and occurs in a very conserved region of the mtDNA genome (97.8%). No causative variants were identified in exome data for any of the Leigh syndrome genes included in the Genomics England PanelApp genes listed for this disorder. We have",13_18,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"PanelApp genes listed for this disorder. We have furthermore shown that complex 1 enzyme activity and complex 1 driven respiration was reduced in the patient's fibroblasts compared with unaffected parental and control cell lines. The high heteroplasmy levels seen in the affected patient's blood, urine, and fibroblast samples, in contrast to the low level (5%) in the unaffected mother's muscle DNA, and the complete absence of the variant in the unaffected maternal grandmother's muscle tissue, and the",13_19,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"maternal grandmother's muscle tissue, and the mother's urine and fibroblast cells, further supports pathogenicity. This variant likely arose de novo in the proband's mother. The findings presented in the manuscript, strongly support pathogenicity of the m.14430 A > C variant in <italic toggle=""yes"">MT-ND6</italic> as a cause of Leigh syndrome in this patient. This work was supported by the <funding-source id=""gts0005"">National Health Laboratory Service Research Trust</funding-source> [grant number",13_20,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"Research Trust</funding-source> [grant number 00494667]. <bold>Surita Meldau:</bold> Writing – review & editing, Writing – original draft, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Sally Ackermann:</bold> Writing – review & editing, Investigation. <bold>Gillian Riordan:</bold> Writing – review & editing, Supervision, Investigation. <bold>George F. van der Watt:</bold> Investigation, Formal analysis, Data curation.",13_21,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"Investigation, Formal analysis, Data curation. <bold>Careni Spencer:</bold> Investigation. <bold>Sharika Raga:</bold> Investigation. <bold>Kashief Khan:</bold> Investigation. <bold>Dee M. Blackhurst:</bold> Supervision. <bold>Francois H. van der Westhuizen:</bold> Writing – review & editing, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. The authors have no conflicts of interest.",13_22,"A novel mitochondrial DNA variant in <italic toggle=""yes"">MT-ND6:</italic> m.14430A>C p.(Trp82Gly) identified in a patient with Leigh syndrome and complex I deficiency",29 3 2024,,Leigh_Syndrome
"Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant Leigh syndrome spectrum (LSS) is a primary mitochondrial disorder defined neuropathologically by a subacute necrotizing encephalomyelopathy and characterized by bilateral basal ganglia and/or brainstem lesions. LSS is associated with variants in several mitochondrial DNA genes and more than 100 nuclear genes, most often related to mitochondrial complex I (CI) dysfunction. Rarely, LSS has been reported in",14_0,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"dysfunction. Rarely, LSS has been reported in association with primary Leber hereditary optic neuropathy (LHON) variants of the mitochondrial DNA, coding for CI subunits (m.3460G>A in MT-ND1, m.11778G>A in MT-ND4 and m.14484T>C in MT-ND6). The underlying mechanism by which these variants manifest as LSS, a severe neurodegenerative disease, as opposed to the LHON phenotype of isolated optic neuropathy, remains an open question. Here, we analyse the exome sequencing of six probands with LSS carrying primary",14_1,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"of six probands with LSS carrying primary LHON variants, and report digenic co-occurrence of the m.11778G > A variant with damaging heterozygous variants in nuclear disease genes encoding CI subunits as a plausible explanation. Our findings suggest a digenic mechanism of disease for m.11778G>A-associated LSS, consistent with recent reports of digenic disease in individuals manifesting with LSS due to biallelic variants in the recessive LHON-associated disease gene <italic toggle=""yes"">DNAJC30</italic> in",14_2,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"gene <italic toggle=""yes"">DNAJC30</italic> in combination with heterozygous variants in CI subunits. Blickhäuser <italic toggle=""yes"">et al.</italic> examine why certain individuals carrying specific mitochondrial DNA variants primarily associated with optic neuropathy experience exceptionally severe Leigh syndrome spectrum disease. They conclude that the co-occurrence of these variants with a second variant in an interacting gene causes the more severe phenotype. Leigh syndrome spectrum (LSS) is a",14_3,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"phenotype. Leigh syndrome spectrum (LSS) is a progressive neurodegenerative syndrome and is the most frequent paediatric manifestation of a primary mitochondrial disease.<sup><xref rid=""awae057-B1"" ref-type=""bibr"">1</xref></sup> Less frequently, LSS is reported in adults. LSS is characterized by bilateral lesions in the brainstem and/or basal ganglia, often in combination with changes in the thalamus, cerebellum, subcortical white matter or spinal cord. Patients manifest with neurological symptoms,",14_4,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"Patients manifest with neurological symptoms, encompassing neurodevelopmental delay or regression, muscle weakness and hypotonia, extrapyramidal movement disorders, spasticity, ataxia, seizures and neuropsychiatric symptoms. The underlying defect in mitochondrial metabolism is evidenced by elevated lactate levels in plasma or CSF, an elevated lactate peak on magnetic resonance spectroscopy (MRS), or measurement of deficient respiratory chain (RC) enzyme activity in affected tissues, among others.<sup><xref",14_5,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"in affected tissues, among others.<sup><xref rid=""awae057-B2"" ref-type=""bibr"">2</xref></sup> To date, >100 monogenic causes of LSS have been reported, with damaging variants in genes of both the mitochondrial (mtDNA) and nuclear genome. Among mtDNA-encoded causes of LSS are the primary Leber hereditary optic neuropathy (LHON) variants m.3460G>A in MT-ND1, m.11778G>A in MT-ND4 and m.14484T>C in MT-ND6.<sup><xref rid=""awae057-B3"" ref-type=""bibr"">3-9</xref></sup> While these three variants account for the",14_6,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"While these three variants account for the majority of reported LHON cases,<sup><xref rid=""awae057-B10"" ref-type=""bibr"">10</xref></sup> they are only rarely reported in LSS patients, with or without LHON features. LHON is a remarkable mitochondrial disease, characterized by subacute (often sequential), bilateral, painless deterioration of central vision, resulting from selective retinal ganglion cell dysfunction and degeneration. Extraocular features are rare. Biochemically, mitochondrial complex I (CI)",14_7,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"rare. Biochemically, mitochondrial complex I (CI) defects underlie most cases. The mechanism by which primary LHON variants present clinically with LSS or a LHON/LSS overlap syndrome is poorly understood, with speculative hypotheses spanning the role for modifying factors in the nuclear or mitochondrial DNA acting synergistically with the primary LHON variant to cause more severe, often multi-systemic disease (such as additional damaging variants and mitochondrial haplogroup)<sup><xref rid=""awae057-B4""",14_8,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"haplogroup)<sup><xref rid=""awae057-B4"" ref-type=""bibr"">4</xref>,<xref rid=""awae057-B8"" ref-type=""bibr"">8</xref></sup> and environmental factors (such as prematurity and oxygen therapy).<sup><xref rid=""awae057-B7"" ref-type=""bibr"">7</xref></sup> Recently, we characterized a recessive form of LHON due to biallelic variants in the nuclear encoded gene <italic toggle=""yes"">DNAJC30</italic>, responsible for CI repair. Reflecting reports of primary LHON variants, we described three patients manifesting with LSS",14_9,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"we described three patients manifesting with LSS or a LHON/LSS overlap syndrome.<sup><xref rid=""awae057-B11"" ref-type=""bibr"">11</xref>,<xref rid=""awae057-B12"" ref-type=""bibr"">12</xref></sup> For each of these patients, in addition to the biallelic pathogenic <italic toggle=""yes"">DNAJC30</italic> variants, a rare heterozygous damaging variant was detected in a nuclear-encoded CI subunit, specifically in <italic toggle=""yes"">NDUFS2</italic> or <italic toggle=""yes"">NDUFS8</italic>.<sup><xref rid=""awae057-B11""",14_10,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"rid=""awae057-B11"" ref-type=""bibr"">11</xref></sup> Since our initial report, this finding has been recapitulated in two unrelated LSS probands, with biallelic <italic toggle=""yes"">DNAJC30</italic> variants plus a damaging heterozygous variant in <italic toggle=""yes"">NDUFS8</italic> and <italic toggle=""yes"">NDUFA9</italic>, respectively.<sup><xref rid=""awae057-B13"" ref-type=""bibr"">13</xref>,<xref rid=""awae057-B14"" ref-type=""bibr"">14</xref></sup> Given the role of DNAJC30 in CI repair and the location of the",14_11,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"of DNAJC30 in CI repair and the location of the heterozygous second digenic hits in CI subunits, our findings suggested a digenic mechanism of disease for the <italic toggle=""yes"">DNAJC30</italic>-associated LSS phenotype. We therefore sought to determine if a similar mechanism may be responsible for the LSS manifestation in patients with primary LHON variants. Herein, we characterize six probands with LSS harbouring LHON variants. For all five probands carrying the m.11778G>A variant, we report evidence",14_12,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"the m.11778G>A variant, we report evidence supporting a digenic mechanism of disease consistent with reports for <italic toggle=""yes"">DNAJC30</italic>-associated LSS, providing a plausible explanation for the more severe disease manifestation in these individuals.   The primary LHON mtDNA variants are known for variable penetrance and expressivity, spanning from the asymptomatic carrier, to isolated optic nerve involvement and, in rare cases, to more severe multisystem phenotypes, such as those resembling",14_13,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"multisystem phenotypes, such as those resembling LSS, as reported here. Focusing on variable expressivity, the mechanism responsible for the observed discrepancy in clinical manifestation in symptomatic individuals remains, to date, an open question. A contributory role of secondary genetic modifiers has been suggested,<sup><xref rid=""awae057-B4"" ref-type=""bibr"">4</xref>,<xref rid=""awae057-B8"" ref-type=""bibr"">8</xref></sup> but was only reported in one family with two affected siblings presenting with",14_14,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"family with two affected siblings presenting with dystonia, motor delay and MRI findings consistent with LSS, with co-occurrence of the m.11778G>A (MT-ND4) primary LHON variant and a novel m.4716C G (MT-ND2) variant at high heteroplasmy level. The novel variant is, however, only moderately evolutionarily conserved and thereby of questionable functional relevance.<sup><xref rid=""awae057-B8"" ref-type=""bibr"">8</xref></sup> Analysing both the mitochondrial and nuclear DNA by WES in our cohort, we consistently",14_15,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"nuclear DNA by WES in our cohort, we consistently observe a second digenic hit in a CI Q-module subunit in all five of the LSS probands carrying the m.11778G>A (MT-ND4) variant at homoplasmy. Each of these variants is nuclear encoded, heterozygous, rare (af <0.0001%) and either nonsense, frameshift or missense in nature, with all missense variants being associated with a moderately deleterious REVEL prediction indicating probable LOF.<sup><xref rid=""awae057-B22"" ref-type=""bibr"">22</xref></sup> The carriage",14_16,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"ref-type=""bibr"">22</xref></sup> The carriage of a variant of this nature in a CI subunit is expected by chance in an estimated 8.7 per 100 individuals and 1.3 per 100 for the Q module, which is significantly lower than our observed rate (5 out of 5), and was not detected in 27 homoplasmic LHON variant carriers without LSS. In all cases, the identified digenic hit was monoallelic. The chance that we missed deep intronic functional relevant compound heterozygous variants to constitute recessive diagnoses in",14_17,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"variants to constitute recessive diagnoses in all five cases is extremely low. Nevertheless, the unavailability of patient tissues (e.g. fibroblasts) to investigate this further, such as by RNA sequencing, is a recognized limitation of our study. As we did not find additional rare, potentially deleterious variants in the CI subunits in LSS patients with m.3460G>A, and this study does not provide evidence for a similar pathomechanism for this variant. Our observation of a second digenic hit in a CI subunit",14_18,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"of a second digenic hit in a CI subunit (NDUFS2, NDUFS7 and NDUFS8) in ND4 variant carriers with LSS is consistent with recent reports proposing a digenic mechanism for <italic toggle=""yes"">DNAJC30</italic>-associated LSS, where second digenic predicted damaging heterozygous hits have been reported in <italic toggle=""yes"">NDUFA9</italic>, <italic toggle=""yes"">NDUFS2</italic> and <italic toggle=""yes"">NDUFS8</italic>, in a total of five probands to date (<xref rid=""awae057-T2"" ref-type=""table"">Table",14_19,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"(<xref rid=""awae057-T2"" ref-type=""table"">Table 2</xref>).<sup><xref rid=""awae057-B11"" ref-type=""bibr"">11</xref>,<xref rid=""awae057-B13"" ref-type=""bibr"">13</xref>,<xref rid=""awae057-B14"" ref-type=""bibr"">14</xref></sup> Notably, each of the subunits in which variants have been observed belong to the CI Q-module, spanning <italic toggle=""yes"">NDUFA9</italic>, <italic toggle=""yes"">NDUFS2</italic>, <italic toggle=""yes"">NDUFS7</italic> and <italic toggle=""yes"">NDUFS8</italic> for <italic",14_20,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"<italic toggle=""yes"">NDUFS8</italic> for <italic toggle=""yes"">DNAJC30</italic> and m.11778G>A variant carriers, collectively. Moreover, biallelic variants in each of these Q module subunit-encoding genes are associated with recessive LSS.<sup><xref rid=""awae057-B2"" ref-type=""bibr"">2</xref></sup> In most recessive patients, the disease progression was significantly more severe than in the cases described here. CI comprises three structurally and functionally defined modules, the N module, that binds and",14_21,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"defined modules, the N module, that binds and oxidizes NADH; the Q module, responsible for the transfer of electrons to ubiquinone; and the P module, responsible for proton pumping.<sup><xref rid=""awae057-B23"" ref-type=""bibr"">23</xref></sup> At the molecular level, the chaperone DNAJC30 is required for the assembly and disassembly of the N module upon the Q module of CI. This is the final step in the assembly of CI. Given that it is a reversible step, DNAJC30 allows replacement of damaged N module",14_22,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"DNAJC30 allows replacement of damaged N module subunits. Patients with LOF variants in <italic toggle=""yes"">DNAJC30</italic> are known to accumulate defective CI.<sup><xref rid=""awae057-B12"" ref-type=""bibr"">12</xref></sup> We therefore hypothesize that DNAJC30 acts synergistically with the deleterious variants in NDUFS2, NDUFS7 or NDUFS8 within the Q module to cause the more severe LSS phenotype, likely due to destabilizing the structural integrity and thereby interfering with fully functional assembly of",14_23,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"interfering with fully functional assembly of CI. Although the m.11778G>A (MT-ND4) variant is in the P module, far away from the Q module, there is an extension of the N-terminus of the Q module subunit NDUFS2 towards ND4 (<xref rid=""awae057-F2"" ref-type=""fig"">Fig. 2</xref>). Direct contact between the NDUFS2 and ND4 subunits may explain the observed synergistic effect of the deleterious Q module and ND4 variants. NDUFS2 has the properties of a molecular tether, facilitating membrane integration of CI, and",14_24,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"facilitating membrane integration of CI, and is required to add the final N module to the complex. This interpretation is underscored both by the location of the m.11778G>A variant, p.Arg340His, at the contact point between NDUFS2 and ND4, and by observation that the turnover of the N module is specifically reduced in patients with the m.11778G>A variant, but not in the LHON-associated variant in ND1 (m.3460G>A).<sup><xref rid=""awae057-B12"" ref-type=""bibr"">12</xref></sup> In conclusion, the genetic",14_25,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"In conclusion, the genetic findings presented here support our hypothesis that the unusually severe clinical manifestation of LSS in patients who harbour the primary m.11778G>A (MT-ND4) LHON variant is caused by a synergistic digenic impairment of CI. The fact that all variants affect the Q module, especially NDUFS2, suggests a mechanistic interaction between the Q module and ND4 and underscores the function of NDUFS2 as a molecular tether for the N, Q and P modules and for the complete functional assembly",14_26,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
modules and for the complete functional assembly of CI.,14_27,Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant,6 2024,,Leigh_Syndrome
"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene Only five children with pathogenic <italic toggle=""yes"">PMPCB</italic> gene variants have been described and all carried missense variants. Clinical features included a Leigh-like syndrome of developmental regression, basal ganglia lesions and ataxia with or without dystonia and epilepsy. Three of the five died in childhood and none was older than age six when described. We",15_0,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"none was older than age six when described. We report the first splice site variant in the <italic toggle=""yes"">PMPCB</italic> gene in a 39-year old individual who experienced developmental regression and ataxia following otitis media in childhood. A minigene assay confirms this variant results in aberrant splicing and skipping of exon 12. To date only five individuals from four families with multiple mitochondrial dysfunctions syndrome 6 (MMD syndrome 6) due to bi-allelic variants in the <italic",15_1,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"6) due to bi-allelic variants in the <italic toggle=""yes"">PMPCB</italic> gene have been described [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Five different missense variants were identified, with the c.523C>T;(p.Arg175Cys) variant occurring in two unrelated children. The described phenotype included typical Leigh-like features of developmental regression and basal ganglia lesions, often associated with febrile illness, and with prominent cerebellar atrophy and increased T2 signal of the cerebellar cortex.",15_2,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"and increased T2 signal of the cerebellar cortex. Symptoms of dystonia, epilepsy and/or ataxia occurred in four. The onset of symptoms was by 12 months in each case and none of the children had obtained ambulation or speech. Three of the five were deceased by the age of six years. The surviving two were age five and six years at the time of the report. We describe to our knowledge the oldest patient to date with multiple mitochondrial dysfunctions syndrome 6 and the first carrying a <italic",15_3,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"syndrome 6 and the first carrying a <italic toggle=""yes"">PMPCB</italic> splicing variant. All clinical procedures were conducted as part of routine clinical care. Written informed consent was obtained to publish clinical details. DNA from the proband and their parents was submitted to the UK Deciphering Developmental Disorder Study for analysis. Results from the proband were confirmed by bi-directional Sanger sequencing carried out in duplicate in an accredited NHS laboratory.  Leigh syndrome is the most",15_4,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"NHS laboratory.  Leigh syndrome is the most common syndromic presentation of mitochondrial disease in early childhood [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Its clinical hallmark is developmental regression often following a minor illness with symmetrical basal ganglia lesions seen on brain imaging. Over 100 nuclear genes have been associated with this syndrome [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Our patient, like others reported with <italic toggle=""yes"">PMPCB</italic> variants, presented",15_5,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"toggle=""yes"">PMPCB</italic> variants, presented with Leigh like developmental regression and ataxia following a minor illness [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The onset of symptoms was later than previous cases and she had obtained both ambulation and speech in the first two years prior to illness. Although significantly impaired by ataxia after the onset of illness she made reasonable gains and has been relatively stable throughout adulthood, surviving to age 39 years. She did not develop the",15_6,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"to age 39 years. She did not develop the additional complications of dystonia or epilepsy described in several others. Her brain imaging revealed comparable changes of basal ganglia and marked cerebellar atrophy (Fig. <xref rid=""Fig1"" ref-type=""fig"">1a</xref>). To our knowledge she is only the sixth person to be described with MMD syndrome 6 due to pathogenic variants in the <italic toggle=""yes"">PMPCB</italic> gene (Fig. <xref rid=""Fig1"" ref-type=""fig"">1c</xref>). She is heterozygous for the p.Arg175Cys",15_7,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"She is heterozygous for the p.Arg175Cys missense variant. This has been seen in two other individuals, p.Arg175His present in a third, indicating this is a common recurring site for variation. In addition she is heterozygous for the first reported variant to affect splicing and cause skipping of exon 12 (Fig. <xref rid=""Fig1"" ref-type=""fig"">1b</xref>), c.1330-2A>T;p.(?). The <italic toggle=""yes"">PMPCB</italic> gene codes for the catalytic β sub-unit of the mitochondrial processing protease (MPP). MPP",15_8,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"the mitochondrial processing protease (MPP). MPP consists of two subunits, α and β, encoded by separate genes and with a high degree of structural similarity. The MPP enzyme is key to ensuring the normal folding and maturation of mitochondrial proteins and, although the PMPCB protein holds the catalytic site, both subunits are required for proper processing [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. The crystal structure of yeast MPP is known [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] and has been used to",15_9,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"rid=""CR6"">6</xref>] and has been used to interpret pathogenicity of human <italic toggle=""yes"">PMPCB</italic> variants [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The known variant identified in this study, p.Arg175Cys, is a variant of a conserved residue in yeast and, when investigated using the yeast MPP crystal structure, was found to stabilise the protein fold through hydrogen bonds, bonds which cannot be maintained through the mutated cystine residue [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]",15_10,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"[<xref ref-type=""bibr"" rid=""CR1"">1</xref>] (Supplementary Figure <xref rid=""MOESM1"" ref-type=""media"">1</xref>). The novel splicing variant identified in this study results in the loss of exon 12 in vitro (Fig. <xref rid=""Fig1"" ref-type=""fig"">1b</xref>). We predict that the resulting protein may not be functional, and that the milder phenotype observed in this individual compared to other reported cases could instead be due to variable aberrant splicing in vivo due to c.1330-2A>T, resulting in at least some",15_11,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"due to c.1330-2A>T, resulting in at least some residual normally spliced <italic toggle=""yes"">PMPCB</italic> mRNA present in tissues.",15_12,"Leigh syndrome with developmental regression and ataxia due to a novel splicing variant in the <italic toggle=""yes"">PMPCB</italic> gene",19 2 2024,,Leigh_Syndrome
"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model Two Jack-Russell Terrier × Chihuahua mixed-breed littermates with Leigh syndrome were investigated. The dogs presented with progressive ataxia, dystonia, and increased lactate levels. Brain MRI showed characteristic bilateral symmetrical T2 hyperintense lesions, histologically representing encephalomalacia. Muscle histopathology revealed",16_0,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"encephalomalacia. Muscle histopathology revealed accumulation of mitochondria. Whole genome sequencing identified a missense variant in a gene associated with human Leigh syndrome, <italic toggle=""yes"">NDUFS7</italic>:c.535G > A or p.(Val179Met). The genotypes at the variant co-segregated with the phenotype in the investigated litter as expected for a monogenic autosomal recessive mode of inheritance. We investigated the functional consequences of the missense variant in a <italic toggle=""yes"">Drosophila",16_1,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"variant in a <italic toggle=""yes"">Drosophila melanogaster</italic> model by expressing recombinant wildtype or mutant canine NDUFS7 in a ubiquitous knockdown model of the fly ortholog ND-20. Neither of the investigated overexpression lines completely rescued the lethality upon knockdown of the endogenous ND-20. However, a partial rescue was found upon overexpression of wildtype NDUFS7, where pupal lethality was moved to later developmental stages, which was not seen upon canine mutant overexpression, thus",16_2,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"not seen upon canine mutant overexpression, thus providing additional evidence for the pathogenicity of the identified variant. Our results show the potential of the fruit fly as a model for canine disease allele validation and establish <italic toggle=""yes"">NDUFS7</italic>:p.(Val179Met) as causative variant for the investigated canine Leigh syndrome<italic toggle=""yes"">.</italic> Subacute necrotizing encephalopathy, or Leigh syndrome, was first described in human patients in 1951<sup><xref ref-type=""bibr""",16_3,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"human patients in 1951<sup><xref ref-type=""bibr"" rid=""CR1"">1</xref></sup>. This predominantly neurological disease encompasses a broad spectrum of mitochondrial encephalopathies, such as defects in oxidative phosphorylation complexes, thiamine transport, or disorders of pyruvate metabolism<sup><xref ref-type=""bibr"" rid=""CR2"">2</xref></sup>. A total of 113 gene-disease relationships have been established for the Leigh syndrome spectrum, 16 of which are linked to the mitochondrial DNA<sup><xref",16_4,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"are linked to the mitochondrial DNA<sup><xref ref-type=""bibr"" rid=""CR3"">3</xref></sup>. The first clinical signs are most frequently observed in children after a metabolic challenge, such as an acute infection<sup><xref ref-type=""bibr"" rid=""CR4"">4</xref></sup>. Patients show developmental regression, dystonia, ataxia, and dysphagia. Clinical progression is then often rapid, and death may occur already in infancy<sup><xref ref-type=""bibr"" rid=""CR4"">4</xref></sup>. One of the main criteria for early",16_5,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"One of the main criteria for early diagnosis of the disease are bilateral and symmetrical T2 hyperintense lesions involving basal ganglia, thalamus, midbrain, and brainstem on magnetic resonance imaging (MRI)<sup><xref ref-type=""bibr"" rid=""CR2"">2</xref></sup>, corresponding to encephalomalacia. These lesions combined with evidence of mitochondrial dysfunction, such as elevated lactate levels, raise the suspicion of Leigh syndrome, which then can be confirmed by genetic testing. In dogs, only two genetic",16_6,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"by genetic testing. In dogs, only two genetic variants have been associated with Leigh syndrome thus far (OMIA #001097-9615)<sup><xref ref-type=""bibr"" rid=""CR5"">5</xref></sup>. In Alaskan Huskies, an <italic toggle=""yes"">SLC19A3</italic>:c.624delinsTGCAA variant leads to multifocal CNS disease with seizures, neurological deficits, blindness, and dysphagia<sup><xref ref-type=""bibr"" rid=""CR6"">6</xref></sup>. The same gene is affected in Yorkshire terriers with juvenile-onset necrotizing encephalopathy, for",16_7,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"juvenile-onset necrotizing encephalopathy, for which a homozygous c.205_210delins35 variant was identified in affected dogs<sup><xref ref-type=""bibr"" rid=""CR7"">7</xref></sup>. In this study, two Jack-Russell Terrier × Chihuahua (Jack-Chi) littermates were presented with clinical and magnetic resonance imaging (MRI) signs strongly resembling human disease of the Leigh syndrome spectrum. Our goal was to characterize the clinical, radiological, and histopathological phenotype, and to investigate a possible",16_8,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"phenotype, and to investigate a possible underlying causative genetic defect. The identified <italic toggle=""yes"">NDUFS7</italic> candidate variant was then further evaluated through overexpression of wildtype or mutant canine NDUFS7 in a previously described UAS-Gal4 mediated fruit fly ND-20-knockdown model<sup><xref ref-type=""bibr"" rid=""CR8"">8</xref></sup>.   In the course of this study, the <italic toggle=""yes"">NDUFS7</italic>:p.(Val179Met) missense variant was identified in two Jack-Chi puppies with",16_9,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"was identified in two Jack-Chi puppies with Leigh syndrome. The <italic toggle=""yes"">NDUFS7</italic> gene encodes the NADH:ubiquinone oxidoreductase core subunit S7 of the mitochondrial respiratory complex I in the oxidative phosphorylation system<sup><xref ref-type=""bibr"" rid=""CR19"">19</xref></sup>. Complex I is the largest electron transfer chain enzyme and is the main entry point of electrons into the respiratory chain<sup><xref ref-type=""bibr"" rid=""CR20"">20</xref></sup>. It is made up of 44 different",16_10,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"It is made up of 44 different proteins, and variants in at least 39 genes have been described to cause complex I deficiency with Leigh syndrome as frequent outcome of the encountered clinical spectrum (OMIM PS252010)<sup><xref ref-type=""bibr"" rid=""CR20"">20</xref></sup>. Several human <italic toggle=""yes"">NDUFS7</italic> variants specifically cause ‘mitochondrial complex I deficiency, nuclear type 3’ (OMIM #618,224)<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref>–<xref ref-type=""bibr""",16_11,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"rid=""CR21"">21</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref></sup>. The known pathogenic variants were speculated to affect the electron transfer from NADH to ubiquinone either through impaired catalytic activity or defective assembly of complex I<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref>,<xref ref-type=""bibr"" rid=""CR23"">23</xref>,<xref ref-type=""bibr"" rid=""CR24"">24</xref></sup>. The clinical consequences for the affected patients were initial respiratory signs followed by muscular weakness and",16_12,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"signs followed by muscular weakness and hypotonia, elevated lactate levels, and characteristic, T2-hyperintense MRI lesions consistent with Leigh syndrome<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>,<xref ref-type=""bibr"" rid=""CR25"">25</xref></sup>. In dogs, clinical phenotypes sharing similarities with Leigh syndrome have been reported in American Staffordshire bull terriers<sup><xref ref-type=""bibr"" rid=""CR26"">26</xref>,<xref ref-type=""bibr""",16_13,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"rid=""CR26"">26</xref>,<xref ref-type=""bibr"" rid=""CR27"">27</xref></sup>, Alaskan huskies<sup><xref ref-type=""bibr"" rid=""CR6"">6</xref></sup>, Yorkshire terriers<sup><xref ref-type=""bibr"" rid=""CR7"">7</xref></sup>, Australian cattle dog<sup><xref ref-type=""bibr"" rid=""CR28"">28</xref></sup>, a Shih Tzu<sup><xref ref-type=""bibr"" rid=""CR29"">29</xref></sup> and a mixed-breed dog<sup><xref ref-type=""bibr"" rid=""CR30"">30</xref></sup>. Canine cases tend to present at an early age with most reported cases being younger",16_14,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"early age with most reported cases being younger than 1.5 years of age<sup><xref ref-type=""bibr"" rid=""CR6"">6</xref>,<xref ref-type=""bibr"" rid=""CR7"">7</xref>,<xref ref-type=""bibr"" rid=""CR26"">26</xref>–<xref ref-type=""bibr"" rid=""CR30"">30</xref></sup>. Similar to human patients, affected dogs show bilateral symmetrical lesions affecting the gray matter in specific areas of the brain and spinal cord, but the exact distribution of the lesions within the neuraxis varies between the different breeds. For example,",16_15,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"varies between the different breeds. For example, the thalamus is commonly affected in Alaskan huskies and Yorkshire terriers with variants in <italic toggle=""yes"">SLC19A3</italic> and was not affected in the dogs from this report<sup><xref ref-type=""bibr"" rid=""CR6"">6</xref>,<xref ref-type=""bibr"" rid=""CR7"">7</xref></sup>. Interestingly, bilateral symmetrical changes affecting the cerebellar nuclei were reported in Bullmastiff dogs with a variant in the <italic toggle=""yes"">MFF</italic> gene encoding",16_16,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"<italic toggle=""yes"">MFF</italic> gene encoding mitochondrial fission factor<sup><xref ref-type=""bibr"" rid=""CR31"">31</xref></sup>. Lactate was significantly increased in blood and CSF in one of the cases from this study and is a very common finding in humans with Leigh syndrome, reported in around 70% of the cases<sup><xref ref-type=""bibr"" rid=""CR32"">32</xref></sup>. Increased lactate levels were also reported in the American Staffordshire bull terriers<sup><xref ref-type=""bibr"" rid=""CR26"">26</xref>,<xref",16_17,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"ref-type=""bibr"" rid=""CR26"">26</xref>,<xref ref-type=""bibr"" rid=""CR27"">27</xref></sup> with severe necrotizing encephalopathy, in Border terriers<sup><xref ref-type=""bibr"" rid=""CR33"">33</xref></sup> that presented with a spongiform leukoencephalopathy with bilateral symmetrical changes in MRI and in which a mitochondrial disorder was also suspected, and interestingly in a young Jack Russell terrier<sup><xref ref-type=""bibr"" rid=""CR34"">34</xref></sup> with mitochondrial myopathy, but in which no",16_18,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"with mitochondrial myopathy, but in which no investigation of the central nervous system was performed. Further, in muscle cryosections in the Jack Russell terrier with mitochondrial myopathy, ragged-red fibers were noted with the modified Gomori trichrome stain<sup><xref ref-type=""bibr"" rid=""CR34"">34</xref></sup>. Such fibers were not found in muscle cryosections from the mixed breed dog of this report. However, punctate COX and SDH positive intramyofiber deposits consistent with mitochondrial",16_19,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"deposits consistent with mitochondrial accumulations were observed. Diagnosis of a complex I deficiency can be achieved by measuring enzymatic activity using spectrophotometric assays in patient-derived cells and tissues. Unfortunately, it was not possible to perform this test with the samples obtained from the dogs reported in this study<sup><xref ref-type=""bibr"" rid=""CR35"">35</xref></sup>. The canine Val179Met change was predicted to be pathogenic or deleterious by all used in silico prediction tools. To",16_20,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"by all used in silico prediction tools. To gain more insight into the role of the Val179Met missense variant in the pathogenesis of Leigh syndrome, we chose the fruit fly as a model organism. Given that a previously investigated ND-20/NDUFS7 knockdown in <italic toggle=""yes"">Drosophila melanogaster</italic> results in near complete lethality before eclosion<sup><xref ref-type=""bibr"" rid=""CR8"">8</xref></sup>, we wanted to test if overexpression of wildtype or mutant canine NDUFS7 protein might be able to",16_21,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"or mutant canine NDUFS7 protein might be able to rescue this phenotype. This is an established approach to investigate pathogenic potential of missense variants in human conditions<sup><xref ref-type=""bibr"" rid=""CR36"">36</xref>,<xref ref-type=""bibr"" rid=""CR37"">37</xref></sup>. Neither the pure knockdown condition of ND-20, nor overexpression of the two tested NDUFS7 rescue lines KD-OE-WT and KD-OE-MUT were able to produce viable flies. This might indicate that either the overexpression of the transgene",16_22,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"that either the overexpression of the transgene together with the knockdown of ND-20 was not strong enough, or that the knockdown phenotype might already have been too strong at the chosen temperature of 23 °C to produce sufficient functional protein in this experiment. As Floriel et al. already pointed out, it might be challenging to obtain full rescue in a developmentally lethal phenotype of this severity<sup><xref ref-type=""bibr"" rid=""CR8"">8</xref></sup>. Nonetheless, clear differences in the",16_23,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"Nonetheless, clear differences in the progression of pupal development before mortality were seen upon simultaneous overexpression of canine NDUFS7 (KD-OE-WT), when compared to ND-20 knockdown alone (Fig. <xref rid=""Fig6"" ref-type=""fig"">6</xref>). Interestingly, simultaneous overexpression of mutant canine NDUFS7 (KD-OE-MUT) was not able to improve pupal development, indicating loss of function of the overexpressed mutant allele. The fact that pupal development in this combined condition was actually more",16_24,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"in this combined condition was actually more severely impaired than upon pure knockdown of ND-20 might even hint to a dominant negative effect of the canine mutant, at least in the investigated <italic toggle=""yes"">Drosophila</italic> context with a residual level of ND-20. The fully recessive mode of inheritance in dogs suggests that in dogs a pure loss-of-function effect is more likely than a dominant negative effect. Taken together, the clinical, imaging and histopathological findings in combination",16_25,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"and histopathological findings in combination with the genetic data and the results of our functional experiments in <italic toggle=""yes"">Drosophila melanogaster</italic> establish the <italic toggle=""yes"">NDUFS7</italic>:c.535G > A, p.(Val179Met) missense variant as disease causing in the two investigated Jack-Chi puppies. To the best of our knowledge, the affected dogs represent the first domestic animals described with a naturally occurring genetic variant causing complex I deficiency. The",16_26,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"genetic variant causing complex I deficiency. The identification of a causative variant enables genetic testing and the detection of heterozygous carriers. Thus, unintentional breeding of further affected dogs can be prevented. If similarly affected dogs should appear in the Jack-Chi population or possibly even purebred Chihuahuas or Jack Russell Terriers, this genetic test can also be used to quickly confirm the suspected diagnosis. Additionally, the studied dogs might serve as a spontaneous large animal",16_27,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
dogs might serve as a spontaneous large animal model to further understand the pathogenesis of Leigh syndrome.,16_28,"<italic toggle=""yes"">NDUFS7</italic> variant in dogs with Leigh syndrome and its functional validation in a <italic toggle=""yes"">Drosophila melanogaster</italic> model",5 2 2024,,Leigh_Syndrome
"Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome  Mitochondrial diseases (MDs) are rare genetic disorders caused by mutations in genes essential for proper mitochondrial function. Since the first mutations were described [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>], more than 350 causal mutations in nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) have been",17_0,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"DNA (nDNA) or mitochondrial DNA (mtDNA) have been identified. This enormous plethora of mutations gives rise to a wide range of heterogeneous diseases that vary in disease onset, prognosis, and tissue susceptibility [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The large number of disease etiologies that involve different defects in mitochondrial biology ultimately affecting oxidative phosphorylation (OXPHOS), partially explains the high degree of heterogeneity and difficulty in establishing effective",17_1,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"and difficulty in establishing effective treatments [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. In this type of disease, it is the central nervous system (CNS) and muscles the most affected tissues since they have elevated energy requirements that rely on correct OXPHOS function, nonetheless, MDs can encompass dysfunction of any organ or tissue [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. During the past decade, substantial knowledge has been obtained regarding the",17_2,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"knowledge has been obtained regarding the pathological mechanism that underlie mitochondrial diseases [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. In recent years, there has been a growing interest in immune-related processes. As organelles with a bacterial origin, mitochondria possess a repertoire of molecules that can be detected by pattern recognition receptors (PRRs). In particular, mtDNA and mtRNAs have a strong",17_3,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"In particular, mtDNA and mtRNAs have a strong resemblance to those of bacterial origin and can trigger both antiviral and bacterial-like innate immune responses [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. In a context of mitochondrial stress, damage, or dysfunction, mtDNA and mtRNAs can escape the mitochondrial matrix, be released to the cytoplasm, and engage an inflammatory response via the inflammasome, TLR9, mitochondrial antiviral signaling proteins (MAVS),",17_4,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"antiviral signaling proteins (MAVS), and/or cGAS-STING pathways [<xref ref-type=""bibr"" rid=""CR10"">10</xref>–<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Noteworthy, these signaling networks allow explaining why throughout many severe disabling diseases, mitochondrial malfunction, degeneration, and persistent inflammation occur together. Therefore, it has been speculated that the mitochondria-innate immune crosstalk contributes to the pathobiology of MDs [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. One",17_5,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"[<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. One example of this crosstalk is observed in polymerase gamma (POLG) mutator mice, a mouse model of mtDNA instability that mirrors some clinical features of patients with POLG-related MD and aging [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. In these mice, aged individuals display chronic cGAS-STING-dependent interferon type-I (IFN-I) signaling in multiple organs, including the heart, liver, kidney, and an expansion of the myeloid cell population [<xref",17_6,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"expansion of the myeloid cell population [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Additionally, in mouse models of mitochondrial-related myopathies, mtDNA has been shown to promote inflammation and muscle atrophy [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Furthermore, recent studies have highlighted the emerging role of microglia and peripheral immune cells in the development of the <italic toggle=""yes"">Ndufs4 KO</italic> encephalopathy, a mouse model of",17_7,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"KO</italic> encephalopathy, a mouse model of Leigh syndrome (LS) [<xref ref-type=""bibr"" rid=""CR17"">17</xref>–<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Immune-related processes have not only been speculated to directly guide the pathology in MDs, but also to influence their onset and their degree of progression [<xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Some forms of MDs can manifest prenatally or during the early stages of life, but a considerable number of",17_8,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"stages of life, but a considerable number of patients may remain asymptomatic until adulthood. Furthermore, even those from childhood-onset usually do not exhibit symptoms at birth [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Importantly, not only can different mutations result in different clinical features, but also the same mutation might lead to different disease onset and severity [<xref ref-type=""bibr"" rid=""CR22"">22</xref>–<xref ref-type=""bibr""",17_9,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"rid=""CR22"">22</xref>–<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. All these pieces of evidence suggest that additional factors, apart from the specific genetic mutation, could contribute to the onset and development of the pathology. Currently, the factors that can trigger the onset and influence the progression of mitochondrial diseases are unknown. Despite this lack of knowledge, clinical evidence in patients suffering from different types of MDs indicates that immune dysregulation or immune distress",17_10,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"that immune dysregulation or immune distress could be important players based on: (i) the concurrence of symptoms with infection, where the presence of an infection may trigger the onset of the disease and (ii) the overlap of infection, periods of deterioration, and mental regression, which, at the same time, coincides with the worsening of the symptoms either during or after the infection [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Altogether, these observations highlight the complex interactions",17_11,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"observations highlight the complex interactions between mitochondrial diseases and the immune system. Mice lacking the subunit NDUFS4 of the complex I (CI) of the electron respiratory chain, known as <italic toggle=""yes"">Ndufs4 KO</italic> mice, develop a fatal fast-progressing encephalopathy and die approximately at the postnatal day 55. Importantly, the disease present in <italic toggle=""yes"">Ndufs4 KO</italic> closely resembles the one found in patients with Leigh syndrome. Leigh syndrome (OMIM 25,600),",17_12,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"Leigh syndrome. Leigh syndrome (OMIM 25,600), also referred to as subacute necrotizing encephalopathy, is a mitochondrial disease that has an estimated prevalence of 1 case per 40,000 individuals [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Usually, disease onset starts at 2 years of age after an initial period of normal development followed by a physiological challenge (i.e., infection, surgery) and has a fatal prognosis with a mean survival of 2 years after the first symptoms [<xref ref-type=""bibr""",17_13,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"after the first symptoms [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Given the growing evidence indicating that immune/inflammatory dysregulation could trigger and exacerbate mitochondrial diseases, we aimed to assess how the chronic induction of a neuroinflammatory state during the presymptomatic phase of <italic toggle=""yes"">Ndufs4 KO</italic> mice would impact the onset and progression of the disease in these animals. For that purpose, we utilized GFAP-IL6 mice, which are a commonly used model for",17_14,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"mice, which are a commonly used model for chronic neuroinflammation, and NDUFS4-deficient mice to generate <italic toggle=""yes"">Ndufs4 KO</italic> mice with chronic neuroinflammation (GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic>). Specifically, GFAP-IL6 mice overexpress the cytokine interleukin-6 (IL-6) under the control of the <italic toggle=""yes"">Gfap</italic> promoter, limiting the overexpression to astrocytes [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. As IL-6 can act as a strong pro-inflammatory",17_15,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"As IL-6 can act as a strong pro-inflammatory cytokine in the brain [<xref ref-type=""bibr"" rid=""CR29"">29</xref>], GFAP-IL6 mice exhibit early microgliosis and astrogliosis, with both cell types displaying reactive morphological features [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR30"">30</xref>]. We found that the phenotype of female <italic toggle=""yes"">Ndufs4 KO</italic> mice was somewhat exacerbated by IL-6 overexpression at the survival level, while that of male mice",17_16,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"at the survival level, while that of male mice remained unaffected. In addition, the motor decline was similar between <italic toggle=""yes"">Ndufs4 KO</italic> mice and GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> regardless of sex. Notably, <italic toggle=""yes"">Ndufs4 KO</italic> mice showed an atypical microglial response to IL-6 overexpression compared to the control group. Altogether, our data suggest that the chronic increase in brain inflammation through overexpression of IL-6 had a limited effect",17_17,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"overexpression of IL-6 had a limited effect on the progression of the disease in <italic toggle=""yes"">Ndufs4 KO</italic> mice and that CI dysfunction may compromise to some extent microglial response to IL-6 stimulation, and potentially to other inflammatory stimuli.  In previous reports, we and others described that decreasing the neuroimmune response by depleting microglial cells has beneficial effects in <italic toggle=""yes"">Ndufs4 KO</italic> mice [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref",17_18,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR37"">37</xref>]. In this study, we wanted to assess whether a chronic induction of a neuroinflammatory state prior to neuropathology onset could affect the pathology of <italic toggle=""yes"">Ndufs4 KO</italic> mice. For that purpose, we took advantage of the GFAP-IL6 mouse [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. As mentioned above, GFAP-IL6 mice overexpress IL-6 guided by the <italic",17_19,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"mice overexpress IL-6 guided by the <italic toggle=""yes"">Gfap</italic> promoter, which confines the overexpression to astrocytes, producing early postnatal astrocyte and microglial reactivity across the brain [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR30"">30</xref>, <xref ref-type=""bibr"" rid=""CR38"">38</xref>]. Our main goal was to assess whether an increased inflammatory environment could influence disease progression in <italic toggle=""yes"">Ndufs4 KO</italic> mice. This was",17_20,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"toggle=""yes"">Ndufs4 KO</italic> mice. This was motivated by clinical evidence indicating that immune-associated processes could trigger the onset of MDs and also modify the pathology to some extent [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. To do so, we used GFAP-IL6 and <italic toggle=""yes"">Ndufs4 KO</italic> mice to generate GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice. GFAP-IL6 mice have been widely used as a model for chronic neuroinflammation [<xref ref-type=""bibr"" rid=""CR29"">29</xref>].",17_21,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"[<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. As mentioned above, these mice overexpress the cytokine IL-6 under the control of the <italic toggle=""yes"">Gfap</italic> promoter leading to abundant microgliosis and astrogliosis, wherein both cell types show morphological signs of reactivity. IL-6 overexpression also promotes tissue vacuolization, angiogenesis, peripheral cell infiltration, and ultimately neurodegeneration [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr""",17_22,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR29"">29</xref>, <xref ref-type=""bibr"" rid=""CR41"">41</xref>]. As result, these mice start to develop serious motor problems around six months of age [<xref ref-type=""bibr"" rid=""CR42"">42</xref>]. Consistent with this, in young mice, we found prominent microgliosis and astrogliosis but no differences in total ambulation and motor coordination between control and GFAP-IL6 mice at any time point. We first hypothesized that IL-6 overexpression would potentiate",17_23,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"that IL-6 overexpression would potentiate and advance disease progression in <italic toggle=""yes"">Ndufs4 KO</italic> mice based on extensive literature indicating that a neuroinflammatory state can be neurotoxic by aggravating neurodegenerative mechanisms [<xref ref-type=""bibr"" rid=""CR43"">43</xref>]. Additionally, the presence of inflammatory by-products could further harm neurons that are already vulnerable to NDUFS4 deficiency [<xref ref-type=""bibr"" rid=""CR44"">44</xref>–<xref ref-type=""bibr""",17_24,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"rid=""CR44"">44</xref>–<xref ref-type=""bibr"" rid=""CR46"">46</xref>]. Strikingly, IL-6 overexpression only reduced the survival and slightly advanced the onset of clasping in <italic toggle=""yes"">Ndufs4 KO</italic> female mice, which may indicate that <italic toggle=""yes"">Ndufs4 KO</italic> female mice are more vulnerable to brain inflammation than male mice, highlighting the importance of considering each sex separately in these types of studies. Apart from the differences observed in survival and clasping",17_25,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"the differences observed in survival and clasping onset, female GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice were phenotypically similar to males in terms of disease progression and gliosis. Given the severe fast-progressing disease that <italic toggle=""yes"">Ndufs4 KO</italic> develop, it is worth considering that specific assessments, like the rotarod test used to evaluate motor decline, might have encountered ceiling or floor effects potentially hampering our ability to detect additional changes",17_26,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"our ability to detect additional changes in the motor function of GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice when compared to their <italic toggle=""yes"">Ndufs4 KO</italic> counterparts. It cannot be ruled out that other motor-related tasks could be more sensitive to detecting further functional deterioration in GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice during the progression of disease, which deserves further attention. We did not directly interrogate the specific cause of the",17_27,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"directly interrogate the specific cause of the sex-dependent differences observed in survival, but since both GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> female and male mice had similar disease progression compared to their <italic toggle=""yes"">Ndufs4 KO</italic> mice counterparts, it is unlikely that this observation is related to increased neuronal loss in females. We suggest that it may be due to alterations in other aspects of the <italic toggle=""yes"">Ndufs4 KO</italic> phenotype, which were not",17_28,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"KO</italic> phenotype, which were not directly addressed in this study. The appearance of seizures in <italic toggle=""yes"">Ndufs4 KO</italic> mice have been previously observed [<xref ref-type=""bibr"" rid=""CR31"">31</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>, <xref ref-type=""bibr"" rid=""CR44"">44</xref>], and there is a significant correlation between inflammation and epilepsy, as seizures can trigger inflammation or inflammation can exacerbate the severity of seizures [<xref ref-type=""bibr""",17_29,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"the severity of seizures [<xref ref-type=""bibr"" rid=""CR47"">47</xref>]. In addition, some studies have observed different sex susceptibilities to the development of specific epilepsy subtypes [<xref ref-type=""bibr"" rid=""CR48"">48</xref>, <xref ref-type=""bibr"" rid=""CR49"">49</xref>]. Therefore, it cannot be ruled out that the sex-dependent effect on survival in GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice is due to a greater susceptibility to developing epilepsy, or a greater severity of seizures in",17_30,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"epilepsy, or a greater severity of seizures in GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> female mice compared to GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> male mice and <italic toggle=""yes"">Ndufs4 KO</italic> mice. Increased susceptibility to epilepsy in females is consistent with the lack of a significant decrease in body weight before death in female mice. In summary, despite this decreased survival in GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> female mice compared to <italic",17_31,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"KO</italic> female mice compared to <italic toggle=""yes"">Ndufs4 KO</italic> mice, IL-6 overexpression had only a minor impact on the disease progression indicating that chronically boosting inflammation by overexpressing IL-6 in the brain of <italic toggle=""yes"">Ndufs4 KO</italic> mice is not sufficient to accelerate disease. Surprisingly, NDUFS4 deficiency partially compromised cerebellar IL-6 production in GFAP-IL6 mice. GFAP levels measured by immunostaining were comparable between both IL-6",17_32,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"immunostaining were comparable between both IL-6 overexpressing mice in the cerebellum and other regions at both disease stages. Since <italic toggle=""yes"">Il6</italic> expression is guided by the <italic toggle=""yes"">Gfap</italic> promoter in GFAP-IL6 mice, one might anticipate a correlation between GFAP and IL-6 protein levels given their mRNA-coupled expression. However, it is well known that mRNA and protein levels do not always correlate [<xref ref-type=""bibr"" rid=""CR50"">50</xref>, <xref",17_33,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"ref-type=""bibr"" rid=""CR50"">50</xref>, <xref ref-type=""bibr"" rid=""CR51"">51</xref>]. Additionally, the levels of GFAP immunoreactivity were already strongly elevated in GFAP-IL6 mice, suggesting that GFAP protein levels may be approaching saturation, even though <italic toggle=""yes"">Gfap</italic> transcription may still be active, and thus <italic toggle=""yes"">Il6</italic>. No studies have described the dynamics between <italic toggle=""yes"">Gfap</italic> and <italic toggle=""yes"">Il6</italic> gene and protein",17_34,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"toggle=""yes"">Il6</italic> gene and protein expression in the context of GFAP-IL6 mice. Indeed, only a few studies have quantified IL-6 protein levels in GFAP-IL6 mice so far [<xref ref-type=""bibr"" rid=""CR39"">39</xref>, <xref ref-type=""bibr"" rid=""CR52"">52</xref>]. On this matter, our results evidence that GFAP immunoreactivity and IL-6 levels do not necessarily correlate in GFAP-IL6 mice. We have formulated two hypotheses to explain why IL-6 is consistently decreased at both mid and late stages in the",17_35,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"decreased at both mid and late stages in the cerebellum of GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> mice when compared to GFAP-IL6 mice. The first explanation is that NDUFS4 deficiency directly affects astrocytic IL-6 production in this region. It is possible that OXPHOS defective astrocytes could not entirely sustain such an abundant IL-6 production in the cerebellum [<xref ref-type=""bibr"" rid=""CR53"">53</xref>]. Another possibility is that NDUFS4-deficient microglia are not able to respond to an",17_36,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"microglia are not able to respond to an inflammatory stimulus such as IL-6 appropriately. In the normal scenario (GFAP-IL6 mice) and given that microglia are important target and effector cells of this cytokine, it was assumed that the primary IL-6 released by astrocytes would engage a paracrine immune response in microglia, which then would release other inflammatory mediators. These microglia-released factors could further exacerbate inflammation, leading to increased astrocyte reactivity and upregulated",17_37,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"to increased astrocyte reactivity and upregulated expression of <italic toggle=""yes"">Gfap</italic>, which, in turn, promotes the production of IL-6, establishing a positive feedback loop. However, a very recent work seems to contradict this previous assumption; the authors found that microglia-depleted GFAP-IL6 mice had similar <italic toggle=""yes"">Il6</italic> expression levels and comparable levels of astrocyte reactivity measured by GFAP [<xref ref-type=""bibr"" rid=""CR54"">54</xref>], indicating that, in",17_38,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"rid=""CR54"">54</xref>], indicating that, in principle, astrocytes could produce identical amounts of IL-6 and become similarly reactive without any microglial input in GFAP-IL6 mice. Furthermore, we consistently observed a decreased microgliosis in response to IL-6 overexpression in <italic toggle=""yes"">Ndufs4 KO</italic> mice across several regions and at both time points studied. Our main hypothesis is that this is due to an abnormal microglial response in NDUFS4-deficient mice to stimulation with IL-6,",17_39,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"NDUFS4-deficient mice to stimulation with IL-6, rather than to the levels of IL-6 alone. This conclusion is supported by the fact that, this decrease in microgliosis was consistently observed in both the cerebellum and cortex, where IL-6 levels were decreased and unchanged, respectively, between GFAP-IL6/<italic toggle=""yes"">Ndufs4 KO</italic> and GFAP-IL6 mice. To our knowledge, the great majority of studies that have investigated the metabolic and mitochondrial adaptations of microglia in response to an",17_40,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"adaptations of microglia in response to an inflammatory stimulus have used lipopolysaccharide (LPS). LPS is a component of the cell wall of gram-negative bacteria that stimulates microglia via Toll-like receptor 4 (TLR4), leading to the production of pro-inflammatory cytokines and the activation of the innate immune response [<xref ref-type=""bibr"" rid=""CR55"">55</xref>]. These studies found that LPS stimulation switches the microglial metabolic profile from OXPHOS to glycolysis (a process known as",17_41,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"from OXPHOS to glycolysis (a process known as glycolytic switch) in rodents. This switch to glycolysis is necessary for the production of pro-inflammatory cytokines, highlighting the crucial role of metabolic reprogramming in the immune response to LPS and potentially to other pro-inflammatory stimuli [<xref ref-type=""bibr"" rid=""CR56"">56</xref>–<xref ref-type=""bibr"" rid=""CR59"">59</xref>]. Interestingly, LPS stimulation has also been reported to induce a transient increase in microglial OXPHOS O<sub>2</sub>",17_42,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"increase in microglial OXPHOS O<sub>2</sub> consumption during this conversion to glycolysis [<xref ref-type=""bibr"" rid=""CR60"">60</xref>]. Additionally, other mitochondrial processes, including mitochondrial dynamics, have been implicated in the microglial response to LPS [<xref ref-type=""bibr"" rid=""CR60"">60</xref>–<xref ref-type=""bibr"" rid=""CR63"">63</xref>]. It is then possible that microglia could exhibit different responses to IL-6 stimulation due to a compromised complex I function. Neuroinflammation",17_43,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"compromised complex I function. Neuroinflammation is a common hallmark of primary mitochondrial diseases and neurodegenerative processes, having been proposed as a trigger of neuronal death and a key mediator in the amplification of pathological processes. Here, we provide evidence that, based on the measurements we have employed, chronic neuroinflammation induced by continuous IL-6 overexpression does not substantially impact the phenotype of a well-established Leigh Syndrome model. On the contrary, our",17_44,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"Leigh Syndrome model. On the contrary, our results underscore the contribution of mitochondrial dysfunction to microglial reactivity, providing novel evidence of the necessity of intact mitochondrial function for microglial responses.",17_45,Interleukin-6-elicited chronic neuroinflammation may decrease survival but is not sufficient to drive disease progression in a mouse model of Leigh syndrome,11 1 2024,,Leigh_Syndrome
"A case of Leigh syndrome presented with paroxysmal body swing Leigh syndrome (LS) is a common mitochondrial encephalomyopathy in childhood caused by mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) variants. It is a severe and progressive neurodegenerative disease that occurs mostly in infants. In recent years, the application of next-generation sequencing (NGS) technology has improved the diagnostic level of mitochondrial diseases, laid a foundation for the further study of genotype and phenotype, and",18_0,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"the further study of genotype and phenotype, and provided an evidence base for genetic counseling and prenatal diagnosis. A 1-year-old boy presented to the hospital because of “paroxysmal whole body swing” (<xref rid=""appsec1"" ref-type=""sec"">Supplementary Material</xref>). The body swing was irregular, and his eyes were closed, occurring mostly during sleep with no cyanosis and incontinence. Each episode lasted approximately 1–2 hours and could be relieved with human intervention. After stimulation, a",18_1,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"with human intervention. After stimulation, a similar onset was observed, but the duration was short, approximately a few seconds to tens of seconds. Prenatal examination showed that the right ventricle was widened, and color Doppler ultrasound showed no abnormalities. The child was G1P1, full term, with a birth weight of 2.7 kg. The growth and development of the child were as follows: at 2 months old, he could hold his head up; at more than 7 months old, he could turn over; and at 11 months old, he could",18_2,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"could turn over; and at 11 months old, he could walk with assistance and shout “baba” and “mama”. After disease onset, the child exhibited comprehensive development regression; could not stand or walk with assistance; was unstable when sitting and standing; and did not cry, laugh, speak, or recognize people. No feeding difficulties were observed. There was no family history of hereditary diseases. The results of the physical examination at admission were as follows: clear consciousness, no facial",18_3,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"were as follows: clear consciousness, no facial abnormality, normal skull size, negative pupil examination on both sides, and no nystagmus or strabismus. The muscle tension of the limbs was high, the limbs were moveable, the knee-tendon reflex was normal, and the pathological sign and the meningeal irritation sign were negative. After admission, relevant examinations were completed as follows: blood ammonia was 53.1 μmol/L (10–47 μmol/L), lactic acid was 3.65 mmol/L (0.5–22 mmol/L), pyruvate was 115.42",18_4,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"3.65 mmol/L (0.5–22 mmol/L), pyruvate was 115.42 μmol/L (20–100 U/L), and β-hydroxybutyric acid was 2.16 mmol/L (0–0.27 mmol/L). Cerebrospinal fluid (CSF) lactic acid was 3.23 mmol/L, and CSF cytology, biochemistry, and pathogen nucleic acid showed no abnormalities. Autoimmune encephalitis antibodies were negative. Electrocardiogram and echocardiography showed no abnormalities. Auditory evoked potentials were abnormal. Visual evoked potentials were normal. The video electroencephalogram (EEG) showed that",18_5,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"The video electroencephalogram (EEG) showed that the background wave was slightly slower (4–5 Hz), and no epileptic discharge was observed during the episode. Cranial MRI showed abnormal signals of the bilateral thalamus, midbrain, periaqueductal gray, and superior cervical medulla. DTI imaging showed decreased white matter fiber bundles in the brainstem, mainly in the midbrain (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>).<fig id=""fig1""><label>Fig. 1</label><caption><p>Cranial MRI (a, T1; b, T2; c, d,",18_6,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"MRI (a, T1; b, T2; c, d, T2-Flair; e, f, DWI) showed abnormal signals of the bilateral thalamus, midbrain, periaqueductal gray, and superior cervical medulla. DTI imaging (f, g) showed decreased white matter fiber bundles in the brainstem, mainly in the midbrain.</p></caption><alt-text id=""alttext0010"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""></graphic></fig> Inherited metabolic diseases were considered, and the patient was treated with a multivitamin cocktail (coenzyme Q10 10",18_7,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"with a multivitamin cocktail (coenzyme Q10 10 mg/kg/d, Vitamin E 10 mg/kg/d, Vitamin B1 5 mg/kg/d, Vitamin B2 10 mg/kg/d, Vitamin C 25 mg/kg/d, levocarnitine 50 mg/kg/d) after admission. A mutation of <italic toggle=""yes"">MT-ND5</italic> (m.13513G > A) was found by NGS; the proportion of the mutation was 68.6 % (18646/27164), and the mother and father were wild type. Combined with genetic testing, a diagnosis of Leigh syndrome was made, and oral vitamin cocktail therapy and rehabilitation training were",18_8,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"cocktail therapy and rehabilitation training were continued. The child did not exhibit paroxysmal body swing after discharge, but psychomotor development was not significantly improved. Unfortunately, after 6 months of follow-up, the child died of COVID-19-related pneumonia. The mitochondrial ND5 subunit is one of the seven subunits of complex I encoded by mitochondria. It is the largest (1811 nt) gene, and its mutation can affect the assembly or stability of complex I [<xref rid=""bib1""",18_9,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"or stability of complex I [<xref rid=""bib1"" ref-type=""bibr"">1</xref>,<xref rid=""bib2"" ref-type=""bibr"">2</xref>]. By far, the most common mutation in the <italic toggle=""yes"">MT-ND5</italic> gene is the m.13513G > A mutation [<xref rid=""bib1"" ref-type=""bibr"">1</xref>]. Studies have shown that the <italic toggle=""yes"">MT-ND5</italic> m.13513G > A mutation can cause disease even under low mutational load, and there is no significant correlation between the degree of mutation heterogeneity and the age of onset",18_10,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"of mutation heterogeneity and the age of onset and disease severity<sup>[1，3]</sup>. To date, this mutation has been reported in at least 50 patients, including multiple patients with mitochondrial encephalomyopathies, most commonly seen in MELAS and LS. Ariel et al. identified the m.13513G > A mutation in 5 (1.88 %) of 265 LS patients [<xref rid=""bib3"" ref-type=""bibr"">3</xref>]. Studies have shown that the m.13513G > A mutation in LS is most frequently combined with optic atrophy and/or",18_11,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"frequently combined with optic atrophy and/or Wolff–Parkinson–White (WPW) syndrome [<xref rid=""bib4"" ref-type=""bibr"">4</xref>]. However, the phenotype of m.13513G > A is variable due to the particularity of mitochondrial genetics. The visual evoked potential, electrocardiogram, and cardiac color Doppler ultrasound of this child were not abnormal at the time of admission to the hospital, but with the progression of the disease, most patients will experience multiple system involvement, so it is necessary to",18_12,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"system involvement, so it is necessary to continue with follow-up observations. Studies on the first symptoms of LS showed that motor abnormalities accounted for 82.8 %, including hypotonia, spasticity of dystonia, ataxia, and chorea, followed by ocular symptoms, feeding difficulties, seizures, and development retardation [<xref rid=""bib5"" ref-type=""bibr"">5</xref>]. In this case, the patient presented with paroxysmal body swing combined with developmental regression, typical brain MRI changes, and",18_13,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"regression, typical brain MRI changes, and mitochondrial gene detection suggesting <italic toggle=""yes"">MT-ND5</italic> m.13513G > A, resulting in a diagnosis of LS. No epileptic discharge was found in the EEG of the child during the onset of the paroxysmal body swing attack, and a nonepileptic episode was considered. No similar phenotype of LS has been described to date, and the motor symptoms are believed to be related to the cerebellar-thalamic-cortex pathway. Brain MRI showed bilateral involvement of",18_14,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"Brain MRI showed bilateral involvement of the thalamus, midbrain, and cervical medulla. DTI imaging showed decreased white matter fiber bundles in the brainstem and increased muscle tension. Subcortical myoclonus is considered a brain stem injury resulting in disconnection between cortical and subcortical structures or the symptoms of stimulation of the olivary nucleus loop under the dentate nucleus caused by metabolic abnormalities. The underlying mechanisms are unclear and may be related to abnormal",18_15,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"are unclear and may be related to abnormal energy metabolism, so this hyperkinetic movement disorder was controlled after treatment with a vitamin cocktail. A recent study and analysis of 209 LS patients in China showed that the worst survival rate was associated with mutations in <italic toggle=""yes"">MT-ND5</italic>, <italic toggle=""yes"">MT-ATP6</italic> (m.8993T > C and m.9176T > C), <italic toggle=""yes"">SURF1</italic> and <italic toggle=""yes"">ALDH5A1</italic> [<xref rid=""bib6"" ref-type=""bibr"">6</xref>].",18_16,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"[<xref rid=""bib6"" ref-type=""bibr"">6</xref>]. After treatment with the vitamin cocktail, the child's paroxysmal movement disorder was improved, and no paroxysmal body swing was observed after discharge. However, psychomotor development was not significantly improved; since onset occurred at an early age, the prognosis was poor. In this patient, paroxysmal body swing was the main clinical manifestation, which added to the clinical manifestation spectrum of LS. This case suggests that LS should be considered",18_17,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"This case suggests that LS should be considered for children with onset of infantile and paroxysmal body swing combined with developmental regression, and early mitochondrial genetic testing can aid in diagnosis and guide early intervention. However, this study is a case report, and there is no similar phenotype description at present; further follow-up observation with larger sample sizes is still needed. Not applicable. The parents gave their written consent for their child personal and clinical details.",18_18,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"for their child personal and clinical details. A copy of the signed, written informed consent for publication form is available for review by the editor. The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author. This work was supported by the <funding-source id=""gs1""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/501100001809</institution-id><institution>National Science",18_19,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"Science Foundation of China</institution></institution-wrap></funding-source> (No. 82071686), the Grant from <funding-source id=""gs2"">Science and Technology Bureau of Sichuan province</funding-source> (No. 2021YFS0093), the Grant from Research Fund of <funding-source id=""gs3"">West China Second University Hospital</funding-source> (No. KL115, KL072). <bold>Jia Zhang:</bold> Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation,",18_20,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
"administration, Resources, Software, Validation, Visualization, Writing - original draft, Writing - review & editing. <bold>Jing Gan:</bold> Funding acquisition, Project administration, Resources, Validation. <bold>Jianjun Wang:</bold> Conceptualization, Project administration, Resources, Supervision, Visualization, Writing - review & editing. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this",18_21,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
appeared to influence the work reported in this paper.,18_22,A case of Leigh syndrome presented with paroxysmal body swing,07 12 2023,,Leigh_Syndrome
Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,19_0,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
<bold>Josef Finsterer:</bold> Investigation; methodology; validation. None. Financial disclosures for the previous 12 months: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.  Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy. Letter to the Editor We read with interest the article by Shabannejadian,19_1,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"read with interest the article by Shabannejadian et al. on a 1‐year‐old female with Leigh syndrome due to the homozygous, missense variant c.484G>A in exon 6 of the <italic toggle=""yes"">NDUFS8</italic> gene.<xref rid=""ccr38274-bib-0001"" ref-type=""bibr"">",19_2,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"<sup>1</sup>
</xref> The variant manifested phenotypically with irritability, continuous crying, seizures, nystagmus, ataxia, dysphagia, muscle weakness, and vomiting.<xref rid=""ccr38274-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref> Despite normal cerebral magnetic resonance imaging (MRI), the patient was diagnosed with Leigh syndrome and coenzyme‐Q, thiamine, and diazepam were prescribed.<xref rid=""ccr38274-bib-0001"" ref-type=""bibr"">
<sup>1</sup>",19_3,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"<sup>1</sup>
</xref> The patient died at age 1 from cardio‐respiratory arrest following aspiration.<xref rid=""ccr38274-bib-0001"" ref-type=""bibr"">
<sup>1</sup>",19_4,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"<sup>1</sup>
</xref> The study is compelling but has limitations that should be discussed. We disagree with the diagnosis of Leigh syndrome in the index patient. Diagnosing Leigh syndrome requires the presence of typical lesions on cerebral MRI. These are usually symmetric T2 hyperintensities in the brainstem, cerebellum, basal ganglia, or thalamus.<xref rid=""ccr38274-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",19_5,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"</xref> Since the index patient had a normal cerebral MRI at age 5 months, the diagnosis of Leigh syndrome should be revised. There is no mention on the development of epilepsy. We should know whether the patient suffered only a single seizure at age 5 months or whether seizures recurred. We also should know whether only diazepam was given as long‐term treatment of epilepsy or whether other antiseizure drugs (ASDs) were added. A limitation in this respect is that results of electroencephalography (EEG)",19_6,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"is that results of electroencephalography (EEG) recording were not reported. Knowing the course of epilepsy is crucial as it can strongly determine the outcome of patients with a mitochondrial disorder (MID). We should also know what the authors mean with the term “weak seizure”.<xref rid=""ccr38274-bib-0001"" ref-type=""bibr"">",19_7,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
<sup>1</sup>,19_8,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"</xref> Do the authors mean a focal seizure, a short‐lasting seizure, or seizures with preserved consciousness and only mild convulsions? Regarding the pedigree shown in figure 3, it is surprising that the grand‐grandmother of the index patient was indicated as a carrier of the <italic toggle=""yes"">NDUFS8</italic> variant. Was she alive and did she really undergo genetic testing? Furthermore, we should know whether any of the nine heterozygous carriers of the culprit <italic toggle=""yes"">NDUFS8</italic>",19_9,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"the culprit <italic toggle=""yes"">NDUFS8</italic> variant manifested phenotypically. A limitation of the study is that it is not discussed whether muscle weakness was due to encephalopathy or due to affection of the peripheral nervous system (PNS). Regarding a suspected PNS lesion, it would be interesting to know whether the patient had myopathy and whether creatine kinase (CK) was elevated. Overall, the interesting study has limitations that put the results and their interpretation into perspective.",19_10,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
and their interpretation into perspective. Addressing these issues would strengthen the conclusions and could improve the status of the study. Diagnosing Leigh syndrome requires typical lesions on cerebral MRI.,19_11,Diagnosing Leigh syndrome requires typical lesions on cerebral MRI,30 11 2023,,Leigh_Syndrome
"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report The genetic disorders may be caused by aberrations in chromosomal number or structure, as well as from point mutations occurring in a single gene, i.e., monogenic, or more than one gene, i.e., multigenic, or additional environmental factors, i.e., multifactorial. Monogenic disorders caused by alterations in a single gene",20_0,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"disorders caused by alterations in a single gene follow Mendelian inheritance (<xref rid=""B1"" ref-type=""bibr"">1</xref>). Most of the monogenic diseases are caused by the point mutations, i.e., mutation altering single nucleotide, e.g., substitution, deletion, and insertion. Apart from chromosomal or nuclear DNA alterations, mitochondrial DNA variation also contributes to genetic diseases. These genes either contribute directly or in combination with the nuclear DNA gene expression. Abnormalities in",20_1,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"the nuclear DNA gene expression. Abnormalities in oxidative phosphorylation pathways leading to abnormal musculoskeletal and neurodevelopmental disorders are a well-known example of mitochondria-related disorders (<xref rid=""B2"" ref-type=""bibr"">2</xref>). Leigh syndrome, a severe neurological condition, typically manifests during the first year of life. Within 2–3 years, respiratory failure is the primary cause of mortality in individuals experiencing psychomotor regression, a condition characterized by a",20_2,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"regression, a condition characterized by a progressive loss of mental and physical functions. Only a small portion of people develop symptoms as adults or see their symptoms get worse with time. Infants with Leigh syndrome usually experience vomiting, diarrhea, and dysphagia as their initial signs of the disorder, which affects their ability to feed. These problems typically prevent a person from growing and gaining weight at the expected rate (failure to thrive). Severe muscular and movement problems are",20_3,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"Severe muscular and movement problems are typical in Leigh syndrome. People who are affected may experience uncontrollable muscle spasms, hypotonia, dystonia, uncontrollable eye movements, and ophthalmoparesis and low muscle tone, as well as balance and mobility problems (ataxia). Peripheral neuropathy, a characteristic manifestation observed in patients diagnosed with Leigh syndrome, is associated with developing limb paralysis and loss of feeling, and can also cause movement issues. Patients with Leigh",20_4,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"also cause movement issues. Patients with Leigh syndrome develop brain tissue that resembles lesions, which contributes to the signs and symptoms of the illness. During a medical examination known as magnetic resonance imaging (MRI), distinctive lesions are discovered in particular regions of the brain. These include the brainstem, which connects the brain to the spinal cord and controls functions such as breathing and swallowing, the cerebellum, which governs balance and coordinates movement, and the",20_5,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"governs balance and coordinates movement, and the basal ganglia, which help control movement. Brain lesions are commonly accompanied with demyelination, a condition that impairs the neurons’ capacity to activate the muscles that are used for movement or transmit sensory data from the rest of the body back to the brain. The mitochondria, serving as the primary energy-producing center of the cell, contribute approximately 90% of the total energy utilized by these cells. There are numerous even thousands of",20_6,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"these cells. There are numerous even thousands of mitochondria that use oxygen and convert food into energy. Similar to the nucleus, the mitochondria possess their own distinct genetic materials. A serious and long-lasting genetic malfunction can result from a DNA error in a mitochondrial gene. The mitochondrial genetic disease will start to manifest at birth or later in life at any age. Every organ in the body, including the brain, muscles, nerves, liver, kidneys, and heart, can be impacted by",20_7,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"liver, kidneys, and heart, can be impacted by mitochondrial dysfunction. Approximately 1,000–4,000 children in the United States are born each year with mitochondrial disorder, which affects one in 5,000 persons (<xref rid=""B3"" ref-type=""bibr"">3</xref>). Consanguinity, which is the union of close blood relatives, raises the possibility that a kid will inherit two copies of a deleterious gene. Consanguinity has a significant role in the development of genetic disorders, particularly in children who inherit",20_8,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"disorders, particularly in children who inherit genetic diseases as a result of the consanguinity (<xref rid=""B4"" ref-type=""bibr"">4</xref>). The leucine-rich pentatricopeptide repeat (<italic toggle=""yes"">LRPPRC</italic>) gene, which has 4.8 kb and codes for a 130 kDa protein, was initially discovered in HepG2 cells in 1994 by Hou J. (<xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B6"" ref-type=""bibr"">6</xref>). Subsequently, it was found that a decrease in <italic toggle=""yes"">LRPPRC</italic> level",20_9,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"in <italic toggle=""yes"">LRPPRC</italic> level and steady-state levels of mitochondrial transcripts were responsible for the development of Leigh syndrome French-Canadian (LSFC). The causative role of the <italic toggle=""yes"">LRPPRC</italic> gene mutation in Leigh syndrome has been established over the previous few decades. Congenital lactic acidosis is a characteristic of the genetically homogenous condition known as LSFC. The patients frequently exhibit neurological changes, developmental delays, abnormal",20_10,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"changes, developmental delays, abnormal facial features, and acute crises such as lactic acidosis, hyperglycemia, hepatic cytolysis, and hyperglycemia (<xref rid=""B7"" ref-type=""bibr"">7</xref>–<xref rid=""B10"" ref-type=""bibr"">10</xref>). In addition, with the exception of LSFC, LRPPRC has the potential to be involved in early onset, multisystemic, and neurological manifestations of mitochondrial disorders (<xref rid=""B11"" ref-type=""bibr"">11</xref>, <xref rid=""B12"" ref-type=""bibr"">12</xref>).   The",20_11,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"<xref rid=""B12"" ref-type=""bibr"">12</xref>).   The mitochondrion serves as a site for the production of cellular energy. The majority of the organs, including the muscles, brain, and lungs, frequently acquire energy through the process of cellular respiration occurring within the mitochondria. The genes that are responsible for mitochondrial functions are found on both the mitochondrial and chromosomal DNA. Any abnormality in the normal functions of the mitochondrial cascade has the potential to abnormal",20_12,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"cascade has the potential to abnormal functions. The current demand in familial mitochondrial disorders necessitates the implementation of molecular diagnosis (<xref rid=""B22"" ref-type=""bibr"">22</xref>). The diagnosis of patients with incomplete phenotypic expression poses challenges in molecular biology laboratories (<xref rid=""B23"" ref-type=""bibr"">23</xref>). However, the recent advancements in next-generation sequencing have brought about a significant transformation in the field of molecular diagnosis",20_13,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"in the field of molecular diagnosis (<xref rid=""B24"" ref-type=""bibr"">24</xref>). This study demonstrated an association between a novel homozygous <italic toggle=""yes"">LRPPRC</italic> gene variant and a lethal type of infantile mitochondrial disease. Due to the patient’s limited survival time, a detailed clinical diagnosis was not possible. The <italic toggle=""yes"">LRPPRC</italic> gene is located on the reverse strand of chromosome 2 (from genomic DNA position 43,886,224 to 43,996,226). The wild-type",20_14,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"position 43,886,224 to 43,996,226). The wild-type sequence of the <italic toggle=""yes"">LRPPRC</italic> gene can be retrieved using the accession number ENSG00000138095 from Ensembl Genome Browser (<ext-link http://www.w3.org/1999/xlink href=""https://asia.ensembl.org/Homo_sapiens/Gene/"" ext-link-type=""uri"">https://asia.ensembl.org/Homo_sapiens/Gene/</ext-link>). The gene consists of 38 exons coding for an mRNA molecule that is 6,603 bases in length (<ext-link http://www.w3.org/1999/xlink",20_15,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"in length (<ext-link http://www.w3.org/1999/xlink href=""https://www.ncbi.nlm.nih.gov/nuccore/NM_133259.4"" ext-link-type=""uri"">https://www.ncbi.nlm.nih.gov/nuccore/NM_133259.4</ext-link>), which in turn translates into a protein consisting of 1,394 amino acids. The function of the <italic toggle=""yes"">LRPPRC</italic> has been reported in the assembly of cytochrome oxidase. Associations have been identified between <italic toggle=""yes"">LRPPRC</italic> variations and lower expression levels of mRNA for",20_16,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"and lower expression levels of mRNA for cytochrome c oxidase I and cytochrome c oxidase III. Such patients presented Leigh syndrome French-Canadian type phenotype, and they shared a founder variation (p.Aal354Val) in the LRPPRC protein (<xref rid=""B8"" ref-type=""bibr"">8</xref>). The human gene mutations database has enlisted a total of 37 variations. The missense variations develop diverse phenotypes including premature ovarian insufficiency (<xref rid=""B25"" ref-type=""bibr"">25</xref>), tetralogy of Fallot",20_17,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"ref-type=""bibr"">25</xref>), tetralogy of Fallot (<xref rid=""B26"" ref-type=""bibr"">26</xref>), mitochondrial respiratory chain complex IV deficiency (<xref rid=""B27"" ref-type=""bibr"">27</xref>), Leigh syndrome, French-Canadian type (<xref rid=""B28"" ref-type=""bibr"">28</xref>), cytochrome c oxidase deficiency (<xref rid=""B9"" ref-type=""bibr"">9</xref>), infantile mitochondrial disease, lethal type (<xref rid=""B16"" ref-type=""bibr"">16</xref>), congenital heart disease (<xref rid=""B29"" ref-type=""bibr"">29</xref>),",20_18,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"(<xref rid=""B29"" ref-type=""bibr"">29</xref>), autism (<xref rid=""B30"" ref-type=""bibr"">30</xref>), inborn errors of metabolism (<xref rid=""B31"" ref-type=""bibr"">31</xref>), failure to thrive, microcephaly, global developmental delay, intellectual disability, hypotonia, and seizures (<xref rid=""B25"" ref-type=""bibr"">25</xref>). There are only two nonsense variations that result in developing Leigh syndrome French-Canadian type and mitochondrial disorder with intellectual disability (<xref rid=""B17""",20_19,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"with intellectual disability (<xref rid=""B17"" ref-type=""bibr"">17</xref>, <xref rid=""B28"" ref-type=""bibr"">28</xref>). Splicing variations can also result in diverse phenotypes, such as Leigh syndrome, French-Canadian type (<xref rid=""B20"" ref-type=""bibr"">20</xref>), cytochrome c oxidase deficiency (<xref rid=""B11"" ref-type=""bibr"">11</xref>), inborn error of metabolism (<xref rid=""B31"" ref-type=""bibr"">31</xref>), and developmental disorder (<xref rid=""B30"" ref-type=""bibr"">30</xref>). The splice-variant",20_20,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"ref-type=""bibr"">30</xref>). The splice-variant c.469 + 2T > A, which was identified in this study, was novel and had not been reported before. The previously reported variant c.469 + 1G > T was found in close proximity to the variant identified in our family. It was confirmed through laboratory analysis using whole genome sequencing. It had been clinically diagnosed as Leigh syndrome with French-Canadian type (<xref rid=""B20"" ref-type=""bibr"">20</xref>). The patient included in this present study also",20_21,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"The patient included in this present study also exhibited a limited life expectancy, similar to those previously reported for the c.469 + 2T > A variant. The utilization of whole exome sequencing has been adopted as a first-line molecular diagnostic tool in most of clinical setups. The phenotype developed by the <italic toggle=""yes"">LRPPRC</italic> gene is clinically diverse, and the survival rate in majority of cases is limited. Thus, relying solely on clinical features is insufficient for accurately",20_22,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"clinical features is insufficient for accurately determining a comprehensive diagnosis. Instead, it is more advantageous to perform whole exome sequencing in patients presenting with symptoms such as failure to thrive, developmental delays, signs of inborn metabolic disorders, intellectual disability, or suspected phenotype of mitochondrial disorders.",20_23,"A novel homozygous splice donor variant in the <italic toggle=""yes"">LRPPRC</italic> gene causing Leigh syndrome with epilepsy, a French-Canadian disorder in a Saudi family: case report",17 11 2023,,Leigh_Syndrome
"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome Leigh syndrome is an inherited neurometabolic disorder. Leigh syndrome is estimated to be the most common form of mitochondrial disease, affecting children with a prevalence of ~1 in 40,000 births [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Leigh syndrome was first described in 1951 by the physician",21_0,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"was first described in 1951 by the physician Archibald Denis Leigh [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. In the 72 years since then, we have made tremendous progress in identifying causal pathogenic variants, which span over 110 different genes in both the mitochondrial and nuclear genomes [<xref ref-type=""bibr"" rid=""CR2"">2</xref>–<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Despite the discovery of the underlying pathogenic variants that cause Leigh syndrome, little progress has been made in the",21_1,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"syndrome, little progress has been made in the treatments available. Owing to the wide array of causal variants across many genes identified in Leigh syndrome, the cellular mechanisms driving disease progression are thought to be heterogeneous [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Different aspects of mitochondrial function are likely altered by the variants in different genes, creating complexity in the biochemical defects and consequently, challenges in",21_2,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"defects and consequently, challenges in identifying drug targets effective across all patients [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. The prognosis for Leigh syndrome is generally poor, with mortality rates of nearly 80% by age 20 [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. No Food and Drug Administration (FDA)-approved therapies for the management of Leigh syndrome are available. The Leigh syndrome research community, and the mitochondrial disease research",21_3,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"community, and the mitochondrial disease research field in general, faces significant barriers to the discovery of novel treatment strategies. Due to the rarity of the disease and heterogeneity in pathogenic variants, it is difficult to recruit patients for adequately sized clinical studies, as patients are geographically dispersed. Limitations in the models available for studying mitochondrial diseases create barriers to drug discovery and as a result, the underlying mechanisms of Leigh syndrome and",21_4,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"the underlying mechanisms of Leigh syndrome and specific causal variants are poorly understood. As such, the Boston University integrative Cardiac Metabolism and Pathophysiology Program (iCAMP) and the Cure Mito Foundation co-hosted a virtual symposium entitled “Empower & Inspire: Understanding and Accelerating Research for Leigh Syndrome” to bring together healthcare providers, scientists, and families to problem solve together. The symposium started with an introduction from Kasey Woleben who described",21_5,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"an introduction from Kasey Woleben who described the history of the Cure Mito Foundation and highlighted the importance of the families coming together. The introduction was followed by a keynote talk by Dr. Vamsi Mootha who ended by sharing that this is an incredibly promising time for Leigh syndrome research but underscored that real progress will require all stakeholders coming together collaboratively. Dr. Saima Kayani then provided a primer and background on the disease in her talk titled, “Leigh",21_6,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"on the disease in her talk titled, “Leigh Syndrome 101.” Her talk primed the attendees for the rest of the symposium, by covering disease etiology, clinical presentation, natural history and disease progression, and current standard of care for Leigh syndrome. All speakers and presentation titles are provided in Table <xref rid=""Tab1"" ref-type=""table"">1</xref> and the link to the free and publicly available video recordings of the presentations is also provided. Most presenters discussed published findings",21_7,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"Most presenters discussed published findings and relevant citations are included throughout the text. It should be noted that some of the data that was presented is unpublished and as such, has not been peer-reviewed, which is indicated when relevant. Competing interests are noted in the case of industry-funded studies. Collectively, we discuss here the advances presented at the symposium. We highlight novel disease models, therapeutics in the pipeline, patient recruitment and database strategies, and",21_8,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"patient recruitment and database strategies, and family needs to bring together the community to accelerate research into this devastating disease.",21_9,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"<table-wrap id=""Tab1""><label>Table 1</label><caption><p>Speakers at the Leigh Syndrome Symposium</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th align=""left"">Speaker</th><th align=""left"">Affiliation</th><th align=""left"">Title of Presentation</th></tr></thead><tbody><tr><td align=""left"">Kasey Woleben</td><td align=""left"">Cure Mito Foundation</td><td align=""left"">Introduction</td></tr><tr><td align=""left"">Vamsi K. Mootha, MD</td><td align=""left"">Harvard Medical School, Broad Institute of",21_10,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"Medical School, Broad Institute of Harvard and MIT</td><td align=""left"">Keynote: ​Advances in Leigh Syndrome Research: Sterling Past, Golden Future</td></tr><tr><td align=""left"">Saima Kayani, MD</td><td align=""left""><p>University of Texas Southwestern </p><p>Medical Center</p></td><td align=""left"">Leigh Syndrome 101</td></tr><tr><td align=""left"">Steven J. Gray, PhD</td><td align=""left""><p>University of Texas Southwestern </p><p>Medical Center</p></td><td align=""left"">General Overview of Nervous System",21_11,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">General Overview of Nervous System Targeted Gene Therapy</td></tr><tr><td align=""left"">Michal Minczuk, PhD</td><td align=""left"">University of Cambridge, Pretzel Therapeutics</td><td align=""left"">Mitochondrial Genome Engineering In Vivo</td></tr><tr><td align=""left"">Jessica L. Fetterman, PhD</td><td align=""left"">iCAMP lab, Boston University School of Medicine</td><td align=""left"">Gaining Insights into Mitochondrial Diseases Using Stem Cells</td></tr><tr><td align=""left"">Alessandro Prigione, MD,",21_12,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">Alessandro Prigione, MD, PhD</td><td align=""left"">University of Düsseldorf, Germany</td><td align=""left"">Patient-Derived Stem Cells and Brain Organoids for Modeling and Drug Discovery of Leigh Syndrome</td></tr><tr><td align=""left"">Simon C. Johnson, PhD</td><td align=""left"">University of Washington, Seattle Children’s Research Institute</td><td align=""left"">Immune-Mediated Disease Pathogenesis in Leigh Syndrome</td></tr><tr><td align=""left"">Joseph J. Bellucci, PhD</td><td",21_13,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">Joseph J. Bellucci, PhD</td><td align=""left"">Rarebase</td><td align=""left"">Applying A Precision Medicine Drug Discovery Platform to SURF1 Leigh Syndrome</td></tr><tr><td align=""left"">Anne N. Murphy, PhD</td><td align=""left"">Cytokinetics</td><td align=""left"">Challenges in Drug Discovery for Mitochondrial Disorders</td></tr><tr><td align=""left"">Matthew B. Klein, MD, MS, FACS</td><td align=""left"">PTC Therapeutics</td><td align=""left"">Insights from over a Decade of Experience in Mitochondrial",21_14,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"from over a Decade of Experience in Mitochondrial Disease Drug Development</td></tr><tr><td align=""left"">Volkmar Weissig, ScD, PhD</td><td align=""left"">Midwestern University</td><td align=""left"">Development of New Drugs for Mitochondrial Diseases with a Focus on Leigh Syndrome</td></tr><tr><td align=""left"">Sophia Zilber</td><td align=""left"">Cure Mito Foundation</td><td align=""left"">Leigh Syndrome Global Patient Registry Updates</td></tr><tr><td align=""left"">Rhonda Facile, MS</td><td",21_15,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">Rhonda Facile, MS</td><td align=""left"">Partnerships and Development, CDISC</td><td align=""left"">CDISC and How Data Standards Can Help Drive Development of Mito Treatments</td></tr><tr><td align=""left"">Parag Shiralkar, MS, MBA</td><td align=""left"">Sumptuous Data Sciences</td><td align=""left"">Interoperability of Leigh Syndrome Patient Registry Data with Regulatory Submission Standards</td></tr><tr><td align=""left"">Alexandre Bétourné, PhD, PharmD, PMP</td><td align=""left"">Critical Path",21_16,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"PharmD, PMP</td><td align=""left"">Critical Path Institute</td><td align=""left"">The Rare Diseases Cures Accelerator Data and Analytics Platform: Accelerating Drug Development for Rare Mitochondrial Disorders.</td></tr><tr><td align=""left"">Shannon Rego O’Rourke, MS, CGC</td><td align=""left"">Allstripes</td><td align=""left"">SURF1-related Leigh Syndrome Health Data Insights</td></tr><tr><td align=""left"">Parents of Patients with Leigh Syndrome</td><td align=""left"">N/A</td><td align=""left""><p>Parent",21_17,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">N/A</td><td align=""left""><p>Parent panel</p><p>Jennifer Linnebach (USA)</p><p>Krisztina Ferencz (Romania)</p><p>Jorgelina Alvarez Barral (Argentina)</p></td></tr><tr><td align=""left"">Rachel Kramer, PhD</td><td align=""left"">Clinical Psychologist, Private Practice</td><td align=""left"">Parenting Children with Mitochondrial Disease: Finding Space for Parental Well-Being</td></tr><tr><td align=""left"">Jessica L. Fetterman, PhD and Kasey Woleben</td><td align=""left"">iCAMP lab, Boston University",21_18,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"align=""left"">iCAMP lab, Boston University School of Medicine and Cure Mito Foundation</td><td align=""left"">Closing Remarks</td></tr></tbody></table><table-wrap-foot><p>The sessions were moderated by Kasey Woleben (Cure Mito), Ethan Perlstein, PhD (Perlara), Kevin Freiert (Salem Oaks, Cure Mito), Danielle Boyce, MPH, DPA (John Hopkins School of Medicine, Cure Mito), Liz Morris (parent and caregiver collaborator).</p></table-wrap-foot></table-wrap>",21_19,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"The Cure Mito/Boston University iCAMP Leigh syndrome symposium was successful in highlighting several points. First, recent advances in gene editing technologies and mitochondrial disease models have facilitated, and will likely accelerate, novel insight into disease mechanisms. Second, clinical trials with small numbers of patients are beginning to identify therapies that improve outcomes in select patients with mitochondrial diseases with similar phenotypes. Third, the Leigh syndrome global patient",21_20,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"Third, the Leigh syndrome global patient registry continues to develop and grow, and will likely facilitate a better understanding of the prevalence of the different symptoms and disease progression. Most importantly, this symposium was successful with a turnout of over 200 participants from 34 countries in attendance, demonstrating the power of the community coming together and laying the groundwork for much more to come. Together, the advances presented, and the push for collaboration between all",21_21,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"and the push for collaboration between all stakeholders, will hopefully result in novel treatment options for patients with Leigh syndrome and bring us into the future of mitochondrial disease management.",21_22,"Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome",16 11 2023,,Leigh_Syndrome
"Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome Additional methods are presented in the Supplementary Material.   Contributed to project conception, design, acquisition of data, interpretation of data, or all: all authors. Contributed to manuscript drafting, approve the version for publication, and are accountable for the integrity of the published work: all authors. Obtained funding: SCJ, MS, PGM, KAS. Conceived and designed the experiments: SCJ. Interpreted data, managed",22_0,Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome,26 9 2023,,Leigh_Syndrome
"the experiments: SCJ. Interpreted data, managed the work, and prepared the manuscript: SCJ. Contributed to manuscript preparation: MS, PGM, KAS, MM, JS, MH, KJ, ARH. We dedicate this study to Ivy Ohlgren, Colleen and Derek Ohlgren, their family, and all those living with the consequences of mitochondrial disease. They continue to inspire us. The authors declare that they have no conflicts of interest. US National Institutes of Health (NIH/GM R01 GM133865 to MS, SCJ; NIH/GM R01 GM144368 to SCJ; T32 GM086270",22_1,Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome,26 9 2023,,Leigh_Syndrome
"MS, SCJ; NIH/GM R01 GM144368 to SCJ; T32 GM086270 to KAS; R35 GM139566 to PGM); Northwest Mitochondrial Research Guild (to SCJ).",22_2,Volatile anaesthetic toxicity in the genetic mitochondrial disease Leigh syndrome,26 9 2023,,Leigh_Syndrome
"Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy Mutations in the NADH dehydrogenase (ubiquinone reductase) iron-sulfur protein 4 (<italic toggle=""yes"">NDUFS4</italic>) gene, which encodes for a key structural subunit of the OXFOS complex I (CI), lead to the most common form of mitochondrial disease in children known as Leigh syndrome (LS). As in other mitochondrial diseases, epileptic seizures constitute one of the most",23_0,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"epileptic seizures constitute one of the most significant clinical features of LS. These seizures are often very difficult to treat and are a sign of poor disease prognosis. Mice with whole-body <italic toggle=""yes"">Ndufs4</italic> KO are a well-validated model of LS; they exhibit epilepsy and several other clinical features of LS. We have previously shown that mice with <italic toggle=""yes"">Ndufs4</italic> KO in only GABAergic interneurons (Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO) reproduce the",23_1,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"toggle=""yes"">Ndufs4</italic>-KO) reproduce the severe epilepsy phenotype observed in the global KO mice. This observation indicated that these mice represent an excellent model of LS epilepsy isolated from other clinical manifestations of the disease. To further characterize this epilepsy phenotype, we investigated seizure susceptibility to selected exogenous seizure triggers in Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. Then, using electrophysiology, imaging, and immunohistochemistry, we studied",23_2,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"imaging, and immunohistochemistry, we studied the cellular, physiological, and neuroanatomical consequences of <italic toggle=""yes"">Ndufs4</italic> KO in GABAergic interneurons. Homozygous KO of <italic toggle=""yes"">Ndufs4</italic> in GABAergic interneurons leads to a prominent susceptibility to exogenous seizure triggers, impaired interneuron excitability and interneuron loss. Finally, we found that the hippocampus and cortex participate in the generation of seizure activity in Gad2-<italic",23_3,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"generation of seizure activity in Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. These findings further define the LS epilepsy phenotype and provide important insights into the cellular mechanisms underlying epilepsy in LS and other mitochondrial diseases. Leigh syndrome (LS), or subacute necrotizing encephalomyelopathy, is a progressive mitochondrial disease that primarily affects the central nervous system. It is the most common pediatric mitochondrial disease with an incidence of 1 in 40,000 live",23_4,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"disease with an incidence of 1 in 40,000 live births (<xref rid=""R48"" ref-type=""bibr"">Rahman et al., 1996</xref>). Mutations in at least 75 different genes of both nuclear and mitochondrial genomes have been linked to LS (<xref rid=""R28"" ref-type=""bibr"">Lake et al., 2016</xref>). They represent defects in genes that encode proteins within the mitochondrial respiratory chain which drives oxidative phosphorylation (OXPHOS). The OXPHOS system comprises five multi-subunit protein complexes and among them the",23_5,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"protein complexes and among them the largest and most intricate is the Complex I (CI) which is composed of 44 subunits in mammals. CI plays an important role in energy metabolism; it serves as a main entry point for electrons into the mitochondrial respiratory chain. In particular, mutations in genes that encode all of CI subunits are known to cause LS and generally in its most severe form. One of these LS-causing CI genes is the <italic toggle=""yes"">Ndufs4</italic> gene, which codes for a subunit that is",23_6,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"gene, which codes for a subunit that is important for the structure and stability of the complex (<xref rid=""R7"" ref-type=""bibr"">Calvaruso et al., 2012</xref>; <xref rid=""R42"" ref-type=""bibr"">Ortigoza-Escobar et al., 2016</xref>). Like most mitochondrial disorders, LS is clinically characterized by a set of multiple and highly variable symptoms. This includes seizures, ataxia, failure to thrive, hypotonia, psychomotor regression, breathing difficulties, dysphagia, cardiomyopathy, lactic acidosis, and",23_7,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"dysphagia, cardiomyopathy, lactic acidosis, and premature death. The disease often presents within the first few months of life then quickly progresses to death by 2–3 years old (<xref rid=""R48"" ref-type=""bibr"">Rahman et al., 1996</xref>; <xref rid=""R61"" ref-type=""bibr"">van de Wal et al., 2022</xref>). However, adult-onset cases have also been reported (<xref rid=""R43"" ref-type=""bibr"">Piao et al., 2006</xref>; <xref rid=""R6"" ref-type=""bibr"">Bris et al., 2017</xref>). Epileptic seizures are typically the",23_8,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"Epileptic seizures are typically the first and one of the most dominant clinical manifestations of LS and other mitochondrial diseases. They have been reported to occur in 35–60% of patients with mitochondrial diseases (<xref rid=""R49"" ref-type=""bibr"">Rahman et al., 2012</xref>). In LS, this prevalence is estimated in the range of 40–79% (<xref rid=""R48"" ref-type=""bibr"">Rahman et al., 1996</xref>; <xref rid=""R1"" ref-type=""bibr"">Arii and Tanabe, 2000</xref>; <xref rid=""R30"" ref-type=""bibr"">Lee et al.,",23_9,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"<xref rid=""R30"" ref-type=""bibr"">Lee et al., 2009</xref>; <xref rid=""R39"" ref-type=""bibr"">Naess et al., 2009</xref>). These seizures are typically of multiple types including partial and/or myoclonic (MC) seizures, generalized tonic-clonic (GTC) seizures, as well as infantile spasms (<xref rid=""R12"" ref-type=""bibr"">Finsterer and Mahjoub, 2012</xref>). They are often resistant to standard antiepileptic drugs and thus are difficult to manage (<xref rid=""R47"" ref-type=""bibr"">Rahman and Copeland, 2019</xref>;",23_10,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"ref-type=""bibr"">Rahman and Copeland, 2019</xref>; <xref rid=""R62"" ref-type=""bibr"">Wesół-Kucharska et al., 2021</xref>). Furthermore, these seizures often significantly contribute to the deterioration of patients’ cognitive function and lead to epileptic encephalopathy. As such, they profoundly affect the patients’ prognosis and quality of life. However, despite their major clinical significance, the pathophysiological mechanisms of seizures in the context of LS or other mitochondrial diseases are still not",23_11,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"LS or other mitochondrial diseases are still not fully understood. Our recent work showed that in LS, epilepsy is driven by GABAergic interneurons. Targeted knock-out (KO) of <italic toggle=""yes"">Ndufs4</italic> in only GABAergic (not glutamatergic) neurons was sufficient to recapitulate the severe and lethal epilepsy of LS in mice (<xref rid=""R4"" ref-type=""bibr"">Bolea et al., 2019</xref>). Mice carrying this type of mutation exhibited spontaneous interictal spikes, MC seizures, GTC seizures, and succumbed",23_12,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"spikes, MC seizures, GTC seizures, and succumbed to sudden unexpected death in epilepsy (SUDEP) (<xref rid=""R4"" ref-type=""bibr"">Bolea et al., 2019</xref>). These mice were also sensitive to thermally induced MC and GTC seizures. Administration of selected standard antiepileptic drugs failed to ameliorate the seizures or prolong lifespan, illustrating resistance to standard epilepsy treatment (<xref rid=""R4"" ref-type=""bibr"">Bolea et al., 2019</xref>). These findings indicate that epilepsy can be reliably",23_13,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"findings indicate that epilepsy can be reliably segregated and modeled away from other clinical manifestations of LS in Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. Therefore, these mice can be leveraged to specifically study the GABAergic mechanisms of epilepsy without the confounding factors of other LS symptoms and mechanisms. In this study, to expand our understanding of the characteristics of epilepsy in LS, we examined the susceptibility of our mouse model to selected seizure triggers. People",23_14,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"mouse model to selected seizure triggers. People with epilepsy exhibit a high susceptibility to different seizure triggers. The latter can influence the timing and occurrence of seizures (<xref rid=""R2"" ref-type=""bibr"">Balamurugan et al., 2013</xref>; <xref rid=""R14"" ref-type=""bibr"">Ge et al., 2022</xref>). Exercise can cause a transient decrease in the seizure threshold and trigger seizures in people with epilepsy (<xref rid=""R2"" ref-type=""bibr"">Balamurugan et al., 2013</xref>). We recently showed that",23_15,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"et al., 2013</xref>). We recently showed that moderate exercise provokes GTC seizures in global <italic toggle=""yes"">Ndufs4</italic> KO mice (<xref rid=""R5"" ref-type=""bibr"">Bornstein et al., 2022</xref>). Here we explored whether this seizure-related phenotypic trait is recapitulated in the Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. We also assessed the seizure-inducing properties of pentylenetetrazol (PTZ), a GABA-A receptor antagonist used at low dose. By inhibiting GABAergic inhibition, PTZ",23_16,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"low dose. By inhibiting GABAergic inhibition, PTZ enables synchronization of forebrain networks (<xref rid=""R60"" ref-type=""bibr"">Van Erum et al., 2020</xref>). When administered at sub-convulsive doses, PTZ commonly leads to MC seizures or absence seizures, whereas at convulsive doses it induces GTC seizures in wildtype rodents (<xref rid=""R11"" ref-type=""bibr"">Erakovic et al., 2001</xref>; <xref rid=""R10"" ref-type=""bibr"">Eloqayli et al., 2003</xref>; <xref rid=""R60"" ref-type=""bibr"">Van Erum et al.,",23_17,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"<xref rid=""R60"" ref-type=""bibr"">Van Erum et al., 2020</xref>). Since the GABAergic network is already affected by the genetic mutation, we examined whether a second hit with a low dose PTZ will reveal an increased susceptibility to seizures in our mouse model. Furthermore, we investigated the cellular, pathophysiological and neuroanatomical mechanisms underlying seizures in LS. Overall, we show that the <italic toggle=""yes"">Ndufs4</italic> KO in GABAergic interneurons leads to an increased susceptibility",23_18,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"interneurons leads to an increased susceptibility to tested exogenous seizure triggers, impaired interneuron excitability, and interneuron loss in the hippocampus and cortex. These findings shed a light on how dysfunctions of GABAergic interneurons drive the epilepsy phenotype in LS.   As in most mitochondrial diseases, epilepsy is a prominent feature among the multiple neurological phenotypes of LS. Epileptic seizures are often difficult to manage with standard antiepileptic drugs and they strongly affect",23_19,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"antiepileptic drugs and they strongly affect the disease prognosis. In our recent work, we showed that Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO exhibit a severe epilepsy phenotype, serving as an excellent preclinical model of LS-epilepsy. The pathophysiological mechanisms underlying LS-epilepsy are not fully understood. In this study, we show that an exogenous trigger such as a low dose of a pharmacological convulsant agent or moderate exercise, readily provokes GTC seizures in Gad2-<italic",23_20,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"readily provokes GTC seizures in Gad2-<italic toggle=""yes"">Ndufs4</italic>-KO mice. We show that KO of <italic toggle=""yes"">Ndufs4</italic> has a direct negative impact on interneuron function and survival. Further, hippocampal and cortical neurons are key participants in the generation of spontaneous and provoked seizures in the mice carrying the <italic toggle=""yes"">Ndufs4</italic> KO in GABAergic interneurons. Taken together, our data provide an important insight into the mechanisms of LS epilepsy. They",23_21,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"insight into the mechanisms of LS epilepsy. They indicate that a LS-causing mutation mainly leads to a significant decrease in interneuron density and impaired excitability of remaining interneurons. In turn, these neuroanatomical and functional changes result in hyperexcitability of neuronal populations in the hippocampus and cortex, along with increased susceptibility to spontaneous and evoked seizures. Since the studied mutation is known to compromise mitochondrial function via suppression of complex I",23_22,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"function via suppression of complex I expression (<xref rid=""R26"" ref-type=""bibr"">Kruse et al., 2008</xref>), we predict that similar mechanisms may underlie the pathogenesis of epilepsy in other forms of mitochondrial diseases. Several pathophysiological mechanisms underlying epilepsy in mitochondrial diseases have been previously hypothesized. Our findings in this study are aligned with the hypothesis that mitochondrial dysfunction leads to reduced interneuron activity and/or interneuron cell loss,",23_23,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"activity and/or interneuron cell loss, leading to an imbalance of excitation and inhibition, and resulting in seizures. A limitation of this part of our study is that our experiments did not assess other hypotheses, namely that mitochondrial dysfunction leads to (1) abnormal ion channel expression/function; (2) impaired Na<sup>+</sup>/K<sup>+</sup> ATPase activity; (3) impaired calcium homeostasis; or (4) the generation of reactive oxygen species (ROS) (<xref rid=""R62"" ref-type=""bibr"">Wesół-Kucharska et",23_24,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"rid=""R62"" ref-type=""bibr"">Wesół-Kucharska et al., 2021</xref>; <xref rid=""R33"" ref-type=""bibr"">Lopriore et al., 2022</xref>). These mechanisms can also lead to network hyperactivity and seizures. However, our work suggests that the hypothesis that mitochondrial dysfunction leads to increased excitability in glutamatergic neurons which translate into seizures may not apply to our model given that the <italic toggle=""yes"">Ndufs4</italic> mutation was not introduced in this cell type. Different interneuron",23_25,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"in this cell type. Different interneuron subtypes are thought to have differential vulnerabilities to mitochondrial dysfunctions due to their distinct electrophysiological properties and associated energy demands. It is therefore conceivable that interneuron subtypes play differential roles in mechanisms of epilepsy in LS or other mitochondrial diseases. However, this hypothesis was not tested in this study. But our future study will investigate the relative contribution of the two main interneuron",23_26,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"relative contribution of the two main interneuron subtypes, parvalbumin (PV) and somatostatin (SST), to the epileptic phenotype in our LS model. Interestingly, impaired PV interneuron excitability is known to alter the balance of excitation and inhibition leading to spontaneous seizures in models of early-onset epileptic encephalopathies (<xref rid=""R52"" ref-type=""bibr"">Rubinstein et al., 2015</xref>; <xref rid=""R18"" ref-type=""bibr"">Inan et al., 2016</xref>; <xref rid=""R44"" ref-type=""bibr"">Piguet et al.,",23_27,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"<xref rid=""R44"" ref-type=""bibr"">Piguet et al., 2018</xref>; <xref rid=""R20"" ref-type=""bibr"">Joseph et al., 2020</xref>). On the other end, impaired SST interneuron excitability only produces a mild epileptic phenotype (<xref rid=""R52"" ref-type=""bibr"">Rubinstein et al., 2015</xref>). Understanding the roles of interneuron subtypes in the mechanisms of epilepsy in mitochondrial disease will help in the development of highly precise therapies for this disease.",23_28,Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy,27 10 2023,,Leigh_Syndrome
"Leigh syndrome global patient registry: uniting patients and researchers worldwide Leigh syndrome is a rare genetic neurometabolic disorder, leading to the degeneration of the central nervous system and subsequently early death. Leigh syndrome is considered the most common type of rare pediatric mitochondrial disease affecting around 1 in 40,000 individuals [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The onset of symptoms usually occurs between the ages of three",24_0,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"symptoms usually occurs between the ages of three months and two years, but some patients present with a later disease onset. Leigh syndrome can be caused by over 110 genetic mutations in mitochondrial or nuclear DNA [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. A patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one",24_1,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. For mitochondrial diseases, it is widely acknowledged that the rarity and heterogeneity of individual genetic diseases combined with the lack of patient registries to understand the natural history of each unique disease and enable designing rigorous clinical trials, contribute to the challenges researchers face in developing targeted therapies. To combat",24_2,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"face in developing targeted therapies. To combat this, innovative partnership across the bioscience ecosystem centered on patients is required [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Patient registries are important to understand the natural history of the disease, measure and improve quality of care, and understand the healthcare burden [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. More importantly in rare diseases, patient registries have become efficient tools in providing valuable patient data,",24_3,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"tools in providing valuable patient data, considering the heterogeneous disease profile, small patient population, and limited funding [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Cure Mito Foundation recognized these challenges and initiated the Leigh syndrome Global Registry in September 2021. Cure Mito Foundation is a parent-led, fully volunteer foundation dedicated to advancing education and research for Leigh syndrome and mitochondrial disease. The goals of the",24_4,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"and mitochondrial disease. The goals of the registry are to further describe Leigh syndrome clinical characteristics and phenotype, enable and facilitate clinical trials recruitment, and unite international patients and researchers. Mesko and colleagues share the viewpoint that a more active, collaborative process that engages with patients as true partners at all times optimizes the wants and priorities of the ultimate stakeholder, the patient. This process is referred to as patient-designed care [<xref",24_5,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"is referred to as patient-designed care [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. To this end, patient foundations led by affected patients and their caregivers (parents) likely represent the true understanding of the impact of the disease on the patients’ immediate needs (real world data) and create a sense of urgency in driving research further. This is reflected in the design of the Leigh syndrome registry, which encourages active patient engagement, data availability at no cost to interested",24_6,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"data availability at no cost to interested researchers and industry partners, and transparent sharing of findings and results with the wider community. We believe there is an increasing need for better understanding of Leigh syndrome with an aim to support the development of transformative therapies, driven by the unmet need of treatment options for patients with this genetic disease. This paper is, to our knowledge, the first available publication on data from a global Leigh syndrome patient registry.",24_7,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"from a global Leigh syndrome patient registry.   Data collected from a global patient registry for individuals with Leigh syndrome is presented. The authors did not find prior studies on Leigh syndrome reporting outcomes described above such as loss of milestones, specialists seen, disease management, or healthcare utilization, making this the first publication of such results. Although the registry and Cure Mito Foundation are US-based, nearly 70% of participants reside outside of the US, spanning 8",24_8,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"participants reside outside of the US, spanning 8 geographic regions, and 25 countries. Of note, this geographical diversity likely represents the first truly global registry for any mitochondrial disease, a product of the broad-reaching recruitment effort through social media platforms and directly via international Cure Mito partner families. Cure Mito builds connections with patient families from around the world by empowering patients to unite (regardless of language and cultural barriers) to advance",24_9,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"of language and cultural barriers) to advance research in the Leigh syndrome community. This was initially accomplished with the assistance of international partner families translating the surveys into their own language, being mindful of cultural sensitivity for participants. Subsequent registry enrollment included surveys that were already translated into various languages (Spanish, Portuguese). Time to diagnosis of Leigh syndrome reported by the participants in the current study is significantly",24_10,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"in the current study is significantly shorter than previously reported in other research on mitochondrial disease overall. A study analyzing data from 210 Rare Diseases Clinical Research Network Contact Registry participants, with self-reported diagnosis of mitochondrial disease found participants saw an average of 8.1 clinicians and over half received 1 or more non-mitochondrial diagnoses before their final mitochondrial diagnosis. [<xref ref-type=""bibr"" rid=""CR11"">11</xref>] Another study, conducted in",24_11,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"rid=""CR11"">11</xref>] Another study, conducted in the Department of Neurogenetics, Royal North Shore Hospital, UK, on 68 participants, found that the mean time to diagnosis was 6.2 years. [<xref ref-type=""bibr"" rid=""CR12"">12</xref>] However, our study focuses on Leigh syndrome specifically, rather than on all mitochondrial disorders. Furthermore, a study of 130 patients with Leigh syndrome by Sofou and colleagues demonstrated a median elapsed time from disease onset to diagnostic testing was 0.9 years",24_12,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"disease onset to diagnostic testing was 0.9 years (interquartile range Q25-Q75: 0.2–3.1 years). [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] This is similar to our results, and underscores the fact that findings for mitochondrial disorders as a group may not necessarily be generalized for individual mitochondrial diseases. Possibly, as Leigh syndrome is a very severe disease and is much harder to overlook or misdiagnose compared to more mild types of mitochondrial disease, the time to diagnosis is shorter.",24_13,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"disease, the time to diagnosis is shorter. Twenty-four (24) distinct genetic loci are represented by the patients in this registry to date, though currently there is a significantly higher number of patients carrying mutations in SURF1. This is likely the result of a significant number of participants being recruited from the Cure Mito Foundation, which originally began as the Cure SURF1 Foundation. While there would undoubtedly be some distortion of normal distribution of clinical data of Leigh syndrome",24_14,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"distribution of clinical data of Leigh syndrome populations due to the higher number of SURF-1 related Leigh syndrome entries, this is expected to diminish as the size and genetic diversity of the registry increases. When the registry size allows, further analyses based on genetic loci, and eventually specific genetic lesions, is likely to offer additional insights into the clinical presentation of Leigh syndrome. Leigh syndrome is typically described as a severe neurological disorder, which is reflected",24_15,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"severe neurological disorder, which is reflected in the high number of registry participants who see neurologists (78%) and therapists for neurodevelopmental disorders. However, the wide variety and quantity (1–30) of specialists seen by participants reflects the severity and multi-system nature of Leigh syndrome. A lot can be learned from the list of other specialists reported by participants including pulmonologists, cardiologists, and gastroenterologists (among others). It is important for general",24_16,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"(among others). It is important for general practice clinicians to look beyond neurodevelopmental concerns and consider referrals to other specialists if appropriate. These percentages also underscore the healthcare burden, financial impact, and imposition on quality of life that multiple specialty visits may have on the individual with Leigh syndrome and their caregiver. It is important to underscore that the number of specialists seen is significantly affected by the country where the participant lives",24_17,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"by the country where the participant lives and the healthcare system as well as standard of living in that country. For example, one of the international participants shared with the Cure Mito Foundation, that their child is bed-bound and unable to ever leave their house due to not having any means of transportation with a wheelchair. The child is occasionally visited at home by their primary care provider. The neurologist sometimes adjusts seizure medications over the phone. Therefore, the child sees only",24_18,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"over the phone. Therefore, the child sees only one specialist, but that speaks to the family’s living situation, rather than the child's health. The first concerns expressed by participants varied but were overwhelmingly connected to developmental delay or regression (68%). A majority, 56%, of participants have never achieved at least one milestone (40% of participants never walked). This again highlights the importance of specialist referral and testing by pediatricians for children losing milestones or",24_19,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"pediatricians for children losing milestones or experiencing developmental delays. However, only 16% of participants reported that their child’s health care provider raised a concern. This discordance underscores the importance of swift referral to appropriate specialists and genetic testing to confirm the diagnosis. This is also evidenced by the fact that most of the participants see neurologists and a variety of therapists. Given the involvement of multiple systems in the disease profile, management of",24_20,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"systems in the disease profile, management of Leigh syndrome requires multimodal therapies to achieve patient outcomes and improve quality of life. Although no curative treatment exists, therapies and devices that target neurological symptoms are commonly used for symptomatic care. Interventions such as mobility devices, feeding tubes including nasogastric, gastro-jejunal, and gastric tubes, orthotics, tracheotomy, communication devices, and secretion management were ranked highly utilized by registry",24_21,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"were ranked highly utilized by registry participants. The reported number of medical interventions used ranged from a minimum of no devices up to seven devices. Although not captured in the initial results from the Cure Mito registry, pharmacotherapies have been proposed to be integral for managing Leigh syndrome. Medications, specifically, nutraceuticals with antioxidant properties or that function in the biochemical pathways that result in Leigh syndrome are frequently suggested as possible therapies,",24_22,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"are frequently suggested as possible therapies, although clinical evidence is controversial. Examples of nutraceuticals include Coenzyme Q10, L-carnitine, α-lipoic acid, creatine-monohydrate, biotin, thiamine, and riboflavin [<xref ref-type=""bibr"" rid=""CR14"">14</xref>–<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. The most common symptoms first reported within the first year are in line with previously reported data [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Our data demonstrates that there is a",24_23,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Our data demonstrates that there is a correlation with symptoms of failure to thrive, gastric reflux, seizures and hypotonia, more commonly reported earlier in life and increasing child age. These suggest that Leigh syndrome presents with early onset of disease in infancy and emphasis on resolving feeding issues, providing nutritional alternatives and seizure management are important. In addition, recognition of these early clinical features may aid earlier diagnosis and disease management. Interestingly,",24_24,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"diagnosis and disease management. Interestingly, the higher prevalence of dystonia and movement disorders is observed above the age of 1 year and remains relatively consistent with age suggesting brain stem and basal ganglia involvement and supports the assessment of early identification by MRI. Of the patients who reported a history of regression or loss of acquired skills, the majority had common symptoms of abnormal development, including verbal delay (2 word speech), gross motor delay (sitting,",24_25,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"(2 word speech), gross motor delay (sitting, crawling, walking) and social delay (toilet training). This data correlates with our findings of disease management and the early requirement for devices to assist daily living. The commonly reported first symptoms of failure to thrive and gastric reflux in infancy correlates with the reported use of a feeding tube in patients less than 1 year old. As the child's age increases, the need for assisted motor and speech devices correlates with reported data of gross",24_26,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"devices correlates with reported data of gross motor and verbal delays. As our registry grows, we anticipate that that our improved understanding of the ages and order of symptom onset in Leigh syndrome will lead to earlier diagnosis and improved opportunities for clinical management. An earlier consideration of Leigh syndrome as a differential diagnosis in pediatric patients displaying any of the early symptoms shown in Fig. <xref rid=""Fig6"" ref-type=""fig"">6</xref> would be expected to contribute to an",24_27,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"would be expected to contribute to an accelerated diagnosis in Leigh syndrome patients. While effective clinical interventions are not yet available, exciting recent preclinical studies have raised the possibility that treatments may soon be available [<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Any progress in accelerating diagnosis will undoubtedly contribute to improved responses to therapy, as it is anticipated that neurodegenerative changes will be easier",24_28,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"that neurodegenerative changes will be easier to prevent than reverse. Earlier diagnosis may also speed drug development, as sicker patients have a narrower therapeutic window for intervention. Progress toward statistically rigorous natural history of disease in Leigh syndrome will also provide improved control data against which to judge the efficacy of any experimental intervention. Healthcare system utilization is significant but varies widely across the respondents, as measured by number of ER visits,",24_29,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"respondents, as measured by number of ER visits, and days spent in inpatient care. The majority of patients did not visit the ER. However, among those who did, the number of visits ranged from 1 to 45 over the previous twelve months. Among non-zero responders, the mean number of days in the hospital were 12.5 and 26.8 for 3 months and 12 months, respectively. Notably, one respondent indicated 150 days of inpatient care. Overall, the data suggest that for patients whose Leigh syndrome is well managed and",24_30,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"patients whose Leigh syndrome is well managed and stable, healthcare utilization is relatively low. However, when patients do experience symptoms they require significantly more medical care. The Everylife Foundation completed a study of the economic burden of rare diseases in the US in 2019 [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. This study concluded that the total excess direct medical cost associated with the 379 diseases studied is $418 billion, which translates to $26,887 excess direct medical",24_31,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"which translates to $26,887 excess direct medical costs per person with a rare disease. In fact, the costs are even higher for children, averaging $32,037 excess medical costs per child. According to the study, the estimated total indirect and non-medical cost of rare disease is $64 billion for children (age less than 18 years). For many Leigh syndrome families, one of the spouses must give up their employment to take care of the affected child. In addition, the costs of absenteeism for the caregivers",24_32,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"the costs of absenteeism for the caregivers surpass those for people with the rare disease. Leigh syndrome was not represented in the 379 rare diseases surveyed in the Everylife study. It is also difficult to extrapolate these cost estimates to the 25 countries represented in the Leigh syndrome global registry due to differing healthcare systems and medical practice. However, the low median age of patients in the registry suggests that the per person cost of healthcare utilization for Leigh syndrome is",24_33,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"of healthcare utilization for Leigh syndrome is likely to be higher than for diseases in older populations. It is interesting to note that despite reported limitations related to pain and energy, the majority responded that participants rated their own health as good, and the majority never or rarely feel depressed. Although this finding may seem counterintuitive, it is supported by other research. A study of 115 children with severe disabilities and their parents, found that parents describe their",24_34,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"their parents, found that parents describe their children's health related quality of life (HRQoL) significantly higher than physicians do and express more optimism regarding their child’s future compared to physicians [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. One way of bridging the disparity between physician and patient/family is for physicians to go beyond solely having a medical outlook and proactively engage patients in discussions about their QofL. Authors of the article, “Asset-Based Health",24_35,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"QofL. Authors of the article, “Asset-Based Health Care for Children With Severe Neurologic Impairment” explain that parents of children with severe neurological impairments want their clinical team to see their child as they do, including knowing what brings the child and the family joy, hope, and meaning [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. They suggest that clinicians have conversations with the family that go beyond the medical diagnosis and proactively ask about the child’s QofL as well as",24_36,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"proactively ask about the child’s QofL as well as what are the hopes of the parents for their child’s future. As illustrated by the current study, the majority of caregivers feel stressed when it comes to providing care to the person with the illness. A significant percentage (over a third) at least sometimes feel drained by their responsibilities as a caregiver. However, the majority reported never or rarely feeling burdened with the responsibility of caring for the person with the illness. In our",24_37,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"of caring for the person with the illness. In our opinion, this could be explained by the continuum of hope and love parents feel for their children. During the shared journey, parents provide care for their children out of love and do not view them as a burden. A cross-sectional study on 249 caregivers of children with chronic diseases revealed that “those caregivers who were responsible for caregiving for a longer period, experienced lower caregiving burden in isolation and disappointment sub-scales. It",24_38,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"in isolation and disappointment sub-scales. It seems that they have found approaches to coping with their responsibilities and caregiving-induced limitations over time” [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. Although our study showed that caregivers are resilient and those living with Leigh syndrome have a positive attitude, we know that Leigh syndrome is a severe progressive disease, and it is important to have support resources available. It is also possible that those families who are coping",24_39,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"also possible that those families who are coping better have joined our registry, while for those having a harder time, it may have been too difficult or time-consuming, and we didn’t capture their responses. One of the main limitations of this study is that most common genetic mutations of the participants may not accurately represent the prevalence and genetic diversity in the general population overall or by country. One of the reasons for this is that Cure Mito Foundation was formerly named Cure SURF1",24_40,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Mito Foundation was formerly named Cure SURF1 Foundation and therefore has been primarily connected with SURF1 families until recently. This should change over time as Cure Mito continues to expand. Additionally, as the majority of patient recruitment has been done by patient families, countries and mutations represented reflect in a large part more active families or patient communities. Moving forward, the global registry will continue to leverage the dedication of the partner families and also broaden",24_41,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"of the partner families and also broaden recruitment efforts. Support of mitochondrial disease clinicians in sharing the registry with patients would be important in order to increase enrollment and get a more even distribution of mutations. It was observed that certain survey prompts were misinterpreted by participants, given the diversity of countries and cultures. For example, race is not a global concept, and the Cure Mito Foundation has discovered that participants in some countries did not understand",24_42,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"participants in some countries did not understand how to respond. After clarifying, some have updated their responses, but not all did, which likely contributes to a high number of unknown responses for race. Other questions may have also been understood slightly differently due to the variety of languages and countries represented. Translation of surveys into multiple languages should mitigate this concern going forward. Other responses, such as specialists seen and healthcare utilization, are also",24_43,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"seen and healthcare utilization, are also affected by the country where the participant lives and the living standard and healthcare system in that country. As described in the discussion above, some international patients are completely house-bound due to not having any way to travel in a wheelchair. An analysis by country may be important to undertake in the future. Another limitation is that genetic diagnosis was typed in by the participants themselves. Participants had an option to upload their genetic",24_44,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"had an option to upload their genetic reports and many did; however, the reports have not been used to verify each participant’s mutation. Additionally, all data is reported by patients or their caregivers and information entered has not been verified by medical professionals. Cure Mito Foundation plans to continue registry recruitment efforts from around the world, expanding the number of languages available for the survey and further clarifying intent for some culturally sensitive questions. Additional",24_45,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"some culturally sensitive questions. Additional subgroup analysis may be undertaken, such as analysis by age group, country, genetic mutation, or other relevant categories. Publication of additional results and findings, as well as additional subgroup analysis, in various communities is forthcoming. As the registry expands, Cure Mito Foundation plans to continue to keep participants engaged by regularly sharing results through posters, papers, newsletters, webinars, and other methods and through",24_46,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"webinars, and other methods and through collaborations with patients and patient advocacy organizations. Additionally, Cure Mito Foundation empowers patients by encouraging them to ask questions, share feedback and suggestions, and by being available and open for communication. Support of the medical community is also important and would greatly assist in expanding the registry. To continue to build partnerships across the entire ecosystem of rare diseases, Cure Mito Foundation is working with the CoRDS",24_47,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Cure Mito Foundation is working with the CoRDS registry to implement a Global Unique Identifier (GUID), making it possible to identify data for the same individuals and different datasets and combine their data for further research. This is only possible if GUID is defined the same way in multiple databases. CoRDS registry will be creating GUID, using the NIH GUID generator [<xref ref-type=""bibr"" rid=""CR24"">24</xref>, <xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Furthermore, since 2021 Cure Mito Foundation",24_48,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Furthermore, since 2021 Cure Mito Foundation has been partnering with Critical Path Institute (C-path) to significantly promote data sharing and accelerate Leigh syndrome and other rare mitochondrial disease data incorporation into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. RDCA-DAP platform is funded by the Food and Drug Administration (FDA) and provides a centralized and standardized infrastructure to support and",24_49,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"and standardized infrastructure to support and accelerate rare disease characterization targeted to accelerate clinical drug development [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Leigh syndrome patient registry data has already been incorporated into RDCA-DAP and Cure Mito Foundation and C-path continue to collaborate to bring other mitochondrial disease stakeholders into the collaboration [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. Cure Mito Foundation is also collaborating with Sumptuous Data",24_50,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"is also collaborating with Sumptuous Data Sciences, LLC on converting patient registry data into Clinical Data Interchange Standards Consortium (CDISC) standard, which is a regulatory standard required by the FDA and PMDA [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. This will make the data useful in order to interact with regulatory agencies and possibly support a regulatory submission. To our knowledge, this is the first patient registry in mitochondrial disease to undergo CDISC conversion. Cure Mito",24_51,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"disease to undergo CDISC conversion. Cure Mito Foundation continues to be committed to collaboration, partnerships, and making sure the data is as accessible and available as possible. Those researchers and industry partners who would like to collaborate, receive data, share research or clinical trial opportunities with the patient community are strongly encouraged to reach out to the Cure Mito Foundation. This study describes the first publication on a global Leigh syndrome patient registry with a variety",24_52,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Leigh syndrome patient registry with a variety of outcomes collected from participants that can serve as a basis for future natural history studies on Leigh syndrome. Results describe a high burden of the disease, as evidenced by the number of specialists seen, disease management interventions, and healthcare utilization. Time to diagnosis is relatively short compared to prior research on mitochondrial disease overall and underscores the importance of differentiating between mitochondrial disease overall",24_53,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"between mitochondrial disease overall and individual mitochondrial disorders. Despite being overall resilient, caregivers report significant amounts of stress, and finding ways to support caregivers is important. Participants in general are described as having a good quality of life, despite the limitations that they are facing. Future efforts with the registry will include continued collaboration with researchers and industry, continued publication of the results, possible subgroup data analysis, learning",24_54,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"possible subgroup data analysis, learning new insights that will come out through integration of the data into the RDCA-DAP platform by C-PATH, and leveraging CDISC conversion of the data in order to advance use of the data with the regulatory agencies. Increased efforts will be made to recruit more participants into the registry. This will be done through continued efforts by the Cure Mito Foundation and international patient families, as well as raising awareness of the registry with the mitochondrial",24_55,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"awareness of the registry with the mitochondrial disease clinicians worldwide. Our belief and hope is that through all these efforts, our patient registry will play a vital role in making treatments for Leigh syndrome approved and available to patients.",24_56,Leigh syndrome global patient registry: uniting patients and researchers worldwide,4 9 2023,,Leigh_Syndrome
"Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome Leigh syndrome (LS) is a mitochondrial disease characterized by subacute necrotizing encephalomyelopathy with an estimated incidence of 1 : 40,000 births [<xref rid=""B1"" ref-type=""bibr"">1</xref>]. Clinically, LS is characterized by psychomotor delay or regression, more or less muscular hypotonia, and brainstem signs [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. Almost all cases of LS develop in infancy or early childhood and die within several",25_0,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"infancy or early childhood and die within several years due to rapidly progressive muscle weakness and respiratory failure [<xref rid=""B1"" ref-type=""bibr"">1</xref>]. The comorbidity of psychotic symptoms noted in mitochondrial and psychiatric diseases has spurred interest in the effects of DNA mutations and psychiatric disorders. There is growing evidence that mitochondrial dysfunction is linked to the pathophysiology of psychiatric disorders such as schizophrenia [<xref rid=""B3"" ref-type=""bibr"">3</xref>].",25_1,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"[<xref rid=""B3"" ref-type=""bibr"">3</xref>]. In our study, we report a rare case with LS. The patient has survived to adolescence and presents schizophrenia-like symptoms, such as persecutory delusions and auditory hallucinations. In Tunisia, only one study on this subject has been published by Mnif et al. [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. Computer-assisted searches on psychotic symptoms associated with LS yielded eight cases. Our work is particularly interesting in view of the limited number of",25_2,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"interesting in view of the limited number of publications and the promising results of our study based on genetic analysis. We report the case of patient who was born for a Tunisian family with a maternally inherited Leigh syndrome (MILS) harboring the mitochondrial T8993G mutation in the ATPase 6 gene. It was the first and the only case in Tunisia that benefited of a genetic research and that was already published [<xref rid=""B4"" ref-type=""bibr"">4</xref>]. Actually, The Tunisian family reported here",25_3,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"Actually, The Tunisian family reported here exemplifies a MILS. Three patients in this family and five of their relatives were diagnosed with LS (<xref rid=""fig1"" ref-type=""fig"">Figure 1</xref>). After getting informed consent from all the participating family members, total DNA was extracted from peripheral blood using a phenol chloroform protocol. The mitochondrial genes were amplified using a thermal cycler. Quantification of the mutant mtDNA with the mitochondrial T8993G mutation was performed with",25_4,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"mitochondrial T8993G mutation was performed with polymerase chain reaction–restriction fragment length polymorphism analysis [<xref rid=""B4"" ref-type=""bibr"">4</xref>]. Our patient is a 28-year-old male (V.1, <xref rid=""fig1"" ref-type=""fig"">Figure 1</xref>) who was born at term to healthy parents after an uneventful pregnancy. He was first admitted at the first month of life for axial and peripheral hypotonia and repetitive seizures. Laboratory investigations revealed raised lactate levels in blood",25_5,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"revealed raised lactate levels in blood (3.89–8.23 mmol/L; normal, <2 mmol/L) and in CSF (5.7–6.3 mmol/L, normal, <2 mmol/L) with increased blood lactate to pyruvate ratios (36.9–79.9; normal, <25). The EEG and fundus examinations were unremarkable, but EMG revealed myopathic findings. The boy also exhibited psychomotor retardation. At the age of 9 months, he was hospitalized for acute and repeated bronchiolitis, accompanied by seizures. To date, at the age of 22 months, no ataxia or retinitis pigmentosa",25_6,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"of 22 months, no ataxia or retinitis pigmentosa had been detected. He was treated with antiepileptic drugs for 5 years (sodium valproate: 1,000 mg/day split into two doses). His history revealed that 6 months ago, gradual onset, the patient developed aggressiveness toward his parents, persecution, mysticism, and difficulty sleeping. Physical examination revealed a patient in a wheelchair. Consciousness was clear, with no confusion. Psychiatric examination revealed low-quality contact with the doctor, with",25_7,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"low-quality contact with the doctor, with a very anxious and distrustful young man. He presented himself in the exmen room, covering his eyes and ears with a sheet to avoid the sounds he heard. His speech is poor in content, barely comprehensible due to anxiety and auditory hallluciantioins. He reports a vague, unsystematized delusion: he is convinced he is being followed, and “they'll be there to kill him if he doesn't do what they ask for.” He is persecuted by strangers who are collaborating with his",25_8,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"by strangers who are collaborating with his parents to kill him. He was overwhelmed by auditory hallucinations and tried constantly throughout the interview to cover his ears. He was anxious and repeated: “they're going to hurt me… they're here… I can hear them screaming my name…” he rubbed his hands and kept moving his legs, telling his mother: “You're their partner in crime, you want to cheat on me … I know all about you.” The prognosis of psychotic symptoms is not specific to Leigh's disease. it",25_9,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"symptoms is not specific to Leigh's disease. it encompasses pathological self-defense reactions. These defensive reactions consist of avoidance or evasive behavior, and sometimes even aggression against the supposed persecutors. In this case, the violent acts are intended to control or eliminate the source of the persecution experienced. They can lead to homicide inside and/or outside the family [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. The specialized neurological examination showed no clinical",25_10,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"neurological examination showed no clinical worsening. Physical examination was normal. Investigations included routine emergency blood tests (complete blood count, blood sedimentation reaction, liver and kidney function tests, serum electrolytes, and electroencephalogram), which were normal. Cranial magnetic resonance imaging (MRI) (<xref rid=""fig2"" ref-type=""fig"">Figure 2</xref>) showed bilateral and symmetrical hyperintense lesions of the mesencephalon and lenticular and caudate nucleus compatible with",25_11,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"lenticular and caudate nucleus compatible with LS, in line with the normal progression of his disease. Cerebrospinal fluid (CSF) and blood lactate levels were normal. According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the diagnosis of schizophreniform disorder was adopted. Initially, the patient was under vitamin supplements only (vitamin B1 combined with vitamin E), since no other drugs were available in Tunisia. We prescribed",25_12,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"drugs were available in Tunisia. We prescribed respiridone in small doses (1 mg/day) at first, with follow-up appointments every 2 weeks, combined with a corrector of extrapyramidal effects (biperiden hydrochloride) at a dose of 4 mg/day. Partial remission was observed under these doses, so we opted for increasing the doses in addition 1 mg every 2 weeks until significant remission was observed at risperidone 3 mg. For an objective assessment of improvement in our case, we used the Psychotic Symptom Rating",25_13,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"in our case, we used the Psychotic Symptom Rating Scales (PSYRATS): their usefulness and properties in first episode psychosis [<xref rid=""B5"" ref-type=""bibr"">5</xref>]. The PSYRATS consists of 17 items focusing on hallucinations and delusions. Each item is rated from 0 (absent) to 4 (severe). Initially, our patient's score was 42, with good outcome on treatment: at 2 weeks: 39, at 4 weeks: 35, at 6 weeks: 26 and at 8 weeks: 11 (and the patient began to criticize his delusions and behavioral disorders).",25_14,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"his delusions and behavioral disorders). The present study showed phenotypic and genotypic variability. The mutated mtDNA was detected with variable heteroplasmic loads in the blood of all the tested members of this family [<xref rid=""B6"" ref-type=""bibr"">6</xref>]. Previous case reports have described memory loss, disturbance of consciousness, and visual hallucinations in a few adult patients with LS [<xref rid=""B7"" ref-type=""bibr"">7</xref>]. Psychotic manifestations of LS are not well documented and",25_15,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"manifestations of LS are not well documented and highly diverse. This clinical presentation has been described by some authors as a persecutory delusion with auditory and visual hallucinations [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. Moreover, the types of LS include [<xref rid=""B8"" ref-type=""bibr"">8</xref>]:<list list-type=""roman-lower""><list-item><p>Early-onset (infantile): The most common form of LS appears before age 2. Providers also call it classical LS or infantile necrotizing encephalopathy. The",25_16,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"LS or infantile necrotizing encephalopathy. The condition affects boys and girls equally.</p></list-item><list-item><p>Late-onset (adult-onset): Symptoms appear after age 2 and may not occur until adolescence or early adulthood. Adult-onset LS is rare. The condition affects more males than females. The disease progresses slower than the infantile type.</p></list-item><list-item><p>Leigh-like syndrome: A person has some symptoms of LS, but imaging scans do not detect signs of the",25_17,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"LS, but imaging scans do not detect signs of the disease.</p></list-item></list> According to our literature review, no subtype is more vulnerable to the development of psychotic symptoms. The normality of explorations in our case raised the issue of the relationship between the two diseases: can psychiatric disorders be simple comorbidity or are they secondary to Leigh's syndrome? Regenold et al. [<xref rid=""B9"" ref-type=""bibr"">9</xref>] have reported that patients diagnosed with mitochondrial disease",25_18,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"patients diagnosed with mitochondrial disease have high incidences of psychiatric disorders or symptoms such as depression, hallucinations, bipolar disorder, or anxiety. They hypothesized that some psychiatric disorders could be linked to glucose-processing problems involving mitochondria. They studied levels of lactate, a product of extra-mitochondrial glucose metabolism, in two groups of 15 patients, each with schizophrenia or bipolar disorder, as well as in healthy controls. Significantly higher",25_19,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"well as in healthy controls. Significantly higher concentrations were observed in the bipolar and schizophrenia patient groups compared with healthy controls. Moreover, studies have come to the conclusion that mitochondrial dysfunction maybe the primary origin of psychotic disorders [<xref rid=""B10"" ref-type=""bibr"">10</xref>]. Kung and Roberts [<xref rid=""B11"" ref-type=""bibr"">11</xref>] studied the pH and lactate levels in the postmortem brains of schizophrenics. They suggest that lactate increases are",25_20,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"They suggest that lactate increases are possibly related to antipsychotic treatment rather than to a primary metabolic abnormality. A marked decrease in the number and density of mitochondria in the prefrontal cortex and caudate nucleus of postmortem brains of patients with schizophrenia was observed compared with control subjects [<xref rid=""B12"" ref-type=""bibr"">12</xref>]. Lower numbers of mitochondria were found in patients not taking antipsychotic medication compared with those taking antipsychotic or",25_21,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"compared with those taking antipsychotic or control medication, suggesting that drug treatment normalizes mitochondrial numbers [<xref rid=""B13"" ref-type=""bibr"">13</xref>]. In fact, neuroleptics are thought to have suppressive effects on mitochondrial function [<xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>]. The fact that atypical antipsychotics, including quetiapine, have insignificant inhibitory effects on mitochondrial oxidative phosphorylation offers a potential",25_22,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"oxidative phosphorylation offers a potential advantage over typical antipsychotics in terms of mitochondrial function. The cost of this drug was very high for the patient's family, and it was available in Tunisian public Hospital. Evidence for the involvement of mitochondria in the pathophysiology of psychiatric disorders such as schizophrenia is increasing [<xref rid=""B16"" ref-type=""bibr"">16</xref>]. In fact, the treatment of psychosis in patients with mitochondrial disorders does not differ mainly from",25_23,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"disorders does not differ mainly from the treatment of psychosis in nonmitochondrial patients. There is no consensus on the therapy of psychosis in patients with mitochondrial disorders, even though these are resistant forms of schizophrenia [<xref rid=""B17"" ref-type=""bibr"">17</xref>]. The objective of this work is to study the relations between mitochondrial dysfunction and psychiatric disorders. This case illustrates the presentation of psychotic symptoms characterized by the acute onset of delusional",25_24,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
"characterized by the acute onset of delusional and hallucinatory syndrome associated with LS, which suggests a better collaboration between neurologists and psychiatrists for the management of these patients. The future study of mitochondrial dysfunction in psychiatric disorders should bring clarification as to how nonspecific mitochondrial dysfunction can cause specific symptoms of psychiatric disorders. Further study of mitochondrial dysfunction in psychiatric disorders is expected to be useful for the",25_25,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
disorders is expected to be useful for the development of cellular disease markers and new psychotropics.,25_26,Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome,2023,,Leigh_Syndrome
Expert panel curation of 113 primary mitochondrial disease genes for the Leigh syndrome spectrum Full text not available in PMC,26_0,Expert panel curation of 113 primary mitochondrial disease genes for the Leigh syndrome spectrum,17 6 2023,,Leigh_Syndrome
"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome Subacute necrotizing encephalopathy, or Leigh syndrome (LS), is the most common pediatric presentation of genetic mitochondrial disease. LS is a multi‐system disorder with severe neurologic, metabolic, and musculoskeletal symptoms. The presence of progressive, symmetric, and necrotizing lesions in the brainstem are a defining feature",27_0,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"lesions in the brainstem are a defining feature of the disease, and the major cause of morbidity and mortality, but the mechanisms underlying their pathogenesis have been elusive. Recently, we demonstrated that high‐dose pexidartinib, a CSF1R inhibitor, prevents LS CNS lesions and systemic disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) mouse model of LS. While the dose–response in this study implicated peripheral immune cells, the immune populations involved have not yet been elucidated. Here, we",27_1,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"involved have not yet been elucidated. Here, we used a targeted genetic tool, deletion of the colony‐stimulating Factor 1 receptor (CSF1R) macrophage super‐enhancer FIRE (<italic toggle=""no"">Csf1r</italic>ΔFIRE), to specifically deplete microglia and define the role of microglia in the pathogenesis of LS. Homozygosity for the <italic toggle=""no"">Csf1r</italic>ΔFIRE allele ablates microglia in both control and <italic toggle=""no"">Ndufs4</italic>(−/−) animals, but onset of CNS lesions and sequalae in the",27_2,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"but onset of CNS lesions and sequalae in the <italic toggle=""no"">Ndufs4</italic>(−/−), including mortality, are only marginally impacted by microglia depletion. The overall development of necrotizing CNS lesions is not altered, though microglia remain absent. Finally, histologic analysis of brainstem lesions provides direct evidence of a causal role for peripheral macrophages in the characteristic CNS lesions. These data demonstrate that peripheral macrophages play a key role in the pathogenesis of disease",27_3,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"play a key role in the pathogenesis of disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model. Microglia and peripheral macrophages contribute to CNS pathology in the <italic toggle=""no"">Ndufs4</italic>(−/−) mouse model of Leigh syndrome, while peripheral macrophages alone are sufficient to drive disease in microglia−deficient <italic toggle=""no"">Ndufs4</italic>(−/−) animals. (A−B) Cortex of Ndufs4(−/−)/Csf1r (wt/wt) (A) and Ndufs4(−/−)/Csf1r (fr/fr) (B) mice stained for the pan−macrophage marker",27_4,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"(B) mice stained for the pan−macrophage marker IBA1 (red) and the microglia−specific marker P2YR12 (green); DNA is co−stained with DAPI (blue). Microglia are absent by both IBA1 and P2YR12 staining in the Ndufs4(−/−)/Csf1r (fr/fr) cortex. (C−D) Brainstem lesions from Ndufs4(−/−)/Csf1r (wt/wt) (C) and Ndufs4(−/−)/Csf1r (fr/fr) (D) mice stained for the pan−macrophage marker IBA1 and the microglia−specific marker P2YR12. Cells positive for IBA1, the pan−macrophage marker, are present in both genotypes, while",27_5,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"marker, are present in both genotypes, while P2YR12 staining is absent in cells in the brainstem lesions of Ndufs4(−/−)/Csf1r (fr/fr) animals. Note: the P2YR12 staining surrounding the lesion site does not appear to be cellular in origin, and is thought to reflect the presence of aggregated platelets, which are P2YR12 positive. (E−F) Cortex of Ndufs4(−/−)/Csf1r (wt/wt) (E) and Ndufs4(−/−)/Csf1r (fr/fr) (F) mice stained for the pan−macrophage marker IBA1 (red) and the peripheral leukocyte marker CD45",27_6,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"(red) and the peripheral leukocyte marker CD45 (green); DNA is co−stained with DAPI (blue). Microglia are absent in the Ndufs4(−/−)/Csf1r (fr/fr) cortex, and microglia (by IBA1 posivitivy and morphology) do not express CD45 (E). A few compact cells with CD45 positivity are present in both genotypes, presumed to be circulating leukocytes. (G−H) Brainstem lesions in Ndufs4(−/−)/Csf1r (wt/wt) (G) and Ndufs4(−/−)/Csf1r (fr/fr) (H) mice stained for the pan−macrophage marker IBA1 and the peripheral leukocyte",27_7,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"marker IBA1 and the peripheral leukocyte marker CD45. CD45 positive cells are present in both in the Ndufs4(−/−)/Csf1r (fr/fr) and Ndufs4(−/−)/Csf1r (wt/wt) lesions, while most or all IBA1 positive cells in the Ndufs4(−/−)/Csf1r (fr/fr) lesion appear to be positive for the peripheral leukocyte marker CD45. Co−staining of CD45 and IBA1 is indicative of peripheral macrophages.<boxed-text position=""anchor"" content-type=""graphic"" id=""bpa13192-blkfxd-0001""><graphic http://www.w3.org/1999/xlink",27_8,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"http://www.w3.org/1999/xlink href=""BPA-33-e13192-g006.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",27_9,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"Subacute necrotizing encephalomyelopathy, Leigh syndrome (LS), is the most common pediatric presentation of genetic mitochondrial disease [<xref rid=""bpa13192-bib-0001"" ref-type=""bibr"">1</xref>, <xref rid=""bpa13192-bib-0002"" ref-type=""bibr"">2</xref>]. LS neuropathology is characterized by symmetric, bilateral, neurodegenerative lesions, which can appear in the basal ganglia, brainstem, and cerebellum [<xref rid=""bpa13192-bib-0001"" ref-type=""bibr"">1</xref>, <xref rid=""bpa13192-bib-0003""",27_10,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"<xref rid=""bpa13192-bib-0003"" ref-type=""bibr"">3</xref>]. Patients are often born without evidence of disease, and symptoms typically first present in early childhood with progressive psychomotor regression and symptoms related to brainstem pathology (e.g., respiratory issues, dysphagia) [<xref rid=""bpa13192-bib-0001"" ref-type=""bibr"">1</xref>]. LS is clinically defined and genetically heterogeneous disease, complicating diagnosis and study. To date, LS has been causally linked to more than 75 distinct genes",27_11,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"causally linked to more than 75 distinct genes [<xref rid=""bpa13192-bib-0002"" ref-type=""bibr"">2</xref>]. These include genes encoded by both nuclear and mitochondrial genomes, coding for proteins involved in electron transport chain (ETC) or ETC complex assembly factors, mitochondrial transcription/translation factors, and enzymes involved in thiamine metabolism [<xref rid=""bpa13192-bib-0002"" ref-type=""bibr"">2</xref>]. One causal gene for LS in humans is <italic toggle=""yes"">NDUFS4</italic>, coding for a",27_12,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"toggle=""yes"">NDUFS4</italic>, coding for a structural/assembly component of ETC complex I. Homozygous deletion of murine <italic toggle=""yes"">Ndufs4</italic> results in a LS phenotype in mice, and the <italic toggle=""yes"">Ndufs4</italic>(−/−) mouse is considered the premier animal model of mitochondrial disease. <italic toggle=""yes"">Ndufs4</italic>(−/−) mice present with a multi‐system disorder similar to human patients, which includes necrotic lesions in the brainstem, neurological and metabolic",27_13,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"in the brainstem, neurological and metabolic dysfunction, and early mortality [<xref rid=""bpa13192-bib-0004"" ref-type=""bibr"">4</xref>, <xref rid=""bpa13192-bib-0005"" ref-type=""bibr"">5</xref>]. Neuroinflammation and lesions also develop in cerebellum. CNS lesions in the brainstem, olfactory bulb, and cerebellum of <italic toggle=""yes"">Ndufs4</italic>(−/−) mice are characterized by astrocytosis and microgliosis. Advanced brainstem lesions are well demarcated, developing into densely packed IBA1(+) phagocytic",27_14,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"developing into densely packed IBA1(+) phagocytic cells with astrocyte accumulation (typically observed via staining with GFAP) surrounding the central lesion. The olfactory bulb and cerebellar neuroinflammation also display increased IBA1(+) cell and astrocytosis. We have recently demonstrated that disease in the <italic toggle=""yes"">Ndufs4</italic>(−/−) is causally mediated by immune cells, and that treatment with the Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor pexidartinib/PLX3397 can provide",27_15,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"inhibitor pexidartinib/PLX3397 can provide potent therapeutic benefits [<xref rid=""bpa13192-bib-0006"" ref-type=""bibr"">6</xref>]. CSF1R regulates the differentiation, function, and survival of macrophages, including microglia [<xref rid=""bpa13192-bib-0007"" ref-type=""bibr"">7</xref>]. High‐dose pexidartinib depletes both CNS and peripheral macrophages, but the effect is relatively microglia‐specific when administered at low dose, and low‐dose pexidartinib has been reproducibly used as an experimental tool for",27_16,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"reproducibly used as an experimental tool for microglia depletion [<xref rid=""bpa13192-bib-0008"" ref-type=""bibr"">8</xref>, <xref rid=""bpa13192-bib-0009"" ref-type=""bibr"">9</xref>]. Phagocytic cell accumulation in LS lesions has been interpreted as microgliosis, with no consideration of a role for peripheral cells [<xref rid=""bpa13192-bib-0010"" ref-type=""bibr"">10</xref>, <xref rid=""bpa13192-bib-0011"" ref-type=""bibr"">11</xref>]. However, histologic methods and markers used in prior studies have been",27_17,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"and markers used in prior studies have been non‐specific, including the pan‐macrophage marker IBA1 and morphologic analysis [<xref rid=""bpa13192-bib-0011"" ref-type=""bibr"">11</xref>, <xref rid=""bpa13192-bib-0012"" ref-type=""bibr"">12</xref>]. In our recent work, we found that low doses of pexidartinib (sufficient to deplete microglia but not peripheral macrophages) fail to substantially alter disease course, while high doses prevent disease. Moreover, staining of lesions using a TMEM119‐GFP reporter revealed",27_18,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"of lesions using a TMEM119‐GFP reporter revealed that a substantial fraction of IBA1(+) cells in CNS lesions do not express this microglia‐specific marker [<xref rid=""bpa13192-bib-0006"" ref-type=""bibr"">6</xref>, <xref rid=""bpa13192-bib-0013"" ref-type=""bibr"">13</xref>]. Defining the roles of individual phagocytic cell populations is important for developing immune‐targeting strategies into therapies, as CNS microglia and peripheral macrophages have distinct pharmacological properties and targets. In",27_19,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"pharmacological properties and targets. In addition, defining the relative roles of peripheral and central macrophages will have significant impact on our basic understanding of the pathogenesis of this mitochondrial disease. To determine the role of microglia in the pathobiology of LS, here we utilize a genetic model for microglia depletion, the <italic toggle=""yes"">Csf1r</italic>ΔFIRE mouse [<xref rid=""bpa13192-bib-0014"" ref-type=""bibr"">14</xref>]. These animals carry deletion of an <italic",27_20,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"These animals carry deletion of an <italic toggle=""yes"">fms‐</italic>intronic regulator element (FIRE) in the <italic toggle=""yes"">Csf1r</italic> gene, an element which regulates expression of <italic toggle=""yes"">Csf1r</italic> in microglia [<xref rid=""bpa13192-bib-0014"" ref-type=""bibr"">14</xref>, <xref rid=""bpa13192-bib-0015"" ref-type=""bibr"">15</xref>]. Mice homozygous for the <italic toggle=""yes"">Csf1r</italic>ΔFIRE allele (here abbreviated <italic toggle=""yes"">Csf1r</italic>[fr/fr] with <italic",27_21,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"toggle=""yes"">Csf1r</italic>[fr/fr] with <italic toggle=""yes"">Csf1r</italic>[wt/fr] and <italic toggle=""yes"">Csf1r</italic>[wt/wt] denoting heterozygous and wild‐type for this allele, respectively) lack microglia and some tissue macrophage populations, but have intact circulating macrophages [<xref rid=""bpa13192-bib-0014"" ref-type=""bibr"">14</xref>]. Here, we report the impact of genetic depletion of microglia on disease and survival in the <italic toggle=""yes"">Ndufs4</italic>(−/−) model. In addition, we",27_22,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"model. In addition, we directly assess the presence of microglia and peripheral macrophages in LS CNS lesions. Our findings support a model whereby peripheral macrophages are a primary causal cell type in the pathogenesis of LS CNS lesions.  Here, we report that genetic depletion of microglia only modestly delays disease onset and progression in the <italic toggle=""yes"">Ndufs4</italic>(−/−) model of LS, contrasting with the previously reported rescue of disease resulting from high‐dose pexidartinib",27_23,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"of disease resulting from high‐dose pexidartinib treatment. Genetic depletion of microglia fails to prevent neuroinflammatory CNS lesion formation, the hallmark feature of LS, and associated sequelae of disease. Furthermore, CNS lesions in both <italic toggle=""yes"">Ndufs4</italic>(−/−)/<italic toggle=""yes"">Csf1r</italic>(fr/fr) animals include IBA(+)/CD45(+) cells, consistent with our prior findings that CNS lesions contain TMEM119(−)/IBA1(+) cells. Finally, while microglia appear to account for the",27_24,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"while microglia appear to account for the majority of lesion cellularity in <italic toggle=""yes"">Ndufs4</italic>(−/−)/<italic toggle=""yes"">Csf1r</italic>(wt/wt) animals, lesion formation is not prevented in the absence of microglia and <italic toggle=""yes"">Ndufs4</italic>(−/−)/<italic toggle=""yes"">Csf1r</italic>(fr/fr) lesions are characterized by IBA(+)/P2YR12(−) peripheral macrophages. Together, these data demonstrate that peripheral macrophages play a prominent role in the pathogenesis of LS, including",27_25,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"role in the pathogenesis of LS, including in CNS disease, and that the absence of microglia does not substantially alter disease course when circulating macrophages are intact. The findings in this study are consistent with recent work by the Hidalgo laboratory, and our own prior work, demonstrating that low dose pexidartinib, used to eliminate microglia while sparing peripheral macrophages, only modestly alters disease course in the <italic toggle=""yes"">Ndufs4</italic>(−/−) [<xref rid=""bpa13192-bib-0006""",27_26,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"[<xref rid=""bpa13192-bib-0006"" ref-type=""bibr"">6</xref>, <xref rid=""bpa13192-bib-0018"" ref-type=""bibr"">18</xref>]. These data indicate that microglia contribute only partially to the pathogenesis of LS and that targeting microglia alone is insufficient to disrupt disease. While depletion of microglia is not <italic toggle=""yes"">sufficient</italic> to prevent disease in the LS model, it remains to be determined whether microglia targeting is <italic toggle=""yes"">necessary</italic> to disrupt disease",27_27,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"to disrupt disease progression in the context of pharmacologic targeting of the immune system. In our histologic analysis of <italic toggle=""yes"">Ndufs4</italic>(−/−) mice with intact microglia, we see evidence for both microglia and peripheral macrophages in overt lesions. It seems likely that both microglia and macrophages causally contribute. The necessity and sufficiency of targeting peripheral macrophages must be assessed in future studies, perhaps through antibody‐mediated depletion of circulating",27_28,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"antibody‐mediated depletion of circulating macrophages. It is possible that some other pexidartinib responsive cell population mediates the benefits of that compound. Positive identification of the key causal cell types will require significant future work. It is notable that the <italic toggle=""yes"">Csf1r</italic>ΔFIRE allele, even in the heterozygous state, provided a modest benefit to disease given that the number of microglia is not measurably reduced in these animals (Figure <xref",27_29,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"measurably reduced in these animals (Figure <xref rid=""bpa13192-fig-0001"" ref-type=""fig"">1</xref>). This finding is consistent with the modest benefits of low dose pexidartinib treatment. While we find that low‐dose pexidartinib is not effective in robustly altering disease course in the <italic toggle=""yes"">Ndufs4</italic>(−/−), these observations suggest that low‐dose CSF1R inhibitors may provide benefits in forms of mitochondrial disease, which involve CSF1R‐dependent cells but are less severe, or",27_30,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"CSF1R‐dependent cells but are less severe, or progress less rapidly. For example, low‐dose pexidartinib may attenuate disease in mitochondrial cerebellar ataxia caused by <italic toggle=""yes"">Aifm1</italic> deficiency, where microglial activation occurs in the absence of overt CNS lesions [<xref rid=""bpa13192-bib-0019"" ref-type=""bibr"">19</xref>, <xref rid=""bpa13192-bib-0020"" ref-type=""bibr"">20</xref>]. It may be that differential activation of peripheral versus CNS immunity contributes to the distinct",27_31,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"versus CNS immunity contributes to the distinct clinical presentations of unique forms of genetic mitochondrial disease, the mechanistic underpinnings of which have so far been elusive. Given that there was no visible difference in the presentation of neurologic symptoms in the <italic toggle=""yes"">Ndufs4</italic>(−/−)/<italic toggle=""yes"">Csf1r</italic>(fr/fr) animals compared to <italic toggle=""yes"">Ndufs4</italic>(−/−) mice with intact microglia, we were surprised to find a general lack of IBA1(+) cells",27_32,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"surprised to find a general lack of IBA1(+) cells or signs of lesions in the cerebellum of <italic toggle=""yes"">Ndufs4</italic>(−/−)/<italic toggle=""yes"">Csf1r</italic>(fr/fr) mice. This finding suggests microglia are the dominant macrophage population driving cerebellar involvement, but that cerebellar involvement is not a major contributor to the overall <italic toggle=""yes"">Ndufs4</italic>(−/−) phenotype. It may be that microglia depletion would provide a significant benefit in forms of mitochondrial",27_33,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"a significant benefit in forms of mitochondrial disease where cerebellar involvement is a prominent feature and survival is not limited by brainstem lesions, such as <italic toggle=""yes"">Aifm1</italic> related mitochondrial cerebellar ataxia. It is also possible that our findings may be relevant to other human diseases which phenotypically mimic the symmetric neuroinflammatory CNS lesions seen in LS. These include progressive supranuclear palsy (PSP) and Wernicke's encephalopathy, diseases associated with",27_34,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"encephalopathy, diseases associated with exposure to environmental toxins that inhibit the mitochondrial ETC and thiamine deficiency, respectively; microglia activation appears to be a prominent factor in both cases [<xref rid=""bpa13192-bib-0008"" ref-type=""bibr"">8</xref>, <xref rid=""bpa13192-bib-0021"" ref-type=""bibr"">21</xref>]. CSF1R targeting has recently been shown to benefit multiple complex neurodegenerative disease models including Parkinson's, multiple sclerosis, and Alzheimer's [<xref",27_35,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"multiple sclerosis, and Alzheimer's [<xref rid=""bpa13192-bib-0022"" ref-type=""bibr"">22</xref>, <xref rid=""bpa13192-bib-0023"" ref-type=""bibr"">23</xref>, <xref rid=""bpa13192-bib-0024"" ref-type=""bibr"">24</xref>, <xref rid=""bpa13192-bib-0025"" ref-type=""bibr"">25</xref>]. These findings suggest that the pathways we are probing here may be common to a range of diseases where evidence suggests causal roles for both immune activity and mitochondrial dysfunction. Future studies will be required to probe links to our",27_36,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"studies will be required to probe links to our findings in the setting of genetic mitochondrial dysfunction and other forms of neurodegeneration, including age‐related neurodegenerative diseases. The relative failure of selective genetic or pharmacologic depletion of microglia to prevent disease, compared to pan‐macrophage depletion with high‐dose pexidartinib (see [<xref rid=""bpa13192-bib-0006"" ref-type=""bibr"">6</xref>]), demonstrates a causal role for peripheral macrophages in the pathogenesis of Leigh",27_37,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"macrophages in the pathogenesis of Leigh syndrome. This is further supported by our findings that peripheral macrophages are present in the lesions of <italic toggle=""yes"">Ndufs4</italic>(−/−) animals whether microglia are present or not. While these data reveal a causal role for peripheral macrophages in the pathogenesis of Leigh syndrome, further studies will be needed to define early events in CNS neuroinflammation. We find that early post‐disease onset brains show an enrichment of peripheral",27_38,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"onset brains show an enrichment of peripheral macrophages in at least one impacted brain region, the olfactory bulb (Figure <xref rid=""bpa13192-supitem-0031"" ref-type=""supplementary-material"">S31</xref>), but have not found evidence for peripheral macrophages in brainstem in the absence of overt brainstem lesions. While genetic and pharmacologic depletion have established their causal role, future studies using macrophage targeted GFP and light‐sheet or two‐photon microscopy may allow for higher resolution",27_39,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"microscopy may allow for higher resolution description of the involvement of peripheral macrophages and microglia early in disease. Many questions remain to be answered. For example, the nature of the inciting immune activating signal remains unknown. Nevertheless, we believe that there is a high potential for clinical translatability of recent work in this field. Supporting this notion, various case reports have indicated that immune modulatory therapies have altered disease course in LS and other genetic",27_40,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"altered disease course in LS and other genetic mitochondrial diseases [<xref rid=""bpa13192-bib-0026"" ref-type=""bibr"">26</xref>, <xref rid=""bpa13192-bib-0027"" ref-type=""bibr"">27</xref>, <xref rid=""bpa13192-bib-0028"" ref-type=""bibr"">28</xref>, <xref rid=""bpa13192-bib-0029"" ref-type=""bibr"">29</xref>] (evidence linking immune function to the pathogenesis of mitochondrial disease is summarized here [<xref rid=""bpa13192-bib-0027"" ref-type=""bibr"">27</xref>]). The data presented here have important implications",27_41,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
data presented here have important implications for any future efforts to translate immune‐targeting strategies into treatments for genetic mitochondrial disease.,27_42,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"<bold>Allison R. Hanaford</bold>, <bold>Nathan Andrew Baertsch</bold>, <bold>Vandana Kalia</bold>, and <bold>Surojit Sarkar</bold>: conception of work; design of work, acquisition and analysis of data; interpretation of data; and manuscript drafting and revision. <bold>Katerina James</bold>, <bold>Yihan Chen</bold>, <bold>Michael Mulholland</bold>, <bold>Vivian Truong</bold>, and <bold>Ryan W. Liao</bold>: acquisition and analysis of data. <bold>Bernhard Kayser</bold> and <bold>Asheema Khanna</bold>:",27_43,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
Kayser</bold> and <bold>Asheema Khanna</bold>: acquisition and analysis of data; interpretation of data. <bold>Phil Morgan</bold> and <bold>Margaret Sedensky</bold>: interpretation of data; and manuscript drafting and revision. <bold>Simon C. Johnson</bold>: conception of work; design of work; acquisition and analysis of data; interpretation of data; and manuscript drafting and revision. National Institutes of Health grant NIH/NINDS R01NS119426 (Simon C. Johnson). National Institutes of Health grant NIH/GM,27_44,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"National Institutes of Health grant NIH/GM R01‐133865 (Margaret Sedensky and Simon C. Johnson). Northwest Mitochondrial Research Guild (Simon C. Johnson, Allison R. Hanaford, Bernhard Kayser). No funder had any direct role in design of the study, collection, analysis, and interpretation of data, or writing of the manuscript. The authors declare no conflicts of interest. All animal experiments were performed at Seattle Children's Research Institute (SCRI), followed SCRI guidelines, and were approved by the",27_45,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"SCRI guidelines, and were approved by the SCRI institutional animal care and use committee (IACUC).",27_46,"Peripheral macrophages drive <styled-content style=""fixed-case"" toggle=""no"">CNS</styled-content> disease in the <italic toggle=""no"">Ndufs4</italic>(−/−) model of Leigh syndrome",08 8 2023,,Leigh_Syndrome
"Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era Mitochondrial diseases are the most common inherited inborn error of metabolism resulting in deficient ATP generation, due to failure in homeostasis and proper bioenergetics. The most frequent mitochondrial disease manifestation in children is Leigh syndrome (LS), encompassing clinical, neuroradiological, biochemical, and molecular features. It typically affects infants but occurs anytime in life. Considering recent",28_0,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"but occurs anytime in life. Considering recent updates, LS clinical presentation has been stretched, and is now named LS spectrum (LSS), including classical LS and Leigh-like presentations. Apart from clinical diagnosis challenges, the molecular characterization also progressed from Sanger techniques to NGS (next-generation sequencing), encompassing analysis of nuclear (nDNA) and mitochondrial DNA (mtDNA). This upgrade resumed steps and favored diagnosis. Hereby, our paper presents molecular and clinical",28_1,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Hereby, our paper presents molecular and clinical data on a Portuguese cohort of 40 positive cases of LSS. A total of 28 patients presented mutation in mtDNA and 12 in nDNA, with novel mutations identified in a heterogeneous group of genes. The present results contribute to the better knowledge of the molecular basis of LS and expand the clinical spectrum associated with this syndrome. Mitochondrial disorders (MD) are the most common group of inherited metabolic disorders. These disorders might result from",28_2,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"disorders. These disorders might result from mutations in mtDNA, nDNA, or even genome interplay misfunctioning. In pediatric populations, LS is the most frequent neurodegenerative MD, reaching up to 1:40.000 live births [<xref rid=""B1-genes-14-01536"" ref-type=""bibr"">1</xref>,<xref rid=""B2-genes-14-01536"" ref-type=""bibr"">2</xref>]. It encloses progressively fatal neurologic failure, high lactate levels, and characteristic symmetrical lesions in brain stem and basal ganglia [<xref rid=""B2-genes-14-01536""",28_3,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"and basal ganglia [<xref rid=""B2-genes-14-01536"" ref-type=""bibr"">2</xref>,<xref rid=""B3-genes-14-01536"" ref-type=""bibr"">3</xref>]. The diagnostic criteria include clinical, neuroradiological, biochemical, and molecular findings. The developments in molecular diagnosis enabled an easy recognizing of this pathology but also expanded the phenotypical features, as well as the knowledge on the molecular basis of this syndrome. Since Holt et al. first reported m.8993T>G in 1990 [<xref rid=""B4-genes-14-01536""",28_4,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"m.8993T>G in 1990 [<xref rid=""B4-genes-14-01536"" ref-type=""bibr"">4</xref>], several mutations in <italic toggle=""yes"">MT-ATP6</italic> were subsequently published, also associated with LS, such as 9176T>C [<xref rid=""B5-genes-14-01536"" ref-type=""bibr"">5</xref>] and m.10191T>C [<xref rid=""B6-genes-14-01536"" ref-type=""bibr"">6</xref>]. The quick advance in nDNA sequencing provided helpful information since biochemical studies and mtDNA sequencing do not allow diagnosis confirmation in every cases. Fatal",28_5,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"diagnosis confirmation in every cases. Fatal early-onset presentations, classically seen associated with complex I (CI) deficiency [<xref rid=""B7-genes-14-01536"" ref-type=""bibr"">7</xref>,<xref rid=""B8-genes-14-01536"" ref-type=""bibr"">8</xref>], were importantly explored through sequencing of structural mitochondrial respiratory chain (MRC) components coding genes. Additional clinical presentations that did not fulfill the clinical and/or radiological criteria for LS but strongly resembled the syndrome were",28_6,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"for LS but strongly resembled the syndrome were named Leigh-like syndrome (LLS), considering that the evolution of symptoms could be sufficient to complete LS criteria in the future [<xref rid=""B1-genes-14-01536"" ref-type=""bibr"">1</xref>,<xref rid=""B2-genes-14-01536"" ref-type=""bibr"">2</xref>,<xref rid=""B9-genes-14-01536"" ref-type=""bibr"">9</xref>]. Since LLS is diagnosed in patients with nuclear-gene-related mutations, the condition is now denominated Leigh syndrome spectrum (LSS) [<xref",28_7,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"denominated Leigh syndrome spectrum (LSS) [<xref rid=""B9-genes-14-01536"" ref-type=""bibr"">9</xref>], where LS and LLS are considered a probable continuum of the same disorder [<xref rid=""B9-genes-14-01536"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-14-01536"" ref-type=""bibr"">10</xref>] (<xref rid=""genes-14-01536-t001"" ref-type=""table"">Table 1</xref>). The molecular advances through NGS and genomics made it possible to obtain huge amounts of information in a timely way, enabling an increase in diagnosis",28_8,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"a timely way, enabling an increase in diagnosis sensitivity, but bringing some uncertainties [<xref rid=""B11-genes-14-01536"" ref-type=""bibr"">11</xref>]. The plethora of information produced by these technologies demanded new data for comparison that is not widely available or extensively established. Furthermore, these techniques demand time and expertise to build robustness [<xref rid=""B12-genes-14-01536"" ref-type=""bibr"">12</xref>,<xref rid=""B13-genes-14-01536"" ref-type=""bibr"">13</xref>]. In mtDNA, for",28_9,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">13</xref>]. In mtDNA, for example, identifying a pathogenic variant may allow a condition to be named, but might fail to explain different phenotypes associated with a common underlying genetic lesion and intrafamilial phenotypic differences [<xref rid=""B14-genes-14-01536"" ref-type=""bibr"">14</xref>]. To address these questions, precision medicine was evolved through approaches known by “omics” (metabolomics, proteomics, and transcriptomics). The integrative medicine studies dive into deep",28_10,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"The integrative medicine studies dive into deep microenvironments to solve these questions. Despite recent advances it is still too early to apply it in routine testing [<xref rid=""B15-genes-14-01536"" ref-type=""bibr"">15</xref>]. While precision medicine is not routine, molecular biology refinements are eventful in promoting faster diagnosis and supporting interventions and counseling to LSS patients. Unfortunately, there are no curative options for MD yet. Supporting treatment is still the best and only",28_11,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Supporting treatment is still the best and only option, and includes dietary management, cofactors administration, specific support of disabilities, and respiratory intervention. Clinical trials for treatments, such as mTOR inhibitors, EPI-743, are undergoing to evaluate its effectiveness in preventing mortality and morbidity, with promising results [<xref rid=""B16-genes-14-01536"" ref-type=""bibr"">16</xref>]. In this paper we present data from a cohort of 40 patients diagnosed with LSS highlighting the",28_12,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"40 patients diagnosed with LSS highlighting the genetic heterogeneity identified in our cohort, contributing to expand the LSS. Patients: A cohort of 40 confirmed LSS individuals, from birth (0 months old (m.o.)) to 36 years, 20 males and 20 females, and respective positive family members, were followed in different clinical reference centers from Portugal. From this group, 11 had already been reported by our group and the remaining 29 were molecularly characterized and reported here for the first time.",28_13,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"and reported here for the first time. This study was approved by the Ethics Committees of the National Institute of Health Doutor Ricardo Jorge, and informed consent for genetic studies was obtained from all investigated subjects, or their relatives, in agreement with the Declaration of Helsinki. DNA extraction, sequencing, and variant analysis: High-purity DNA was extracted from peripheral blood leucocytes and/or muscle biopsy material according to standard procedures. A custom-made targeted nuclear gene",28_14,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"procedures. A custom-made targeted nuclear gene panel was designed using Suredesign software (Agilent 2023 7.10.1.1, Agilent Technologies, Santa Clara, CA, USA) and includes 209 nuclear genes, from which 188 were known to be involved in MD and 21 were candidates based on their role or participation in different pathways that include genes responsible for clinical presentations mimicking MD (<xref rid=""app1-genes-14-01536"" ref-type=""app"">Appendix A</xref>). Genes of interest were captured with a SureSelect",28_15,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Genes of interest were captured with a SureSelect QXT kit (Agilent Technologies), followed by sequencing on the Illumina MiSeq platform. Variant calling and annotation were performed using available commercial programs such as Surecall (Agilent Technologies) and wAnnovar (wannovar.wglab.org/ (accessed on 23 January 2023)). Variants were filtered, taking into account (i) the type of pathogenic variant (missense, frameshift, stop-gain or stop-loss, and splice-site variants), (ii) in silico predictors (SIFT,",28_16,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"variants), (ii) in silico predictors (SIFT, PolyPhen-2, MutationTaster) [<xref rid=""B17-genes-14-01536"" ref-type=""bibr"">17</xref>,<xref rid=""B18-genes-14-01536"" ref-type=""bibr"">18</xref>,<xref rid=""B19-genes-14-01536"" ref-type=""bibr"">19</xref>] and presence in databases (dbSNP, 1000 Genomes, HGMD professional, ClinVar, ExAC, OMIM, gnomAD), and (iii) the population frequency (variants with a minor allele frequency (MAF) > 1% in the 1000 Genomes Project (<uri http://www.w3.org/1999/xlink",28_17,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Project (<uri http://www.w3.org/1999/xlink href=""http://www.1000genomes.org"">http://www.1000genomes.org</uri> (accessed on 23 January 2023) and Exome Variant Server databases (<uri http://www.w3.org/1999/xlink href=""http://evs.gs.washington.edu"">http://evs.gs.washington.edu</uri> (accessed on 23 January 2023) were filtered out). Furthermore, we searched copy number variations through the analysis of coverage data, using cnMOPS [<xref rid=""B20-genes-14-01536"" ref-type=""bibr"">20</xref>]. The entire human",28_18,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">20</xref>]. The entire human mtDNA was enriched by a single amplicon, using back-to-back primers, by long-range PCR [<xref rid=""B21-genes-14-01536"" ref-type=""bibr"">21</xref>]. Indexed paired-end DNA libraries were prepared and an equimolar pool was sequenced, according to the manufacturer’s instructions. FASTQ files were aligned to the mtDNA reference sequence with SeqMan NGen (DNAStar). Variant calling and annotation were performed using the following commercial programs: SeqMan NGen and",28_19,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"following commercial programs: SeqMan NGen and SeqMan Pro (DNASTAR). Variants were filtered considering (i) the type of pathogenic variant, (ii) the population frequency, (iii) in silico predictors and presence in databases (Mitomap, MitImpact2, HmtVar), and (iv) heteroplasmy > 5%. All variants detected that had the potential to be disease-causing were confirmed by Sanger sequencing using the BigDye Terminator Cycle Sequencing Version 3.1 (Applied Biosystems, Foster City, CA, USA), and analyzed on an ABI",28_20,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Foster City, CA, USA), and analyzed on an ABI 3130XL DNA Analyzer. When DNA from additional family members was available, co-segregation studies were also performed [<xref rid=""B22-genes-14-01536"" ref-type=""bibr"">22</xref>].  The first group of patients in our cohort were molecularly characterized using targeted molecular approaches, the only available in previous decades, as PCR/RFLP and sanger sequencing of selected gene regions. The complete mtDNA sequencing by NGS was an important achievement that",28_21,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"by NGS was an important achievement that enabled the analysis of the total mtDNA genes, increasing the detection power and allowing the identification of several other mutations already linked to other phenotypes that are now part of the LSS. A total of 48% of the patients from our cohort presented mutations in the <italic toggle=""yes"">MT-ATP6</italic> gene, which is higher than could be expected based on published results [<xref rid=""B39-genes-14-01536"" ref-type=""bibr"">39</xref>]. This result could be the",28_22,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"This result could be the reflection of a particular molecular background of Portuguese LSS patients, or a bias associated with the studied cohort. Most index cases had m.8993T>G/C with mutation loads over 95% in muscle and/or blood and recurrent symptoms such as hypotonia, weakness, neurodevelopmental delay or regression, epilepsy, movement disorders, and deafness. The discovery of variable phenotypes of m.8993T>G/C was important to distinguish LSS from and NARP [<xref rid=""B40-genes-14-01536""",28_23,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"LSS from and NARP [<xref rid=""B40-genes-14-01536"" ref-type=""bibr"">40</xref>], for which the heteroplasmic rates showed that LSS classically display higher than 85% and NARP up to 85%. An additional explanation for the differences in clinical expression is the highly conserved position in <italic toggle=""yes"">MT-ATP6</italic> resulting in less tolerance to T>G rather than T>C in 8993-point mutations due to the amino acid change, as T>C results in maintaining nonpolar amino acids while the T > G results in",28_24,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"nonpolar amino acids while the T > G results in substitution of nonpolar amino acid for a charged one, which could produce an important destabilization in the catalytic site of the ATP synthase where this mutation occurs [<xref rid=""B4-genes-14-01536"" ref-type=""bibr"">4</xref>,<xref rid=""B16-genes-14-01536"" ref-type=""bibr"">16</xref>,<xref rid=""B41-genes-14-01536"" ref-type=""bibr"">41</xref>]. In family members of our cohort, we identified two mothers with 75% of heteroplasmy in m.8993T>G: one yet",28_25,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"with 75% of heteroplasmy in m.8993T>G: one yet asymptomatic, the other exhibiting NARP syndrome. P7′s mother with NARP displayed the same heteroplasmic rates, but this was calculated in DNA extracted from blood, while P7′s heteroplasmy was accessed in muscle tissue, making the correlation difficult to perform. Our hypothesis for the observed clinical presentations is based not only on the overall different mutation load but also on the distribution of mutated mtDNA by the different tissues. Plasma amino",28_26,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"mtDNA by the different tissues. Plasma amino acids profiles can exhibit changes that point to these mutations, namely, low citrulline levels [<xref rid=""B42-genes-14-01536"" ref-type=""bibr"">42</xref>,<xref rid=""B43-genes-14-01536"" ref-type=""bibr"">43</xref>]. Even at newborn screening (and after excluding urea cycle disorders), low citrulline is suggestive of <italic toggle=""yes"">MT-ATP6</italic> mutations 8993T>G/C and m.9176T>C/G [<xref rid=""B44-genes-14-01536"" ref-type=""bibr"">44</xref>]. A recent paper",28_27,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">44</xref>]. A recent paper [<xref rid=""B45-genes-14-01536"" ref-type=""bibr"">45</xref>] tried to correlate these mutations to an assertive metabolic profile phenotype, such as the one we found in P19, with low citrulline levels at newborn screening and m.9176T>G (p.Leu217Arg) in homoplasmy [<xref rid=""B45-genes-14-01536"" ref-type=""bibr"">45</xref>]. The study’s results showed that reduced citrulline levels and increased propionylcarnitine (C3) and 3-hydroxy-isovaleryl/2-methyl-butyrylcarnitine",28_28,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"3-hydroxy-isovaleryl/2-methyl-butyrylcarnitine (C5-OH) might be associated with <italic toggle=""yes"">MT-ATP6</italic> mutations [<xref rid=""B45-genes-14-01536"" ref-type=""bibr"">45</xref>,<xref rid=""B46-genes-14-01536"" ref-type=""bibr"">46</xref>]. P17 was investigated due to psychomotor delay, hypotonia, and microcephaly and harbors m.9185T>C (p.Leu220Pro) in 70% of mtDNA molecules while P18 had an LSS and harbors the same mutation in homoplasmy. This mutation is particularly relevant in LSS presenting with",28_29,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"is particularly relevant in LSS presenting with ataxia and late-onset cases where ataxia is the core symptom [<xref rid=""B47-genes-14-01536"" ref-type=""bibr"">47</xref>,<xref rid=""B48-genes-14-01536"" ref-type=""bibr"">48</xref>], albeit fulminant presentation being known as an early-onset LSS with infantile spasms with this mutation [<xref rid=""B49-genes-14-01536"" ref-type=""bibr"">49</xref>].  In the tRNA<sup>leu</sup> <italic toggle=""yes"">MT-TL1</italic>, the MELAS (mitochondrial myopathy, encephalopathy,",28_30,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) mutation m.3243A>G has been also identified in different phenotypes such as LSS, maternally inherited deafness and diabetes (MIDD), and isolated myopathy [<xref rid=""B50-genes-14-01536"" ref-type=""bibr"">50</xref>,<xref rid=""B51-genes-14-01536"" ref-type=""bibr"">51</xref>,<xref rid=""B52-genes-14-01536"" ref-type=""bibr"">52</xref>]. In our cohort, P20 presented m.3243A>G and epilepsy, ataxia, hyperlactacidemia, and learning",28_31,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"epilepsy, ataxia, hyperlactacidemia, and learning disabilities, with imaging studies characteristics of LSS, an expected phenotype to this mutation [<xref rid=""B31-genes-14-01536"" ref-type=""bibr"">31</xref>]. The m.3243A>G usually has a variable heteroplasmy percentage in different tissues and does not respect the usual threshold for MD, as mentioned by Chinnery et al. and by Pann et al. [<xref rid=""B50-genes-14-01536"" ref-type=""bibr"">50</xref>,<xref rid=""B53-genes-14-01536"" ref-type=""bibr"">53</xref>].",28_32,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">53</xref>]. Another mutated gene associated with LSS is <italic toggle=""yes"">MT-ND3</italic>, where we also found mutations in our cohort. The m.10191T>C (p.Ser45Pro) may manifest as a remarkable CI deficiency, inducing an early neonatal fulminant phenotype [<xref rid=""B54-genes-14-01536"" ref-type=""bibr"">54</xref>] or milder cases of encephalopathy, such as P21 [<xref rid=""B55-genes-14-01536"" ref-type=""bibr"">55</xref>], and small fiber neuropathy [<xref rid=""B56-genes-14-01536""",28_33,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"fiber neuropathy [<xref rid=""B56-genes-14-01536"" ref-type=""bibr"">56</xref>], but configuring dystonia and dysarthria as main symptoms [<xref rid=""B57-genes-14-01536"" ref-type=""bibr"">57</xref>]. It can also be associated with a slowly clinical progression from infancy to adulthood [<xref rid=""B58-genes-14-01536"" ref-type=""bibr"">58</xref>], leading to the association of mtDNA mutations to “spectrum” nomenclature, which was only acknowledged to nDNA mutations [<xref rid=""B9-genes-14-01536""",28_34,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"to nDNA mutations [<xref rid=""B9-genes-14-01536"" ref-type=""bibr"">9</xref>]. P22 with the mutation m.10197G>A (p.Ala47Thr) in <italic toggle=""yes"">MT-ND3</italic> also presented a mild phenotype, similar to P21. Mutations in the <italic toggle=""yes"">MT-ND5</italic> gene were also identified in our cohort. We found m.13094T>C (p.Val253Ala) in homoplasmy in P23, a mutation previously described associated with cerebellar syndromes [<xref rid=""B59-genes-14-01536"" ref-type=""bibr"">59</xref>], CI deficiency, or",28_35,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">59</xref>], CI deficiency, or combined complexes deficiencies [<xref rid=""B60-genes-14-01536"" ref-type=""bibr"">60</xref>], presenting our patient a marked hypotonia. In pediatric populations, LSS appears to represent a less favorable prognosis [<xref rid=""B61-genes-14-01536"" ref-type=""bibr"">61</xref>]. P24 and P25 presented m.13513G>A (p.Asp393Asn), a mutation that has already been outlined by Ruiter et al. in a patient with CI deficiency, cardiac rhythm perturbation, and optic atrophy",28_36,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"cardiac rhythm perturbation, and optic atrophy [<xref rid=""B62-genes-14-01536"" ref-type=""bibr"">62</xref>], with our patients presenting cardiomyopathy and hypotonia, and ataxia and apnea, respectively. Our cohort also includes a patient with m.4142G>T (p.Arg279Leu) in <italic toggle=""yes"">MT-ND1</italic> (P26 [<xref rid=""B30-genes-14-01536"" ref-type=""bibr"">30</xref>]) and another one with m.6547T>C in <italic toggle=""yes"">MT-CO1</italic> (P27 [<xref rid=""B30-genes-14-01536"" ref-type=""bibr"">30</xref>]).",28_37,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">30</xref>]). Another group of mutations in mtDNA are the rearrangements, such as single-large-scale mtDNA deletions (LMD), a genetic cause of MD expressing a wide range of clinical features. The rearrangements result into a spectrum of syndromes: Pearson, Kearns Sayre Syndrome (KSS), a subtype of chronic progressive external ophthalmoplegia (CPEO), and CPEO itself [<xref rid=""B63-genes-14-01536"" ref-type=""bibr"">63</xref>,<xref rid=""B64-genes-14-01536"" ref-type=""bibr"">64</xref>]. P28 was",28_38,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">64</xref>]. P28 was investigated due to epilepsy, short stature, cerebellar ataxia, and tremor, and Southern-blot analysis detected an LMD of 4977bp-del (m.8470-m.13447). This association is extremely rare because the early-onset spectrum of LMD, Pearson syndrome, is usually a potentially fatal disorder disabling the progression of the spectrum to other clinical entities, namely, LSS, which makes the association rare [<xref rid=""B65-genes-14-01536"" ref-type=""bibr"">65</xref>,<xref",28_39,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">65</xref>,<xref rid=""B66-genes-14-01536"" ref-type=""bibr"">66</xref>]. Despite the prognosis, the patients who survive may develop LSS or a multiorgan deficiency in the future [<xref rid=""B63-genes-14-01536"" ref-type=""bibr"">63</xref>].  The patients of our cohort identified with nDNA mutations were all screened by NGS, which represents a satisfactory middle-term cost-utility approach, providing a significant amount of data in a reasonable time, delivering a broader diagnostic performance when",28_40,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"delivering a broader diagnostic performance when set side by side to conventional procedures. The complexes are the major structural components of the MRC resulting in mitochondrial optimized ATP generation [<xref rid=""B57-genes-14-01536"" ref-type=""bibr"">57</xref>]. As we observed in our cohort, the CI and CIV most frequently harbor pathogenic mutations, followed by non-OXPHOS defects. In total, in nDNA we identified ten pathogenic mutations, three likely-pathogenic variants, one reclassified in our",28_41,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"variants, one reclassified in our perspective through ACMG, symptomatology, and biochemical analysis, and one VUS that did not meet criteria to be reclassified.  The CI is the first and largest MRC complex [<xref rid=""B67-genes-14-01536"" ref-type=""bibr"">67</xref>] and is widely associated with LSS, with several genes involved [<xref rid=""B3-genes-14-01536"" ref-type=""bibr"">3</xref>,<xref rid=""B57-genes-14-01536"" ref-type=""bibr"">57</xref>], resulting in 33 subtypes of mitochondrial CI deficiency (MCID), from",28_42,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"of mitochondrial CI deficiency (MCID), from first year of life rapidly progressing to fatal course [<xref rid=""B68-genes-14-01536"" ref-type=""bibr"">68</xref>,<xref rid=""B69-genes-14-01536"" ref-type=""bibr"">69</xref>] to a wide range of presentations [<xref rid=""B70-genes-14-01536"" ref-type=""bibr"">70</xref>,<xref rid=""B71-genes-14-01536"" ref-type=""bibr"">71</xref>,<xref rid=""B72-genes-14-01536"" ref-type=""bibr"">72</xref>]. P30 presented the c.470A>T (p.Lys157Met)/c.1798G>C (p.Glu600Gln) variants in <italic",28_43,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"(p.Glu600Gln) variants in <italic toggle=""yes"">NDUFS1</italic>, which are not reported in databases so far. Standard classification scores by ACMG resulted in class IV, likely pathogenic, for both variants. In silico predictors such as Polyphen-2 and SIFT described them as deleterious, and Mutation Taster as probably damaging. Segregation studies showed heterozygous parents. The clinical manifestations are described in LSS and CI deficiency, altogether supporting a probable pathogenicity. P31 displayed,",28_44,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"a probable pathogenicity. P31 displayed, with homozygous mutation, c.120+5_120+8delGT in <italic toggle=""yes"">NDUFV2</italic>, a classic <italic toggle=""yes"">NDUFV2</italic> phenotype represented by hypertrophic cardiomyopathy and encephalopathy [<xref rid=""B73-genes-14-01536"" ref-type=""bibr"">73</xref>,<xref rid=""B74-genes-14-01536"" ref-type=""bibr"">74</xref>], alongside with a rare skin condition. In less frequent cases, <italic toggle=""yes"">NDUFV2</italic> mutations manifest as LSS, which was reported by",28_45,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"mutations manifest as LSS, which was reported by Liu et al. in two families [<xref rid=""B75-genes-14-01536"" ref-type=""bibr"">75</xref>].  The CIV Is also a critical part of the MRC as the terminal catalytic site to transfer electrons into oxygen [<xref rid=""B76-genes-14-01536"" ref-type=""bibr"">76</xref>]. <italic toggle=""yes"">SURF1</italic> is a gene that plays part in the assembly of CIV, while <italic toggle=""yes"">LRPPRC</italic> impacts the mitochondrial translation [<xref rid=""B77-genes-14-01536""",28_46,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"translation [<xref rid=""B77-genes-14-01536"" ref-type=""bibr"">77</xref>]. We identified P35 with <italic toggle=""yes"">SURF1</italic> mutations displaying atypical presentation with isolated psychiatric symptoms represented by visual hallucinations with suggestive LSS neuroimaging. Molecular assessment retrieved homozygous c.19_35dup17* (p.Ala13Cysfs*65) in <italic toggle=""yes"">SURF1</italic>, a gene typically related to a group of homogeneous symptoms (hypertrichosis [<xref rid=""B78-genes-14-01536""",28_47,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"(hypertrichosis [<xref rid=""B78-genes-14-01536"" ref-type=""bibr"">78</xref>] and peripheral neuropathy), specific imaging findings (leukodystrophy), and high mortality in childhood [<xref rid=""B79-genes-14-01536"" ref-type=""bibr"">79</xref>]. However, heterogeneous phenotypes linked to <italic toggle=""yes"">SURF1</italic> mutations have been reported [<xref rid=""B80-genes-14-01536"" ref-type=""bibr"">80</xref>]. P36 was investigated for encephalopathy and brain atrophy. NGS revealed the homozygous mutation c.74G>A",28_48,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"NGS revealed the homozygous mutation c.74G>A (p.Arg25His) in <italic toggle=""yes"">LRPPRC</italic> gene, a rare variant in population, classified as ACMG class III. Segregation studies were performed, confirming inheritance in our patient. In silico predictors are controverse; Polyphen-2 and SIFT pointing to deleterious role, and Mutation Taster to benign role, while ClinVar classifies it as a VUS associated with congenital lactic acidosis Saguenay-Lac-Saint-Jean, a subtype of LSS [<xref",28_49,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"Saguenay-Lac-Saint-Jean, a subtype of LSS [<xref rid=""B81-genes-14-01536"" ref-type=""bibr"">81</xref>]. This feature gives us a likely connection between the genotype and the patient’s phenotype, with this variant having the potential to be, in the future, reclassified as likely pathogenic.  Thiamine pyrophosphate is an important cofactor of several steps in energy production and SLC19A3, a biotin-dependent thiamine transporter in the central nervous system, is fundamentally present in the basal ganglia",28_50,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"is fundamentally present in the basal ganglia system [<xref rid=""B82-genes-14-01536"" ref-type=""bibr"">82</xref>]. BBGD is a well-known cause of LSS [<xref rid=""B83-genes-14-01536"" ref-type=""bibr"">83</xref>] frequently manifesting in childhood with vomiting, seizures, encephalopathy, movement disorders, and free-thiamine dosage in cerebrospinal fluid typically low to absent [<xref rid=""B84-genes-14-01536"" ref-type=""bibr"">84</xref>,<xref rid=""B85-genes-14-01536"" ref-type=""bibr"">85</xref>]. P37 and P38",28_51,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"ref-type=""bibr"">85</xref>]. P37 and P38 investigated in our cohort had mutations in <italic toggle=""yes"">SLC19A3</italic>. P37 developed neonatal epileptic encephalopathy with homozygous c.980-14A>G in <italic toggle=""yes"">SLC19A3</italic> and P38 displayed episodic ataxia with homozygous c.74dupT (p.Ser26Leufs*19). Both patients are under treatment with biotin and thiamine and had important recovery of symptoms, which demonstrates the importance of recognizing the phenotype and starting effective",28_52,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"recognizing the phenotype and starting effective intervention [<xref rid=""B82-genes-14-01536"" ref-type=""bibr"">82</xref>,<xref rid=""B83-genes-14-01536"" ref-type=""bibr"">83</xref>].  Organic acidurias are also a proven cause of LSS. In the case of <italic toggle=""yes"">ECHS1</italic> and <italic toggle=""yes"">HIBCH</italic> genes, encoding a hydratase and a hydrolase enzyme, respectively, in the final valine metabolism, LSS is the most common clinical manifestation of these genetic deficiencies [<xref",28_53,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"of these genetic deficiencies [<xref rid=""B86-genes-14-01536"" ref-type=""bibr"">86</xref>,<xref rid=""B87-genes-14-01536"" ref-type=""bibr"">87</xref>,<xref rid=""B88-genes-14-01536"" ref-type=""bibr"">88</xref>]. Frequent symptoms identified in these cases are developmental delay or regression, hypotonia, and epilepsy [<xref rid=""B89-genes-14-01536"" ref-type=""bibr"">89</xref>]. A recent Spanish study demonstrated that <italic toggle=""yes"">HIBCH</italic> deficiency was completely correlated to LSS, and <italic",28_54,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"was completely correlated to LSS, and <italic toggle=""yes"">ECHS1</italic> deficiency displayed LSS, but also fatal neonatal lactic acidosis and paroxysmal dystonia. The biochemical profile was divergent between them, which could guide the diagnosis [<xref rid=""B90-genes-14-01536"" ref-type=""bibr"">90</xref>]. P39 was confirmed with HIBCH deficiency, being homozygous for c.488G>T (p.Cys 163Phe). P40 is a compound heterozygous for a known pathogenic mutation in <italic toggle=""yes"">HIBCH</italic> c.129dupA",28_55,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"in <italic toggle=""yes"">HIBCH</italic> c.129dupA (p.Gly44Argfs*20) alongside an unreported variant c.910C>T (p.Pro304Ser). The new variant meets ACMG criteria as class III. In silico estimates in Polyphen-2, SIFT, Mutation Taster suggest a deleterious behavior. Also, in this case, the positive segregation pattern, clinical manifestations expressed as LSS and biochemical analysis of acylcarnitine profile displaying elevation of 3-hydroxyisobutyryl carnitine, and urinary organic acids showing intermediate",28_56,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"and urinary organic acids showing intermediate metabolites of valine degradation were associated with a reported pathogenic variant we would consider to be a likely pathogenic variant, ACMG Class IV, under this information. The present work presents data on a Portuguese cohort of 40 LS patients and allows the expansion of the molecular knowledge on this syndrome and the clinical spectrum associated with it. The present data stress the high clinical and genetic heterogeneity associated with this syndrome.",28_57,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"heterogeneity associated with this syndrome. The evolution of the molecular technics from PCR/RFLP to sanger sequencing and finally NGS was a path leading to an unprecedent increase in sensitivity in the diagnosis of LS. The adoption by our lab of NGS allowed the clarification of unsolved cases for many years, being useful in revealing the molecular etiology in children and adult patients by identifying new variants, characterizing more cases, and expanding the LSS scenery of mutations, since rare and",28_58,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
"the LSS scenery of mutations, since rare and nondescribed variants were pivotal for our cases; albeit this is only the beginning.",28_59,Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era,27 7 2023,,Leigh_Syndrome
Cerebral Magnetic Resonance Imaging Lesions in Leigh Syndrome are Variegated Nil. There are no conflicts of interest.,29_0,Cerebral Magnetic Resonance Imaging Lesions in Leigh Syndrome are Variegated,Jul-Sep 2023,,Leigh_Syndrome
